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Abstract 
This thesis is comprised of six scientific articles and is preceded by an overview 
that contextualises all of this published/submitted work. 
The first section of this thesis is comprised of Publications 1-3 and is concerned 
with the synthesis of novel, oxygenated analogues of the natural and non-natural 
enantiomeric forms of the Amaryllidaceae alkaloid galanthamine, a reversible and 
selective acetylcholine esterase (AChE) inhibitor that is used clinically in the 
treatment of Alzheimer’s disease. 
 
Specifically, Publication 1 is an invited book chapter that details synthetic 
approaches to galanthamine and certain analogues pursued by the Banwell Group. 
It contextualises the strategy employed in preparing oxygenated analogues of 
galanthamine by the author in latter part of the first section of this thesis.  
Publication 2 is an invited review article that showcases the methodologies that 
have been developed within the Banwell Group for manipulating enzymatically-
derived and homochiral cis-1,2-dihydrocatechols such as A so as to generate a 
significant range of biologically active natural products. 
 
Publication 3 describes the synthesis of certain oxygenated derivatives of both 
(+)- and (–)-galanthamine such as B and C (and their enantiomers) and the 
evaluation of these as AChE inhibitors.  
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The key intermediate D is accessible in both enantiomeric forms, either by 
manipulation of the aforementioned cis-1,2-dihydrocatechol A (to give ent-D) or 
from L-(+)-tartaric acid via methodology detailed in Publication 4. Intermediate 
D is engaged in a 3-step sequence involving Suzuki-Miyaura cross-coupling, 
intramolecular Mitsunobu and Eschenmoser-Claisen reactions to rapidly assemble 
the ABC-ring system of galanthamine, as embodied in compound E, with high 
levels of stereocontrol. 
 
The second section of this thesis is comprised of Publications 4 and 5. These detail 
the synthesis of chiron F and its enantiomer from L-(+)- and D-(–)-tartaric acid, 
respectively, and their elaboration into various natural product scaffolds.  
 
Specifically, Publication 4 describes the preparation of chiron F in 6 steps from  
L-(+)-tartaric acid via esterification/1,2-diacetal formation, one-pot DIBAL-H 
reduction-Grignard reagent addition, ring closing metathesis, oxidation and 
diastereoselective reduction reactions. Compound F is itself elaborated to diol D 
through bromination, reduction and Mitsunobu inversion processes. Chiron D is 
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the enantiomer of a key intermediate described in Publication 3 that is used to 
produce oxygenated analogues of (–)-galanthamine. 
Publication 5 further demonstrates the utility of these new chirons in total 
synthesis by employing ent-F [prepared from D-(–)-tartaric acid] as a key 
intermediate in the first total synthesis of the structurally unusual natural product 
aspergillusol B. Key steps in this synthesis are an efficient Mitsunobu-iodination 
sequence and Sonogashira cross-coupling reaction (with a commercially available 
alkyne) followed by selective cyclic carbonate formation so as to generate the 
natural product.  
 
The final section of this thesis is comprised of Publication 6. This details work on 
the total synthesis of the four diastereomeric forms of the pro-angiogenic 
guaiacylglycerol 8-O-4ʹ-coniferyl ethers (GGCE) shown below in an effort to 
establish the role stereochemistry plays on their capacities to act as pro-angiogenic 
agents. 
 
The syntheses feature an Evans/Seebach syn-aldol reaction utilising auxiliaries 
derived from either L-(+)- or D-(–)-valine. In the case of syntheses of the  
anti-compounds this was followed by a Mitsunobu inversion of the benzylic 
alcohol. The four diastereomers were assessed for their pro-angiogenic properties 
4 
 
in a human microvascular endothelial cell tubule assay. Whilst they were all active, 
the compounds containing the 8S-ether linkage (viz. G and H) were the most 
potent. 
The Appendices to this thesis are comprised of a series of reports arising from the 
single-crystal X-ray analyses of a number of key compounds synthesised by the 
author. These analyses and the derived reports are the result of work carried out 
by Dr Brett Schwartz, Dr Paul Carr and Dr Anthony Willis, the latter two being 
members of the Research School of Chemistry’s Crystallographic Analysis Unit.  
5 
 
Thesis Overview 
Publication 1: Devising New Syntheses of the Alkaloid Galanthamine, a 
Potent and Clinically Deployed Inhibitor of Acetylcholine Esterase 
(–)-Galanthamine is an alkaloid found in the bulbs of various Amaryllidaceae 
species including the Red Spider Lily (Lycoris radiate), the Caucasian snowdrop 
(Galanthus woronowii) and daffodils (Narcissus poeticus).1–5 It is a centrally acting, 
selective and reversible competitive inhibitor of acetylcholine esterase (AChE).3 
The HBr salt (marketed as, inter alia, Nivalin, Razadyne and Reminyl) is currently 
used for the treatment of Alzheimer’s Disease and is regarded as a frontline drug 
in the management of the growing dementia pandemic.6,7 Its high cost of isolation 
and intriguing structure has resulted in it being an attractive target for total 
synthesis, as well as the focus of analoguing programs seeking systems displaying 
improved efficacy and/or reduced side-effects.8–12 
 
Publication 1 is an invited book chapter that highlights a number of important 
historical syntheses of galanthamine as well as new strategies being undertaken in 
the Banwell Group that are directed the towards the synthesis of this alkaloid and 
certain analogues. 
The chapter highlights how work on the synthesis of the structure assigned to the 
bioactive benzofuran natural product ribisin C (Scheme 1) inspired the author’s 
own synthetic strategy towards the galanthamine framework. Specifically, when 
the functionalised bromoconduritol 2, itself prepared from the cis-1,2-
dihydrocatechol 1 (the focus of Publication 2), is subjected to Suzuki-Miyaura 
cross-coupling conditions with commercially available boronic acid ester 3 
spontaneous cyclisation occurs to give 2,3-dihydrobenzofuran 4, albeit in just 24% 
yield. This was converted, over four additional steps, into the structure assigned to 
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ribisin C. Analysis of the derived optical rotation and other spectral data revealed 
that this was actually the enantiomer of the natural product (viz. ent-ribisin C) and 
that, therefore, the structure of this end-product had been misassigned by the 
original workers.13  
 
Scheme 1: Key steps used in the synthesis of ent-ribisin C 
Inspired by this work, the author coupled compound 5, itself derived from  
cis-1,2-dihydrocatechol 1, with boronic acid ester 6 (Scheme 2) and was then able 
to effect a Mitsunobu cyclisation involving the product of this reaction to generate 
the ABC-ring containing 2,3-dihydrobenzofuran 7. This last compound was then 
converted, over six additional steps, into the oxygenated derivative of  
(+)-galanthamine ent-8. This strategy is described in full in Publication 3.14 
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Scheme 2: Key steps used in constructing the ABC-ring system of (+)-galanthamine 
Publication 2: Chemoenzymatic Pathways for the Synthesis of Biologically 
Active Natural Products 
This review article details some of the ways in which enzymatically-derived  
cis-1,2-dihydrocatechols can be manipulated so as to generate a range of 
biologically active natural products. These metabolites are produced in homochiral 
form (>99.8% ee) through the enzymatic dihydroxylation of benzene derivatives 
using a genetically mutated strain of E. coli that overexpresses the enzyme toluene 
dioxygenase.15 Figure 1 shows some of the key reactivities of cis-1,2-
dihydrocatechols. Thus, the two centres of chirality can be used to direct the 
construction of other stereocenters associated with various complex molecules and 
additional functionality can be introduced via several means e.g. stereoselective 
electrophilic addition at the non-halogenated double bond,16 cross-coupling to the 
alkenyl-halide residue,17 or Diels-Alder reactions with the diene.18 
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Figure 1: Key reactivities of cis-1,2-dihydrocatechols 
The author’s work on oxygenated analogues of (+)-galanthamine such as ent-8 
(Figure 2), which is itself the subject of Publication 3,14 is highlighted as are 
syntheses of the ribisin class of natural product (including ribisin D),19  
(–)-platencin18 and compound 10 which embodies the ABCDE-core of vindoline.20 
 
Figure 2: Examples of compounds prepared from the homochiral 
 cis-1,2-dihydrocatechols 1 and 9 
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Publication 3: The Synthesis of Certain Derivatives and Analogues of (–)- 
and (+)-Galanthamine and an Assessment of their Capacities to Inhibit 
Acetylcholine Esterase 
Publication 3 details the author’s investigations into syntheses of oxygenated 
analogues of the Amaryllidaceae alkaloid (–)-galanthamine and its enantiomer as 
well as an assessment of their AChE-inhibiting capacities. 
 
Figure 3: The ABCD ring system of galanthamine and partial numbering scheme 
Building upon the results highlighted in Publications 1 and 2, the author initially 
pursued the development of a total synthesis of (+)-galanthamine from cis-1,2-
dihydrocatechol 1. Intriguing results from docking studies (Table 1) of certain 
oxygenated derivatives such as compounds ent-8 and ent-11 (Figure 4) suggested 
that some of these would be potent inhibitors of AChE despite being related to the 
non-natural enantiomeric form of galanthamine. 
Compound Docking BE (kcal mol-1) 
8 –8.9 
ent- 8 –9.6 
11 –8.4 
ent- 11 –9.5 
(–)-galanthamine –10.2 
Table 1: Docking energies of compounds 8, 11 and their enantiomers 
Given that the activity of galanthamine analogues oxygenated at the C5 position 
had not been previously explored and could, in principle, improve water solubility 
and provide a handle for conjugation,10–12 the author pursued the synthesis of these 
derivatives and certain analogues in both enantiomeric series (Figure 4) in order 
that they could be subjected to biological evaluation. 
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Figure 4: Compounds synthesised for biological evaluation in Publication 3 
 (not shown: ent-8, ent-11, ent-12, ent-13, and ent-14) 
Compound 5 and its enantiomer are both accessible from cis-1,2-dihydrocatechol 
1 (Publications 1 and 2) or L-(+)-tartaric acid (Publication 4), respectively. As 
shown in Scheme 3, compound 5 was engaged in a 3-step sequence involving 
Suzuki-Miyaura cross-coupling, intramolecular Mitsunobu and Eschenmoser-
Claisen reactions to generate amide 19. This sequence results in the rapid assembly 
of the ABC-ring system of galanthamine possessing the required stereochemistries 
at C6, C4a, C8a, and with an appropriate functional handle for constructing the  
D-ring. N,N-Dimethylamide 19 was then converted, over three steps, into the 
corresponding N-methylamide ent-13 which, upon exposure to modified Pictet-
Spengler conditions, cyclised to form lactam ent-8, thereby installing the  
D-ring. Reduction of compound ent-8 with Red-Al® then delivered  
(+)-5-hydroxygalanthamine (ent-11). Compounds 12 and 14 (and their 
enantiomers) were prepared by hydrolysing the acetal unit of 19 and ent-13, 
respectively, under aqueous acidic conditions. 
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Scheme 3: Key steps in the synthesis of oxygenated galanthamine analogues from  
cis-1,2-dihydrocatechol 1  
Compounds 15 – 17 were prepared by Mr Ehab Taher using similar chemistries but 
where an aryl cross-coupling partner containing an aldehyde residue on the 
aromatic ring was employed. 
Interestingly, although not without precedent,21 when compound 20 was subjected 
to Eschenmoser-Claisen conditions the expected [3,3]-sigmatropic rearrangement 
did not take place.  Rather, ionisation of the derived mixed acetal occurred and this 
was followed by its nucleophilic capture with 1-methoxy-N,N-dimethylethen-1-
amine (a product of the thermal cracking of DMADMA) to give amide 21 and its 
C5 epimer 22 in a ca. 6:1 ratio (Scheme 4). The free phenolic residue was also 
methylated in the course of the reaction which is itself a well-known 
transformation observed upon thermolysis of compounds containing such 
functionalities with DMADMA or DMFDMA.22 
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Scheme 4: ‘Thwarted’ Eschenmoser-Claisen rearrangement of allylic alcohol 20  
leading to compounds 21 and 22 
Compounds 8, 11 – 14 and their enantiomers as well as compounds 15 – 17 were 
evaluated for capacities to inhibit AChE and, in contrast to the predictions of the 
docking simulations outlined in Table 1, none bound strongly to this enzyme. 
Publication 4: The Synthesis of Polyfunctionalized, Cyclohexene-Based 
Chirons from Tartaric Acid 
Despite the considerable utility of the cis-1,2-dihydrocatechols showcased in 
Publication 2, a major drawback is the inaccessibility of the enantiomers of these 
materials in homochiral form.23 During our studies into the synthesis and 
biological evaluation of analogues of galanthamine (Publication 3), we required 
the enantiomer of compound 5 (Scheme 5).  
 
Scheme 5: Synthesis of compounds 5 and ent-5 
A 12 step synthesis of target ent-5 is reported in Publication 4 and is summarised 
in Scheme 6. Thus, L-(+)-tartaric acid was first converted into the 1,2-diacetal 23 
13 
 
using an established a one-pot procedure.24 Compound 23 was treated sequentially 
with two equivalents of DIBAL-H then seven equivalents of vinylmagnesium 
bromide, thereby generating bis-allylic alcohol 24.  This last compound was 
subjected to a ring closing metathesis then a 2-fold oxidation (using Dess-Martin 
periodinane) to afford the C2-symmetric ene-dione 25. Compound 25 itself was 
then reduced under modified Luche conditions at –78 °C to generate  
-hydroxyenone 26 as a single diastereomer and this last compound was 
brominated to afford -bromocyclohexenone 27. Compound 27 was elaborated to 
the target chiron ent-5 over five additional steps that included reduction of the 
ketone moiety and subsequent Mitsunobu inversion of the undesired, pseudo-
equatorial alcohol. 
 
Scheme 6: Key steps employed in the synthesis of compound ent-5 from L-(+)-tartaric acid 
Figure 5 highlights some of the key features of the aforementioned homochiral 
cyclohexenones (viz. 26 and 27).  These are interesting chirons as both these and 
their enantiomers are available from cheap starting materials and contain various 
functional handles for further elaboration (e.g. cross-coupling to the alkenyl 
halide, Michael addition to the enone or Wittig olefination of the carbonyl). The 
1,2-diacetal motif enforces a rigid conformation which aids stereocontrol25 and the 
remaining stereogenic centres are easily manipulated through selective reductions 
and/or Mitsunobu chemistry. One such example of their utility in natural product 
synthesis is presented in Publication 5.  
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Publication 5: A Total Synthesis of the Cyclic Carbonate-Containing 
Natural Product Aspergillusol B from D-(–)-Tartaric Acid 
In 2014 two novel cyclic carbonate-containing natural products were isolated, 
alongside the known compound (+)-asperpentyn,26 from the culture broth of the 
fungus Aspergillus sp. PSURSPG185 found in soil samples collected from the Surat 
Thani Province in Thailand.27 These were named aspergillusols A and B and 
assigned the structures shown in Figure 6.  
 
Figure 6: Structures assigned to the natural products (+)-asperpentyn,  
aspergillusol A and aspergillusol B 
In 2015 Banwell and co-workers published total syntheses of (+)-asperpentyn and 
the enantiomer of aspergillusol A from cis-1,2-dihydrocatechol 9 in 5 and 8 steps, 
respectively (Scheme 7).28 
 
Scheme 7: Syntheses of (+)-asperpentyn and aspergillusol A from  
enzymatically-derived chiron 9 
Figure 5: Key reactivities of tartaric acid-derived chirons  
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Cyclic carbonate-containing natural products are rare in nature29,30 and it is likely 
that both aspergillusol A and B are formed via the trans-diaxial opening of the 
epoxide of (+)-asperpentyn with a carbonate nucleophile followed by a cyclisation 
event involving the adjacent cis-hydroxyl moiety.31 
Publication 5 details a 12-step synthesis of the structure assigned to aspergillusol 
B from D-(–)-tartaric acid, thereby validating the structural assignment of 
Rukachaisirikul and co-workers.27 Specifically (Scheme 8), D-(–)-tartaric acid is 
converted into the -hydroxyenone ent-26 over 6 steps using the protocols outlined 
in Publication 4. Compound ent-26 readily participated in a Mitsunobu reaction 
with p-nitrobenzoic acid to give ester 28 that was iodinated, reduced and 
deprotected to generate iodoconduritol 29, the absolute stereochemistry of which 
was confirmed by single-crystal X-ray crystallography. This last compound 
engaged in Sonogashira reaction with the commercially available 2-methylbut-1-
en-3-yne, efficiently installing the conjugated side-chain and generating tetraol 30. 
Cyclic carbonate formation was then achieved by treating tetraol 30 with 
triphosgene in the presence of triethylamine and so producing aspergillusol B, 
albeit in rather modest yield. All the derived spectral data matched those of the 
naturally derived material but, as an optical rotation measurement was not 
obtained by Rukachaisirikul and co-workers the absolute stereochemistry of the 
natural product cannot be established at this time. 
 
Scheme 8: Key steps associated with the author’s synthesis of aspergillusol B  
from D-(–)-tartaric acid 
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Publication 6: Developing Neolignans as Pro-Angiogenic Agents: 
Stereoselective Total Syntheses and Preliminary Biological Evaluations of 
the Four Guaiacylglycerol 8-O-4ʹ-Coniferyl Ethers 
Angiogenesis, the growth of new blood vessels, is central to the physiological 
processes of growth and repair in mammalian systems.32 Whilst imbalances 
leading to excessive angiogenic activity can contribute to many ailments including 
inflammatory disorders, cancer and diabetes, insufficient angiogenesis can lead to 
problems with wound healing and organ repair.33 Accordingly, compounds with 
pro-angiogenic activity are of interest for wound-healing as well as in the treatment 
of conditions such as acute muscle degeneration, diabetic retinopathy and the 
revascularization of ischemic tissues encountered in stroke victims and those 
suffering from cardiac disorders.32–34  
In 2010, efforts by Djordjevic Group located within the ANU’s Research School of 
Biology and the Parish Group in the John Curtin School of Medical Research (ANU) 
resulted in the isolation of two pro-angiogenic compounds from extracts of 
soybean Glycine max.35 Although only small quantities were isolated, 2D NMR 
spectroscopic studies and mass spectral analyses led to the identification of these 
compounds as the two diastereoisomeric forms of guaiacylglycerol-8-O-4’-
coniferyl ether (GGCE). Since the absolute stereochemistry of the active 
compounds could not be determined, the four possible structures that need to be 
considered are 31, ent-31, 32 and ent-32 (Figure 7). 
 
Figure 7: The four possible stereoisomeric forms of GGCE: 31, ent-31, 32 and ent-32  
and partial numbering scheme 
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Publication 6 details the author’s unambiguous total syntheses of compounds 31, 
ent-31, 32 and ent-32 and the evaluation of all four compounds as  
pro-angiogenic agents. 
Initial attempts focused on the SN2 displacement of tosylate 35 (Scheme 9), that 
was itself prepared from the known bis-MOM ether 33 through asymmetric 
dihydroxylation, selective oxidation of the benzylic alcohol and tosylation of the 
remaining free alcohol. After extensive experimentation, the reaction of compound 
35 with the caesium salt of coniferaldehyde could be achieved in 47% yield but, 
unfortunately and not entirely surprisingly, the stereocenter at C8 underwent 
base-induced racemisation in the process. Despite this, syntheses of both 
compounds (±)-31 and (±)-32 were completed in two further steps which provided 
material for further biological evaluation and a means for determining the 
enantiomeric excesses of the subsequently generated enantiomerically enriched 
materials.  
Scheme 9: First-generation syntheses of (±)-31 and (±)-32 
The second-generation syntheses of the target compounds achieved by the author 
are detailed in Scheme 10. This strategy utilises the valine-derived auxiliary 38 
introduced by Seebach36 and features an Evans’ syn-aldol reaction of  compound 
37 with the TBS-ether of vanillin to establish the C7 and C8 stereochemistries 
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associated with the targets. After reductive cleavage of the auxiliary, the terminal 
alkene is engaged in an aerobic and palladium catalysed acetoxylation37 to afford 
41 and, after global deprotection under basic conditions, delivered compound  
ent-31 in essentially homochiral (>99% ee) form (as judged by chiral HPLC 
analysis). 
 
Scheme 10: Key steps used in the synthesis of compound ent-31 
Subjection of alcohols 39 and 40 or certain related derivatives to Mitsunobu 
conditions in an effort to invert the stereochemistry at C7 and deliver the  
anti-compounds only led to complex mixtures of products. To attenuate the 
electron donating properties of the attached aryl oxygen that the author envisaged 
was facilitating ionisation of the activated benzylic alcohol intermediate,38  
silyl ether 40 was converted into tosylate 42 (Scheme 11). Gratifyingly, this ester 
engaged in a Mitsunobu reaction with p-nitrobenzoic acid with clean inversion of 
the stereochemistry at C7 and, after cleavage of the p-nitrobenzoate ester, 
acetoxylation and then global deprotection, compound ent-32 was secured in 
essentially homochiral (>99% ee) form. 
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Scheme 11: Key steps in the synthesis of compound ent-32 
Compounds 31 and 32 were prepared by analogous protocols using an auxiliary 
derived from D-(–)-valine. The absolute and relative stereochemistries of 
compounds 39 and ent-39 were initially assigned based upon the well-established 
syn-selective outcomes of the Evans’ boron aldol reaction.36,39,40 Further support 
was later provided by the recent work of Nair and coworkers,41 who prepared 
compound 32  using an anti-aldol protocol and undertook certain chemical 
correlation studies and a single-crystal X-ray analysis to establish the selectivities 
of their pivotal reaction. 
Interestingly, all four compounds are active but exhibit different levels of pro-
angiogenic activity, with the 8S- configured congeners 31 and 32 being the most 
potent. This is the first time that variations in stereochemistry have been shown to 
affect efficacy in small-molecule pro-angiogenic agents.  
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5. An Abortive, Radical-Based Approach to (±)-Galanthamine
6. Doing Things the Hard Way – De Novo Construction of the Aromatic C-ring as a
Focal Point
7. Conclusions
Abstract: The alkaloid (–)-galanthamine (1), a potent inhibitor of acetylcholine esterase 
(AChE), is used clinically for the symptomatic treatment of mild to moderate forms of 
Alzheimer’s disease. The clinical demand for (–)-galanthamine together with the erosion of 
habitat of at least some of the source plants has created supply issues that have prompted 
numerous synthetic studies. Four distinct approaches for the assembly of the tetracyclic 
framework of compound 1 developed in the authors’ laboratories are described here. Two of 
these exploit an enantiomerically pure metabolite produced through the whole-cell 
dihydroxylation of bromobenzene as a precursor to the A-ring of natural product 1. The second 
of these rapidly provides enantiomerically pure compounds that molecular docking studies 
suggest should be strong inhibitors of AChE. A third synthesis of (–)-galanthamine involving 
the de novo assembly of the aromatic C-ring is also described, as is a failed radical cyclization-
based approach. 
Keywords: Alkaloid synthesis, Benzannulation, Bischler–Napieralski reaction, 
Bromoetherification, cis-1,2-dihydrocatechol, Eschenmoser–Claisen rearrangement, 
Galanthamine, Intramolecular Alder-ene reaction, Mitsunobu reaction, Pictet–Spengler reaction, 
Radical cyclization, Ribisins, Smiles rearrangement, Suzuki–Miyaura cross-coupling reaction 
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1. Introduction
The alkaloid (–)-galanthamine (a.k.a. galantamine, 1) has been obtained from a variety of 
plant sources including Caucasian snowdrops (Galanthus woronowii), the summer snowflake 
(Leucojum aestivum), the wild daffodil Narcissus pseudonarcissus and the Red Spider Lily 
(Lycoris radia).1 Various mythologies suggest that crude extracts of such plants have been used 
for millennia to treat a range of ailments but it was only in 1950 that a rather more specific 
report seems to have emerged on the utility of these materials. In particular, at this time a 
Bulgarian pharmacologist was supposed to have noted that rural populations in certain parts of 
Eastern Europe would rub snowdrops on their foreheads to alleviate headaches.1a,d Within a few 
years, and perhaps prompted in part by these observations, Russian researchers extracted (–)-
galanthamine from Galanthus woronowii and were using it as a treatment for poliomyelitis, and 
seemingly to considerable effect.1a,d,2 At about the same time it was also being employed in 
anaesthesiology as a curare reversal agent, as a treatment for myasthenia (an autoimmune or 
congenital neuromuscular disease) and myopathy (a muscular disease resulting in weakness) as 
well as for sensory and motor dysfunctions associated with CNS disorders.1,3 However, it was 
the recognition that this alkaloid is a selective, competitive and reversible inhibitor of the 
enzyme acetylcholinesterase (AChE)1 that can cross the blood-brain barrier that propelled it into 
the limelight and thence into the clinic (in the US, Europe and Japan) as an agent for the 
symptomatic treatment of mild to moderate vascular dementia and Alzheimer’s disease.1,4 It has 
also been shown to act at the nicotinic acetylcholine receptor as an allosteric potentiation ligand 
with the result that it triggers increased release of dopamine, serotonin, γ-aminobutyric acid, 
norepinephrine and related neurotransmitters.1,5 The HBr salt of compound 1 (marketed as, inter 
alia, Nivalin, Razadyne and Reminyl) is now considered a frontline drug in helping combat the 
27
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emerging dementia pandemic. Various recent clinical case studies stand as testimony to its 
utility in this regard.6  
 
 
 
 The clinical demand for (–)-galanthamine together with the erosion of habitat of at least 
some of the source plants has created supply issues.1b,7 As a result new means of production of 
the alkaloid are being sought with in vitro cultivation and pathway optimization techniques7 (in 
which the biosynthetic pathway8 is “tweaked”) being prominent amongst these. To date no 
industrially applicable (cost-effective) chemical synthesis of compound 1 has emerged9 that 
addresses this supply problem although a pilot scale and biomimetic production process has 
been reported.10  
 As is almost invariably the case with natural-product based drug development programs, 
significant effort has been directed towards the identification of analogues of (–)-galanthamine 
with improved efficacy and/or reduced side effects (compound 1 causes, inter alia, 
gastrointestinal problems). Such studies, which are now assisted by high-resolution X-ray 
structures of AChE/1 and related complexes,11 have involved traditional medicinal 
chemistry,1b,12 sophisticated QSAR analyses,13 “biomimetic diversity-oriented synthesis”14 and 
related techniques exploiting various multicomponent reactions.15 In parallel, natural products 
chemists continue to screen extracts from various biological sources for new metabolites 
(notably alkaloids) that display AChE inhibitory properties.16  
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 The circumstances described in the preceding paragraphs when considered together with 
the intriguing molecular architecture of (–)-galanthamine have, unsurprisingly, prompted a 
significant number of research groups to undertake total synthesis studies. In order to put our 
own group’s contributions to this area into an appropriate context, some commentary on other 
studies of the synthesis of galanthamine is warranted. This is provided in the following section.   
 
2. Studies on the Synthesis of Galanthamine – A Potted History 
 In 1960 Barton and Kirby reported17 the first synthesis of (±)-galanthamine and thereby 
confirming its structure. This involved a biomimetic but low yielding (1.4%) intramolecular 
phenolic oxidative coupling of compound 2 (Scheme 1) to generate the spiro-fused dienone 3 
that engages in a reversible intramolecular hetero-Michael addition reaction to give narwedine 
(4) that was itself converted into (±)-galanthamine on exposure to LiAlH4.17  
 
 
SCHEME 1: The Barton–Kirby Biomimetic Synthesis of Narwedine (4). 
 
 Various improvements to this process have been achieved by using, inter alia, slightly 
different substrates and/or other oxidants (notably hypervalent iodine compounds) in the pivotal 
coupling step.18 An asymmetric variant of this process has been introduced19 although this is not 
essential because racemic narwedine is resolved, through crystallization, into its (–)-form in the 
presence 1% (+)-galanthamine (viz. ent-1).20,21 Reduction of (–)-narwedine with L-Selectride 
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then affords (–)-galanthamine in 99% yield.20,22 In 2009 Magnus and co-workers reported23 a 
somewhat related synthesis of compound 1 in which an intramolecular phenol alkylation was 
applied to a biphenyl-containing substrate and thus affording a spiro-dienone that could be 
converted, over three simple and efficient steps, into (±)-narwedine (4).  
 The ABC-ring system of (–)-galanthamine has also been constructed using 
intramolecular Heck reactions with a particularly notable and early example being described by 
Trost and Toste.24 Specifically, they showed (Scheme 2) that on exposure to 15 mol % 
Pd(OAc)2, 15 mol % of the ligand diphenylphosphinopropane (dppp) and 3 mole equiavlents of 
Ag2CO3 the allylic ether 5, itself the product of an asymmetric allylic alkylation (AAA) 
reaction, was converted into compound 6 (91%). This was then carried forward over a further 
four steps into (–)-galanthamine.  
 
 
SCHEME 2: The Pivotal Intramolecular Heck Reaction Associated with the Trost/Toste 
Synthesis of (–)-Galanthamine (1). 
 
 Several variations on this type of approach have been reported25 as have other ingenious 
schemes26,27 leading to compound 1, the corresponding racemate or its optical antipode (viz. ent-
1). Of particular relevance to the present discussion is Chida’s synthesis of (+)-galanthamine 
from D-glucose using a combination of type-II Ferrier and Claisen rearrangement protocols. 
Details of this elegant work have recently been described in a personal account27b and are not, 
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therefore, presented here. It is, however, appropriate to note that, like Chida’s, a significant 
fraction of our research effort has been devoted to devising means by which certain chiral-pool 
derived starting materials can be elaborated to a range of biologically active natural products. 
The chirons we have chosen to investigate for this purpose, including in developing certain of 
the various approaches to galanthamine reported here, are the cis-dihydrocatechols of the 
general form 7.28 Many of these compounds are available in kilogram quantities and essentially 
enantiomerically pure form through the whole-cell biotransformation of the corresponding 
aromatic, e.g. bromobenzene.  
 
 
 
3. A First-Generation Chemoenzymatic Synthesis of (+)-Galanthamine 
 Our initial foray into the area of galanthamine synthesis was motivated a desire to see if 
we could parlay our knowledge28e of the chemistry of cis-1,2-dihydrocatechols into a reaction 
sequence that would allow for the elaboration of compound 7 (X = Br) into the A-ring of (+)-
galanthamine (ent-1). This non-natural form of the alkaloid was targeted in the first instance 
simply because this seemed to “map” more appropriately onto the chirality of the proposed 
starting material. That having been said, the compound ent-7 (X = Br) is also available28e 
(although it is not quite as accessible as its enantiomer) and so any success achieved in gaining 
access to (+)-galanthamine from cis-1,2-dihydrocatechol 7 (X = Br) automatically “translates” 
into a means for obtaining the natural product, viz. compound 1.  
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 The opening steps of our ultimately successful synthesis of (+)-galanthamine (ent-1)29 
from metabolite 7 (X = Br) are shown in Scheme 3 and involved the initial conversion of the 
latter into the corresponding and well known acetonide 8.  
 
 
SCHEME 3: Opening Stages of a First-Generation Chemoenzymatic Synthesis of  
(+)-Galanthamine (ent-1). 
 
 This step provides a trap for young players in that if not carried out carefully an almost 
explosive acid-catalyzed dehydration and re-aromatization reaction of the substrate and/or 
product occurs. Regio- and stereo-controlled epoxidation at the β-face of the non-halogenated 
double bond within compound 8 is readily effected using m-chloroperbenzoic acid (m-CPBA) 
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and the epoxide 9 (90% over two steps) so-formed is then engaged in a completely selective and 
mineral acid catalyzed ring opening reaction with acetic acid serving as the nucleophile so as to 
generate alcohol 10 (81%). This is immediately protected as the corresponding MOM-ether 11 
(91%) (forcing conditions required) and the associated acetate group hydrolyzed to the 
corresponding alcohol 12 (95%). This cyclohexenyl bromide participated in a Suzuki–Miyaura 
cross-coupling reaction with the readily obtained boronic acid 13 to afford the arylated 
cyclohexene 14 (98%). The single free hydroxyl group embedded within this last compound was 
engaged in a Mitsunobu reaction using α-chloroacetic acid as the nucleophile and the product 
ester immediately hydrolyzed using potassium carbonate in methanol to give the epimeric 
compound 15 (93% over two steps).  
 The next and particularly crucial phase of the synthesis was the construction of the 
quaternary carbon center associated with galanthamine as well as the formation of the furan or B 
ring. While it took sometime to establish the right sequence of reactions to realize such an 
outcome, this was eventually achieved in just three steps (Scheme 4), the first being the 
engagement of the allylic alcohol moiety within compound 15 in an Eschenmoser–Claisen (EC) 
rearrangement by treating it with the dimethyl acetal of N,N-dimethylacetamide in refluxing 
toluene for seven days. The amide 16 (89%) so-formed now embodies the requisite quaternary 
carbon center with the illustrated configuration and thus dictating that it is the (+)-form of 
galanthamine that will ultimately be obtained by this route.  
33
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SCHEME 4: Establishing the Quaternary Carbon Center and B-ring of (+)-Galanthamine 
 
 Notably, the epimer of and precursor to allylic alcohol 15, namely compound 14, also 
engages in an analogous but even more sluggish EC rearrangement and thereby delivering the 
epimer of compound 16. In principle, this epimer could serve as a precursor to (–)-
galanthamine. Treatment of compound 16 with molecular bromine in toluene resulted in three 
distinct events: (i) cleavage of both the isopropyl aryl ether and acetonide residues; (ii) a bromo-
etherification reaction (to form the desired B-ring) and, (iii), a SEAr reaction at the electron-rich 
arene moiety. As a result compound 17 (69%) was obtained but on attempting to reductively 
debrominate it through exposure to dihydrogen in the presence of 10% Pd on C and potassium 
carbonate then, inter alia, a transannular etherification reaction took place and so producing the 
undesired 7-oxabicyclo[2.2.1]heptane 18 (67%). However, through the simple expedient of 
treating substrate 15 with molecular bromine in the presence of a mixture of toluene and acetone 
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then the acetonide residue could be retained while the isopropyl aryl ether was still cleaved and 
with the product phenol participating, once again, in a bromoetherification reaction involving 
the pendant double bond of the A-ring and so affording the dibromide 19 (93%). Reductive 
debromination of this last compound now proceeded as desired to afford compound 20 (68%) 
that embodies the desired ABC-ring substructure of target ent-1.  
 The next phase of what was rapidly becoming a distinctly lengthy synthesis was the 
replacement of the now “longstanding” acetonide residue within the developing A-ring by a 
double bond residue. As is almost inevitable, a Corey–Winter olefination protocol was 
employed for this purpose. Thus, the free hydroxyl group within the A-ring of compound 20 
was protected (Scheme 5) as the corresponding acetate 21 (90%) and the acetonide residue 
within the latter was cleaved and the diol so-formed immediately converted into the 
corresponding cyclic thiocarbonate, 22 (99%), by treating it with thiophosgene in the presence 
of 4-(N,N-diemthylamino)pyridine (DMAP). Exposure of compound 22 to a large excess of 
trimethylphosphite in toluene then gave the desired olefin 23 (72%).  
 
 
SCHEME 5: Installing the A-Ring Double Bond 
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 The heroic end-game “played” by Dr Xinghua Ma in completing our first generation 
chemoenzymatic synthesis of (+)-galanthamine is outlined in Scheme 6 and involved, as the first 
steps, subjecting compound 23 to an initial cleavage of the A-ring acetate group and 
reprotection of the resulting alcohol 24 (95%) as the corresponding tert-butyldiphenylsilyl 
(TBDPS) ether 25 (95%). This was a necessary prelude to using Superhydride™ to reduce the 
associated amide residue to the corresponding 2°-alcohol and thus forming compound 26 (95%). 
A two-pot reaction sequence followed wherein the alcohol 26 was oxidized to the corresponding 
aldehyde (using the Dess–Martin periodinane – DMP) that was itself subjected to a free-radical 
bromination with the product acyl bromide then being trapped in situ by added methylamine. 
This afforded the mono-N-methylated amide analogue 27 (76%) of precursor 25. Desilylation of 
compound 27 using tetra-n-butylammonium fluoride (TBAF) and engagement of the product 28 
(85%) in a Pictet–Spengler reaction using paraformaldehyde in trifluoroacetic acid (TFA) 
resulted in closure of the D-ring and, thereby, formation of the lactam 29 (88%). The final two 
steps were devoted to establishing the correct stereochemistry of the A-ring hydroxyl group and 
this required engagement of compound 29 in a Mitsunobu reaction using α-chloroacetic acid as 
the nucleophile and then subjecting the product ester/lactam 30 (93%) to a “global” reduction 
using LiAlH4 and so providing (+)-galanthamine (ent-1) (85%), the high-field NMR spectral 
data for which matched those recorded on an authentic sample of its enantiomer.  
 
36
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SCHEME 6: The End-Game Associated with the First-Generation Chemoenzymatic Synthesis 
of Galanthamine (ent-1). 
 
 Clearly there are many deficiencies associated with this synthesis. While it could be 
certainly be tweaked in various ways (perhaps most notably by “fiddling” with protecting group 
regimes), the more important aspects of this work were the lessons learnt en route. In particular, 
the EC rearrangement reaction “shone through” as an almost uniquely effective means for 
establishing the quaternary carbon center of (+)-galanthamine from a precursor 2-cyclohexen-1-
ol. This lesson came to the fore in our next and almost accidentally discovered second-
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generation chemoenzymatic approach to galanthamine. How all this unfolded is described in the 
following section.  
 
4. Total Syntheses of Members of the Ribisin Class of Neurologically Active Natural 
Product Inspire a Second-Generation Chemoenzymatic Approach to 
(+)-Galanthamine 
 4.1  The Ribisins 
 In 2012 Fukuyama and co-workers reported30 the isolation of four new and structurally 
novel natural products from the fungus Phellinus ribis, the fruiting bodies of which are 
employed in traditional Chinese medicine for enhancing immunity and treating gastrointestinal 
cancer. On the basis of various spectroscopic analyses the benzofuran structures 31, 32, 33 and 
34 were assigned to these compounds that were named ribisins A–D, respectively.  
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 It was also noted that at 1 to 30 μM concentrations these natural products promote 
neurite outgrowth in NGF-mediated PC12 cells and could thus represent new leads for 
developing drugs to treat various neurodegenerative diseases. 
 The resemblance of the polyoxygenated rings of the ribisins to the cis-1,2-
dihydrocatechols of the general form 7 immediately struck us and prompted consideration of 
methods by which we could effect the necessary conversion. Our initial efforts31 were focused 
on synthesizing the structure, 33, assigned to ribisin C since this was the most active of the four 
compounds in the PC12-based assay. The reaction sequence used to obtain this compound is 
shown in Scheme 7.  
 
 
SCHEME 7: A Chemoenzymatic Synthesis of the Structure 33, Assigned to Ribisin C 
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 As with our first-generation synthesis of (+)-galanthamine, the reaction sequence leading 
to compound 33 started with the same cis-1,2-dihydrocatechol and this was first converted into 
the previously described epoxide 9. Opening of this with aqueous HCl then provided the 
expected trans-diol 35 (63%) that was subjected to a two-fold methylation reaction and so 
generating compound 36 (90%) embodying the two trans-related methoxy residues associated 
with target compound 33. Hydrolysis of the acetonide residue within bis-O-methyl ether 36 then 
afforded the cis-diol 37 (90%) that participated in a Suzuki–Miyaura cross-coupling reaction 
with the commercially available o-hydroxyphenyl boronic acid ester 38. As a result the 
cyclohexannulated benzofuran-type system 39 (24%) was obtained and this presumably arises 
from the spontaneous cycloetherification of the initially formed cross-coupling product. In 
anticipation of introducing a hydroxyl group as a precursor to the required ketone carbonyl, 
alcohol 39 was protected as the corresponding α-chloroacetate 40 that we knew, from previous 
experience, could be removed under exceptionally mild conditions. Treatment of cyclohexene 
40 with m-CPBA afforded the benzofuran 41 (49% from 39) that presumably arises through 
rearrangement of the initially formed epoxide, a process driven by rupture of the strained three-
membered ring and accompanying formation of the aromatic heterocycle associated with the 
observed product. Swern of oxidation of the alcohol residue within compound 41 and cleavage 
of the α-chloroacetate moiety within the product ketone using zinc acetate in methanol then 
gave target 33 (47% from 41), the structure and relative stereochemistry of which were 
established by single-crystal X-ray analysis. While the 1H and 13C NMR data acquired on 
compound 33 matched those reported for ribisin C, the similar magnitudes but opposite signs 
associated with the specific rotations of these two materials clearly indicated that the absolute 
stereochemistry of the natural product had been assigned incorrectly.  
40
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 As a result of the outcome just described, and because of a desire to acquire biologically 
active materials for testing for their neurite outgrowth promoting properties, we rapidly 
established31 a reaction sequence that enabled the synthesis of compound ent-33 and thus 
determining that this is the true structure of ribisin C. Once again, the staring material used for 
this purpose was the cis-1,2-dihydrocatechol 7 (X = Br). Using related chemistries we also 
prepared compounds 31, 32 and 34 and thereby establishing32 that the first and third of these do 
indeed represent the structures of ribisins A and D. Such work also enabled us to identify the 
true constitution of ribisin B as being represented by structure 42 and not 32. The substantial 
collection of compounds produced during the course of our work on the synthesis of the ribisins 
has been submitted for testing in a range of relevant assays.  
 
 
 
 
 4.2  A Second-Generation Chemoenzymatic Approach to the Synthesis of (+)-Galanthamine  
 Rather belatedly, it occurred to us that our synthetic work on the ribisins might provide a 
means of readily assembling the ABC-ring system associated with galanthamine and perhaps 
even the alkaloid itself. There certainly appears to be some validity to this proposition as 
evidenced by the completion of the reaction sequence shown in Scheme 8.33  
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SCHEME 8: A Second-Generation Chemoenzymatic Approach to (+)-Galanthamine (ent-1). 
 
 Once again, the reaction sequence starts with the cis-1,2-dihydrocatechol derived from 
the whole-cell biotransformation of bromobenzene, viz. compound 7 (X = Br), but the derived 
epoxide 9 is now opened with p-methoxybenzyl alcohol (PMBOH) in the presence of BF3•Et2O 
to give the tri-protected bromoconduritol 43 that upon exposure to pyridinium 
p-toluenesulfonate (PPTS) in methanol affords its mono-protected counterpart 44 (70% from 9). 
Reaction of this last compound with 2,2,3,3-tetramethoxybutane in the presence of catalytic 
quantities of p-TsOH then provided the Ley-type34 bis-ketal 45 (86%) in which, by virtue of the 
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operation of the anomeric effect, completely selective protection of the vicinally-related and 
trans-oriented hydroxyl groups within substrate 44 had occurred together with cleavage of the 
PMB ether moiety. Suzuki–Miyaura cross coupling of compound 45 with the arylboronic acid 
ester 46, a compound that is readily obtained in a one-pot process from o-methoxyphenol using 
a protocol described by Hartwig,35 afforded the anticipated product (60%) that readily engaged 
in an intramolecular Mitsunobu reaction to give the targeted ABC-ring containing product 47 
(96%). This last compound might have been expected to be vulnerable to double-bond migration 
and thereby forming the isomeric and fully aromatic benzofuran. Nevertheless, and gratifyingly, 
it engaged in a very efficient and remarkably facile EC rearrangement reaction on being heated 
with dimethyl acetal of N,N-dimethylacetamide and so affording compound 48 in 86% yield. A 
distinctly cumbersome four-step sequence closely related to that deployed in the end-game 
associated with our first generation galanthamine synthesis (Scheme 6) was then used to convert 
this N,N-dimethylacetamide derivative into its mono-methylated counterpart 49 (73% over four 
steps). This last compound participated in a Pictet–Spengler reaction on treatment with 
paraformaldehyde in TFA, a process that was accompanied by cleavage of the associated bis-
ketal moiety, and so forming the galanthamine analogue 50 (47%). 
 Efforts are now underway to effect the conversion of lactam 50 into (+)-galanthamine 
(ent-1). Interestingly, molecular docking studies similar to those reported previously36 suggest 
this compound (viz. 50) should bind at the active site of AChE with similar affinity to (–)-
galanthamine itself. This is because the cyclohexene C-ring (of 50) is oriented almost identically 
to its counterpart in (–)-galanthamine and so maintaining an architecture complementary to that 
of the active site of AChE and whereby it stacks against the indole ring of Trp84. Whether or 
not this rather tantalizing prediction is indeed correct remains to be tested experimentally. 
43
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5. An Abortive, Radical-Based Approach to (±)-Galanthamine 
 During the course of studies focused on the synthesis of certain crinine alkaloids we 
conceived of another and now exceptionally concise route to the ABC-ring substructure of 
galanthamine and hoped that the product so-formed would be capable of elaboration in such a 
way that the nitrogen-containing D-ring of the alkaloid could be annulated to it. The steps 
associated with the first stage of this study36 are shown in Scheme 9 and involved a thermally-
induced electrocyclic ring-opening of the readily available C3-oxygenated 6,6-
dibromocyclopropane 51 and engagement of the product dibromocyclohexene 52 in an SN2 
reaction with phenol 53 to give the allyl aryl ether 54 (ca. 80% from 51). This last compound  
 
 
SCHEME 9: A Concise, Cyclopropane-Based Route to the ABC-Ring Substructure of 
Galanthamine 
 
then participated in a Pd-catalyzed and intramolecular arylation reaction under conditions 
developed by Willis et al.37 to give the tetrahydrodibenzo[b,d]furan 55 (ca. 65%). Reductive 
amination of compound 55 with N-methyl-2-aminoethanol in the presence of sodium 
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borohydride gave the desired 3°-amine 56, the hydroxyl group within which was subjected to an 
Appel reaction using Ph3P/CBr4 and so affording bromide 57 (61% over two steps).  
 With compound 57 to hand we hoped that on treating it with tri-n-butyltin hydride this 
would form, through homolysis of the associated C–Br bond, the corresponding 1°-radical that 
would, in turn, engage in a 7-exo-trig cyclization reaction and so generating the D-ring of 
galanthamine. Alas, this was not to be. So, when bromide 57 was subjected to the relevant 
conditions two unexpected events took place (Scheme 10). First of all, the initially formed 
radical 58 participated in a spirocyclization onto the pendant and electron-rich arene residue and 
the resulting and extensively delocalized radical 59 then fragmented to give the nitrogen-
stabilized congener 60 (overall a radical-based Smiles rearrangement) that now engaged in an 
8-endo-trig radical cyclization to give isomer 61. 
 
 
SCHEME 10: The Unexpected Radical-Based Reactions of the Tricyclic Iodide 57 – Formation 
of the D-Ring Galanthamine Isomer 63. 
57
MeO
O
TBSO
N
Me
Br
n-Bu3SnH
58
MeO
O
TBSO
N
Me
•
59
MeO
O
TBSO
•
60
MeO
O
TBSO
N
Me•
N
Me
61
MeO
O
TBSO
N
Me
•
step 1 of radical 
Smiles reaction
step 2 of radical 
Smiles reaction
8-endo-trig
cyclization
62
MeO
O
HO
N
Me n-Bu3SnH
63
MeO
O
HO
N
Me – H•
then TBAF
then TBAF
45
 22 
 This latter mode of cyclization is presumably driven by the formation of a benzylic 
radical rather than a homobenzylic one (that would have arisen from the hoped for but 
unobserved 7-exo-trig cyclization process). Reduction of radical 61 would then deliver, after 
desilylation with TBAF, the observed dihydrobenzofuran 62 (<1%) while loss of a hydrogen 
atom from the former species would afford, again after a TBAF treatment, benzofuran 63 
(12%). The structures of products 62 and 63 were established by single-crystal analyses. Given 
the latter is a D-ring isomer of galanthamine we wondered if it would act as an inhibitor of 
AChE. Molecular docking studies predicted it wouldn’t because of the distinctly different 
molecular shapes of the two compounds and in the event this prediction was borne out – 
tetracycle 63 is not an effective inhibitor of the enzyme.36  
 
6. Doing Things the Hard Way – De Novo Construction of the Aromatic C-Ring as a 
Focal Point   
 In 2010 we reported38 that various nitrogen-linked 1,6-enynes including compound 64 
engage in rather efficient palladium-catalyzed intramolecular Alder-ene (IMAE) reactions so as 
to generate angularly substituted polyhydroindoles such as 65. Subsequently, we exploited this 
kind of transformation as a key step in the synthesis of the racemic modification of the crinine 
alkaloid hamayne.39 A notable feature of these processes is the need to “cap” the alkyne residue 
of the substrate with, for example, a methyl group (as seen in 64) so as to prevent competing 
hetero-dimerization reactions. 
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 In seeking to understand the scope and limitations of such IMAE-based processes we 
wondered whether or not the corresponding oxygen-linked systems would undergo an analogous 
isomerization and thus affording angularly substituted perhydrobenzofurans related to the AB-
ring system associated with galanthamine. It quickly became apparent that this was so as 
illustrated by the successful execution of the reaction sequence shown in Scheme 11.40 Thus, the 
commercially available monoketal, 66, of cyclohexane-1,4-dione was subjected to an α-
oxidation protocol developed by Tomkinson and co-workers41 and thus affording, in racemic 
form, the acyloin derivative 67 that was converted into the corresponding enol triflate 68 (73% 
over two steps) under standard conditions. Using a very effective procedure developed by 
Kamatani and Overman,42 this last compound could then be cross-coupled with an organoborane 
derived from enamine 69 and so affording the β-aminoethyl-substituted compound 70 (79%). 
Saponification of the benzoate residue within the last compound proceeded uneventfully to give 
the corresponding alcohol 71 (71%) that was immediately reacted with propargyl bromide in the 
presence of sodium hydride to give the anticipated ether 72 (89%), the terminal alkyne moiety 
of which was “capped” by successive treatment with n-BuLi then paraformaldehyde and so 
giving the 1°-alcohol 73 (ca. 85%). This was then acetylated to give ester 74 (93%). 
Gratifyingly, on subjection to the types of conditions we have used previously for effecting 
IMAE reactions of related but somewhat simpler substrates, compound 74 could be efficiently 
isomerized to the benzofuran derivative 75 (71%). 
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SCHEME 11: The IMAE Route to the AB-Ring System of Galanthamine. 
 
 Compound 75 embodies the A and B rings of galanthamine as well as an angular 
substituent that could serve as a precursor to the D-ring. Of course, a significant challenge 
associated with seeking to exploit the results shown in Scheme 11 concerns the matter of 
incorporating the aromatic C-ring, a structural element that has been present from the outset in 
all previous syntheses of this alkaloid. As such, we became intrigued by the possibility that we 
could benzannulate compound 75 in some way and so assemble the requisite ABC-ring 
substructure by such means. Provided relevant protocols could be identified then novel C-ring 
variants of galanthamine might become accessible using this type of approach. In the event, and 
66 67 68
72 71 70
OO
O
OO
O
BzO
OO
BzO
OTf
OO
BzO
N
Ts
Me
OO
HO
N
Ts
Me
OO
O
N
Ts
Me
H
73 74 75
OOOO
O
N
Ts
Me
HOH2C
OO
O
N
Ts
Me
AcOH2C
O
OAc
N
Me
Ts
MeNHOBz
DMSO
LiHMDS
PhNTf2
N
Ts
Me
9-BBN then Pd[0]
69
aq. NaOHHCCCH2Br
NaH
(H2CO)n n-BuLi
Ac2O Pd[0]
48
 25 
as shown in Scheme 12, a suitable benzanulation protocol was identified and a synthesis of (–)-
galanthamine thereby established. Thus, treatment of allylic acetate 75 with a Pd[0] catalyst in 
the presence of the base DBU resulted in elimination of the elements of acetic acid and, thereby, 
formation of the electron-rich and semi-cyclic 1,3-diene 76 (85%). This was readily engaged in 
a regio-selective Diels–Alder reaction with propynal and the rather unstable primary adduct so-
formed treated, in situ, with manganese dioxide to effect its aromatization and thereby 
generating benzaldehyde 77 (61%). Dakin oxidation of this last compound using m-CPBA and 
cleavage of the resulting formate using potassium carbonate in methanol then gave phenol 78 
(69%) that upon O-methylation afforded ether 79 (quantitative) that now embodies the essential 
“elements” of the ABC-ring substructure of galanthamine. As such it proved to be a relatively 
simple matter to elaborate compound 79 to (±)-narwedine, an established precursor (+)- or (–)-
galanthamine.20 Specifically, then, treatment of this last compound with magnesium turnings in 
methanol resulted in cleavage of the sulfonamide residue and the ensuing 2°-amine 80 (83%) 
was then reacted with ethyl formate to give the expected amide 81 (quantitative). Finally, 
subjection of compound 81 to a modified Bischler–Napieralski reaction using triflic anhydride 
and 2-chloropyridine,43 reduction of the resulting acyliminium ion with NaBH(OAc)3 and a mild 
acidic work-up (to cleave the ethylene ketal moiety) gave (±)-narwedine (4) albeit in an as yet 
unoptimized yield of 24%. 
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SCHEME 12: Assembling the Aromatic C-Ring of Galanthamine Using Diels–Alder 
Cycloaddition Chemistry and Completion of a Synthesis of (±)-Narwedine (4) 
 
7. Conclusions 
 Only one of the synthetic sequences reported above has any reasonable prospect of 
providing an especially useful route to (–)-galanthamine and that is the so-called second-
generation chemoenzymatic approach shown in Scheme 8. This was inspired by our work on the 
ribisins. Of course, and almost by definition, this chemistry was informed by the lessons learnt 
during the course of developing its first-generation counterpart. Currently the IMAE approach to 
the title alkaloid, as outlined in Schemes 11 and 12, is too long to be a useful means for 
obtaining significant quantities of galanthamine. However, and regardless of whether 
75
OO
O
OAc
N
Me
Ts
Pd[0]
76
OO
O N
Me
Ts
77
OO
O N
Me
Ts
OHC
DBU
OHC
then MnO2
80
OO
O NH
Me
79
OO
O N
Me
Ts
78
OO
O N
Me
Ts
HOMeOMeO
(i) m-CPBA
(ii) K2CO3, MeOH
MeI, NaH
81
OO
O N
Me
MeO
ethyl formate
CHO
O
N
MeO
O
Me
4
(i) Tf2O, 2-chloropyridine
(ii) NaBH(OAc)3
(iii) aq. HCl
Mg
MeOH
50
 27 
refinements of it give any cause to change this assessment, it offers the capacity to construct 
novel aromatic C-ring analogues that might act as even more effective AChE inhibitors than 
(−)-galanthamine. As such it provides a quite distinct, if not a unique approach to the 
galanthamine framework. 
 In each of the instances discussed above, the successful construction of the D-ring 
associated galanthamine has relied on engaging an angular β-aminoethyl moiety (located at the 
junction between the A and B rings) in a Pictet–Spengler or Bischler–Napierlaski reaction. In 
two instances, the precursor to this moiety is obtained through an EC rearrangement reaction 
and several steps were necessary to convert the initially formed N,N-dimethylamide moiety into 
its mono-methyl counterpart. Clearly, then, there would be great merit in identifying a 
replacement for the dimethyl acetal of N,N-dimethylacetamide used in the EC rearrangement 
reaction with a species that generates the required mono-methylated amide directly. An even 
more attractive possibility would be to identify one that generates an acyl imminium ion 
immediately after the EC rearrangement and that thus engages in an in situ cyclization reaction 
to produce the D-ring directly. Such possibilities are under active investigation in our 
laboratories. 
 Another focus of efforts to extend our work in this area will be generating compounds 
such as 50 and the diol, 82, derived from hydrolysis of bis-acetal 48. These readily accessible 
systems could be regarded as hybrids of the ribisin and galanthamine structures44 and might be 
expected to act as effective inhibitors of AChE. Certainly, as noted above, molecular docking 
studies suggest compound 50 should be active in this regard.  
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 Regardless of the outcomes of the studies foreshadowed immediately above, it is clear 
that the intriguing molecular architecture of galanthamine has prompted a significant number of 
research groups to develop new strategies and tactics for its synthesis. Not all of these have been 
successful but in essentially every instance important lessons have been learnt along the way 
and these may well provide solutions to other, yet to be recognized challenges.  
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Abstract
The whole-cell biotransformation of  mono-nuclear aromatic compounds using certain genetically-
engineered micro-organisms that over-express the enzyme toluene dioxygenase (TDO) allows for the 
large scale production of  compounds known as cis-1,2-dihydrocatechols.  These metabolites, which 
are normally obtained in enantiomerically pure form, can be manipulated, by chemical means, in a 
range of  distinct (and predictable) ways with the result that they have proven to be especially versatile 
starting materials for the assembly of  a range of  structurally diverse and biologically active systems. 
Herein we describe, on a case-by-case basis, the recent applications of  various combinations of  
TDO-mediated and chemical steps in so-called chemoenzymatic total syntheses of  a range of  organic 
compounds with therapeutic potential.
Introduction
Chemical space (viz. the space spanned by all possible small molecules and chemi-
cal compounds) is essentially infinite.1  The 
challenge, then, has been to access the most 
meaningful or useful parts of  it.  Nature 
has provided critical inspirations.  So, 3.8 
billion years of  evolution has produced a 
global molecular library of  unsurpassed size, 
structural diversity and functional value – 
our planet’s chemome.2,3,4  Humankind has 
sought to “mine” this bioactive molecule 
resource for its benefit and such endeav-
ors have been spectacularly successful as 
evidenced by the existence of  the remark-
able array of  medicines, materials and agro-
chemicals that underpin society as we know 
it today.  As a result the world we live in has 
been transformed.  This is evidenced by our 
exploitation of  drugs with household names 
such as penicillin, morphine and Taxol®. 
There are many additional but perhaps less 
well-known examples.  For instance, organ 
transplant surgery would fail completely 
without the post-operative application of  
the chemome-derived anti-rejection drugs 
such FK506 and cyclosporin A.5  Similarly, 
a significant number of  agents that control 
agricultural pests, and so helping to ensure 
both the security and efficiency of  world 
food production, have also come from 
Nature/the global chemome.6
Despite such successes, enormous chal-
lenges remain.  So-called unmet scientific 
and societal needs include those arising 
from the development of  resistance to cur-
rent therapies (perhaps seen most promi-
nently in the area of  antibiotics7) and, in the
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agrochemical sector, pest-control agents.8 In 
addition, there is a desperate need for small 
molecule entities that provide, inter alia, 
effective control of neurodegenerative 
diseases and diabetes in a globally aging 
population, for ones that treat certain types of 
refractory cancers and for others that 
effectively modulate mammalian and other 
immune systems. 
After forays into areas such as 
combinatorial chemistry,9 major players in the 
pharmaceutical industry, sometimes in 
partnerships with Government-funded 
agencies, are returning to interrogation of the 
chemome (or at least portions thereof) as a 
means for productively probing chemical and 
thence biological space.10  There are a number 
of reasons for such moves10 including the 
recognition that, for example, the current 
pharmaceutical industry is built on <10% of 
the biosynthetic capacity of the microbial 
world, one that continues to show a 
remarkable ability to deliver biologically 
relevant small molecules.11 
Occurring in tandem with these trends is 
the emergence of a plethora of new 
techniques and concepts concerned with the 
generation of biologically relevant molecular 
diversity involving the use of, inter alia, 
techniques of de novo biosynthesis for 
producing functionally annotated chemome 
components,12 the creation of new metabolic 
pathways,12 synthetic fermentation,13 and 
activity-directed synthesis.14  Simultaneously, 
new synergies are being recognized between 
in vitro, in vivo and in silico studies of drug 
metabolism 15 and thus allowing for much 
more efficient/rapid assessments of the utility 
of certain compounds as molecular probes, 
drugs and/or agrochemicals. 
The development of new methods and 
protocols for effecting the chemical synthesis 
of biologically active natural products and 
various analogues remain important parts of 
the range of activities concerned with 
exploiting components of the global 
chemome for therapeutic and other purposes. 
At least two motivations drive such efforts, 
the first being the need to address issues of 
supply.  Thus, it is often the case that 
secondary metabolites2 are only available in 
miniscule amounts from their natural source 
with the result that insufficient material is 
available for development purposes. 
Chemical synthesis is often the best method 
for addressing such issues.  Secondly, truly 
useful chemical syntheses offer the capacity to 
generate analogues of the natural product that 
would not normally be available through 
manipulation of the natural product itself.  
This article, which is based on a lecture 
presented by the senior author at the 
University of Sydney as part of the RSNSW’s 
2014 Liversidge Award, details work being 
undertaken at the Australian National 
University on the exploitation of certain 
chemoenzymatic methods for the synthesis of 
biologically active natural products and their 
analogues.  The work is presented according 
to the class of natural product being targeted 
as well as the structural and chemical 
relationships between them. 
Results and discussion 
The term chemoenzymatic synthesis used in 
this article, and elsewhere,16 refers to the 
assembly of target compounds using a 
combination of chemical and enzymatic 
techniques.  While there are many variations 
on this theme that reflect the extraordinarily 
diverse range of chemical and enzymatic 
transformations available these days, the 
specific form of the latter that applies here 
involves the whole-cell biotransformation of 
a range of simple and readily available 
aromatic compounds of the general form 1 
(Scheme 1) into the corresponding cis-1,2-
dihydrocatechols (2).16  When genetically 
engineered micro-organisms such as E. coli 
JM109 (pDTG601)17 are used for such 
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purposes, these metabolites can be readily 
produced at kilogram scales and are often 
obtained in >99.95 enantiomeric excess (ee). 
In the illustrated cases the enzyme 
responsible for these conversions is toluene 
dioxygenase (TDO) but a number of related 
ones are known including biphenyl 
dioxygenase, naphthalene dioxygenase and 
toluate dioxygenase.  The end result is that a 
remarkable suite of cis-1,2-dihydrocatechols 
and related metabolites is known - these 
number in the many hundreds at the present 
time.16c  Given the capacities to produce 
numerous mutants, and thus expand the 
range of substrates that can be 
biotransformed, the possible extensions of 
such processes would appear to be vast.  A 
further fascinating aspect of them is the 
“chemoselectivities” they can display.  So, for 
example, styrene (1, X = CH=CH2) is 
converted into the triene 2 (X = CH=CH2), a 
process wherein the aromatic ring is oxidised 
in preference to the exocyclic olefin, a 
functional group selectivity that cannot be 
achieved by any of the strictly chemical 
methods known at the present time.18 
Scheme 1 
The utility of the cis-1,2-dihydrocatechols (2) 
as starting materials in chemical synthesis has 
taken some time to be recognised in a 
broader sense.  Various groups, especially 
those led by Ley in the UK19 and Hudlicky in 
North America,16a,d have carried out the 
pioneering work in the area.  Such studies 
established the reactivity “patterns” shown in 
Figure 1 as well as attendant hazards arising 
from the dehydrative re-aromatisation of 
these substrates20 and the propensity of 
certain derivatives, most notably the 
corresponding acetonides, to engage in 
normally unproductive Diels-Alder (DA) 
dimerization reactions.21 
Figure 1 
Our own contributions in the area began in 
the late 1980s22 and in the intervening period 
we have been able to establish a series of total 
syntheses (Figure 2) that emphasise the 
extraordinary range of natural product targets 
available through manipulation of these 
metabolites.  Some specific examples arising 
from our recent research are discussed on a 
case-by-case basis in the following sections. 
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Figure 2 
 
The Ribisins 
Ribisins A-D were isolated by Fukuyama and 
co-workers from Phellinus ribis (Schmach.) 
Quél (Hymenochaetaceae),23 a fungus used in 
traditional medicine for various purposes.  
Using a range of spectroscopic methods they 
were assigned structures 3-6 (Figure 3), 
respectively, and shown to enhance neurite 
outgrowth in PC12 cells at ca. 1 μM 
concentrations.  As such they have potential 
for development as agents for the treatment 
of certain neurological disorders. 
 
 
 
 
 
Figure 3 
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Given the structural resemblance of the 
polyoxygenated cyclohexane ring of these 
natural products to the cis-1,2-
dihydrocatechols 2 (X = Br) we sought a 
means for effecting the relevant chemical 
conversions.  The route used for establishing 
a synthesis of compound 5, the structure 
assigned to ribisin C and the most active 
compound in the series, is shown in Scheme 
2.24  
 
 
 
 
 
Scheme 2 
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The opening stages of this reaction sequence 
are typical of the manner in which the cis-1,2-
dihydrocatechols can be manipulated and 
involve the initial conversion of compound 2 
(X = Br) into the corresponding acetonide 
and the regio- and stereo-selective 
epoxidation of the latter to give the oxirane 7.  
Treatment of compound 7 with aqueous 
mineral acid resulted in a regioselective ring-
opening reaction to afford the trans-diol 8 that 
could be bis-O-methylated under conven-
tional conditions and the resulting acetonide 
was then cleaved, again under conventional 
conditions, to give the cis-diol 9 that embodies 
most of the key elements of the Eastern 
hemisphere of target 3.  Compound 9 could 
be engaged in a Suzuki-Miyaura cross-
coupling reaction with the commercially 
available boronate ester 10 and two products 
thereby formed, namely the bis-phenol 11 and 
the dihydrobenzofuran 12.  Product 12 is 
presumably formed through cyclisation of the 
initially produced cross-coupling product 
while congener 11 arises from successive loss 
of the elements of water and methanol (no 
particular order implied) from the same 
intermediate.  The lone hydroxyl group within 
compound 11 could be protected as the 
corresponding α-chloro-acetate 13, a 
necessary step because of the looming 
introduction of a second hydroxyl group as 
the precursor to the ketone moiety.  The use 
of the α-chloroacetate as a protecting group 
proved essential as in the final step of the 
reaction sequence attempts to remove the less 
labile parent acetate resulted in 
decomposition of the substrate. Epoxidation 
of compound 13 using m-chloroperbenzoic 
acid (m-CPBA) led, presumably via 
spontaneous rearrangement of the initially 
formed oxirane, to the benzofuran alcohol 14 
that could be oxidised to the corresponding 
ketone 15 under Swern conditions.  Cleavage 
of the α-chloroacetate residue within this last 
compound was accomplished using zinc 
acetate in methanol and thus forming the 
target compound 5.  While all the usual 
spectroscopic data acquired on compound 5 
matched those reported for ribisin C, the 
specific rotation derived from the synthetic 
material was of the same magnitude but the 
opposite sign to that reported for the natural 
product.  The implications are clear – the 
structure of ribisin C is represented by 
structure ent-5 rather than 5. Since we 
required an authentic sample of ribisin C (ent-
5) for biological testing, a synthesis of it was 
pursued.  This could be achieved (Scheme 3) 
using the same starting material and many of 
the same transformations as employed in 
generating its enantiomer (5).  A key step of 
the fourteen-stage reaction sequence involved 
the inversion of configuration at C3 within a 
derivative of compound 2 (X = Br) using 
Mitsunobu chemistry.  As a result ribisin C 
was obtained and all of the derived data, 
including the specific rotation, matched those 
reported for the natural product. 
 
 
 
Scheme 3 
 
Extensions of this sort of chemistry enabled 
the synthesis of all of the structures originally 
assigned to the ribisins and thus revealed that 
while ribisins A and D are constituted as 
originally described23 that attributed to 
congener B is, like C, incorrect.25 The true 
structures of all the ribisins are shown in 
Figure 4 with the corrected stereocentres 
within compounds B (16) and C (ent-5) 
highlighted in red. Extensive biological 
evaluations of the ribisins and the range of 
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congeners prepared during the course of our 
synthetic studies are now underway. 
 
 
 
Figure 4 
 
Analogues of Galanthamine 
Ribisin D (6) bears a “provocative” structural 
resemblance to the ABC ring-system of the 
alkaloid galanthamine (17) that is used in 
many countries for the symptomatic 
treatment of Alzheimer’s disease (Figure 5).26  
As such we were prompted to explore means 
by which the chemistry described above 
could be adapted so as to produce 
compounds bearing greater similarities to 
galanthamine (or, in the first instance at least, 
the enantiomer thereof). 
 
 
 
Figure 5 
 
An efficient reaction sequence leading to a 
dioxygenated derivative of ent-galanthamine is 
shown in Scheme 427 and involves an initial 
reaction of the abovementioned oxirane 7 
with p-methoxybenzyl alcohol (p-MBOH) in 
the presence of boron trifluoride diethyl 
etherate to generate the anticipated addition 
product that upon treatment, in a second 
step, with methanol containing pyridinium p-
toluenesulfonate (PPTS) affords triol 18.  This 
last compound could be converted into the 
corresponding Ley ketal 1928 through 
treatment with 2,2,3,3-tetramethoxybutane 
(2,2,3,3-TMB) in the presence of p-
toluenesulfonic acid (p-TsOH)/trimethyl 
orthoformate (TMOF) and Suzuki-Miyaura 
cross-coupling of this with the boronate ester 
20 (produced directly from o-methoxyphenol 
using a C-H functionalization protocol) 
afforded the arylated cyclohexene 21. This last 
compound that was itself engaged in an 
intramolecular Mitsunobu reaction using di-
iso-propyl azodicarboxylate (DIAD) to afford 
the dihydrobenzofuran 22. 
Despite the potential for aromatisation 
(through simple double-bond migration), 
compound 22 could be engaged in an 
Eschenmoser-variant of the Claisen 
rearrangement reaction using the dimethyl 
acetal of N,N-dimethylacetamide29 and thus 
affording the angularly substituted ABC-ring 
analogue 23 of ent-galanthamine. Over three 
conventional steps compound 23 could be 
converted into its mono-methylated 
counterpart 24.  The last compound 
participated in a Pictet-Spengler cyclisation 
reaction on exposure to a mixture of 
paraformaldehyde and trifluoroacetic acid 
(TFA) and the presumably first-formed 
product 25 underwent cleavage of the Ley 
acetal residue to give diol 26 as the only 
isolable product of reaction.  Compound 26, 
representing a dioxygenated derivative of ent-
galanthamine (ent-17), and various congeners 
that have been prepared using related reaction 
sequences are currently being subjected to 
evaluation as inhibitors of the neurologically 
significant enzyme acetylcholine esterase 
(AChE). 
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Scheme 4 
 
It is worth noting, at this point, that the 
enantiomer of certain of the cis-1,2-
dihydrocatechols described above are also 
available.30  So, for example, biotransform-
ation of p-iodotoluene or p-iodobromo- 
benzene [27a (X = Me) and 27b (X = Br), 
respectively] (Scheme 5) using E. coli JM109 
(pDTG601) affords metabolite 28 that upon 
exposure to dihydrogen in the presence of 
palladium on carbon undergoes 
hydrogenolytic cleavage of the associated C-I 
bond and thus delivering either cis-1,2-
dihydrocatechol ent-2 (X = Me) or ent-2 (X = 
Br). 
 
Scheme 5 
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The Opiates 
Morphine and its congener codeine are 
members of opiate family. They are used 
extensively for the management of pain and 
represent the most widely applied and highest 
grossing medicines in the world today.31 Their 
structural complexity means that for the 
moment, at least, opiates such as morphine 
are obtained from natural sources and then 
derivatized by simple chemical means so as to 
produce related drugs.  Nevertheless, much 
progress has been made in terms of 
developing commercially viable total 
syntheses of these systems. Hudlicky and co-
workers have defined the current “gold 
standard” in the area.32  Given the tantalising 
structural resemblance between the readily 
available compound 23 and ent-codeine (29) 
(Figure 6) we are now attempting to modify 
the synthesis of the former so as to access the 
latter.  This will likely involve introducing the 
necessary additional two-carbon unit by using 
a variant of boronate ester 20 and completing 
the synthesis of the less functionalised 
cyclohexane ring within target 29 using an 
intramolecular SN′ reaction that 
simultaneously cleaves the Ley acetal subunit. 
 
 
Figure 6 
 
Vinblastine, Vincristine and Vindoline 
Vinblastine (30) and vincristine (31) (Figure 
7) are indole-indoline-based alkaloids derived 
from various plant sources, perhaps most 
notably the Madagascan rosy periwinkle.33 
They are used in the clinical treatment of 
non-Hodgkin’s lymphomas as well as 
testicular, breast and lung cancers.  These 
compounds are derived in vivo from the 
significantly more abundant and co-occurring 
alkaloid vindoline (32).  Given the 
development of direct, chemically based and 
“bio-inspired” methods for effecting the 
conversion of this simpler compound into 
alkaloids 30 and 31, vindoline has become the 
focus of considerable attention as a synthetic 
target.34 
Our own efforts in this area have been 
inspired by the observation (Figure 8)35 that 
the mutant organism P. putida BGXM1 can 
effect, in an enantioselective fashion, the 
whole-cell biotransformation of abundant m-
ethyltoluene (33) into the carboxylic acid diol 
34 that bears a striking resemblance to the 
highly functionalised C-ring of vindoline. 
Accordingly, a recent focus of some of our 
work in the area of chemoenzymatic synthesis 
has been on identifying methods for 
converting this metabolite into vindoline (32) 
and thence into vinblastine (30) and 
vincristine (31). 
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Figure 7 
 
Figure 8 
 
The model study outlined in Scheme 6 has 
provided encouragement.36 Thus, the cis-1,2-
dihydrocatechol 2 (X = Br), representing a 
model for congener 34, was converted, by the 
means described earlier, into the oxirane 7.  
Treatment of this last compound with acetic 
acid in the presence of mineral acid afforded a 
trans-diol mono-ester that was protected 
under standard conditions as the 
corresponding MOM-ether and thus 
affording compound 35 that could be cross-
coupled with ethyl boronic acid in the 
presence of a Pd[0] catalyst to give, after 
completing cleavage of the acetate residue 
using methanolic potassium carbonate, the 
allylic alcohol 36. This last compound was 
engaged in a sluggish Eschenmoser-Claisen 
rearrangement reaction to give amide 37, the 
side-chain of which could be elaborated, over 
three steps, into the nitrile 38. Over a further 
three conventional steps this was converted 
into the α-iodocyclohexenone 39 that itself 
served as a substrate for a palladium-catalysed 
Ullmann cross-coupling reaction37 with o-
iodonitroarene 40 and so delivering the α-
arylated cyclohexenone 41. On exposure to 
dihydrogen in the presence of Raney cobalt38 
and a proton source compound 41 engaged in 
a series of chemoselective reductions and two 
cyclisation reactions with the result that the 
tetracyclic compound 42 was formed.  The 
completion of the synthesis of the pentacyclic 
framework of vindoline proved straight-
forward and involved reaction of the last 
compound with 2-bromoethanol in the 
presence of base, mesylation of the resulting 
alcohol 43 and treatment of the sulfonate 
ester so formed with potassium tert-butoxide 
to generate the isoindole 44.   
In an effort to introduce the 
carbomethoxy group associated with alkaloid 
32, compound 44 was subjected to successive 
treatment with tert-butyllithium then Mander’s 
reagent (NCCO2Me).39 However, rather than 
obtaining the hoped-for C-carbomethoxy-
lated imine, carbamate 45 was produced, 
presumably by a pathway whereby the tert-
butyllithium acts as a hydride source40 with 
the resulting indoline anion then reacting (at 
nitrogen) with the added electrophile.  Efforts 
are now underway to adapt these chemistries 
so as to convert metabolite 34 into vindoline.  
The most challenging issue associated with 
doing so will be finding a means for 
introducing the C-C double bond 
incorporated within the D-ring of target 32. 
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Scheme 6 
The Protoilludanes 
The title sesquiterpenes embody a distinctive 
tricyclic framework wherein a central 
cyclohexane ring is annulated, in an angular 
arrangement, to both a four- and a five-
membered ring.41  The protoilludane aryl 
ester (+)-armillarivin (46) (Figure 9) has been 
found in the edible sugar mushroom 
Armillaria mellea42 while representative 
additional natural products in this family 
include 4743 and 4844 that are derived from 
the saprotrophic wood decomposing fungus 
Granulobasidium vellereum (Ellis & Cragin)
J h. 
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Figure 9 
 
 
In 2013 we described the first and thus far 
only total synthesis of (+)-armillarivin.45 A key 
element of our approach (Scheme 7) was an 
initial high-pressure promoted and completely 
regio- and stereo-selective Diels-Alder 
reaction between the cis-1,2-dihydrocatechol 2 
(X = Me) and cyclopentenone.46  Relatively 
conventional but rather extensive 
manipulations of the resulting adduct lead to 
the cyclopentannulated bicyclo[2.2.2]octen-
one 49 that engaged, as a second pivotal step 
of the synthesis, in a photochemically-
promoted 1,3-acyl migration reaction (Givens 
rearrangement)47 to afford the tricyclic isomer 
50.  This last compound, which embodies the 
tricyclic protoilludane framework, was readily 
manipulated over just three steps to deliver 
(+)-armillarivin.  The structure of this 
synthetically produced material was 
confirmed by single-crystal X-ray analysis and 
all the derived spectroscopic data, including 
specific rotation, matched those reported for 
the natural product.  
Subjection of the acetonide derivative of 
compound 2 (X = Me) to a Diels-Alder 
reaction with cyclopentenone affords, via 
addition of the dienophile to the face of the 
diene opposite to that “occupied” by the 
hydroxyl groups, cyclopentannulated bicyclo- 
[2.2.2]octenones that are enantiomerically 
related to those obtained by the pathway 
described immediately above.  In essence, 
then, by controlling the facial selectivity of 
such cycloaddition reactions either 
enantiomeric form of the relevant Diels-Alder 
adduct can be obtained. 
 
 
 
 
 
Scheme 7 
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By such means we have recently been able to 
complete total syntheses of the enantiomeric 
forms of the protoilludanes 47 and 4848 and 
thus confirming, for the first time, the 
structures assigned to them. 
 
Platencin 
The Diels-Alder cycloaddition chemistry 
involving cis-1,2-dihydrocatechols as the 4π-
component can be effectively extended to 
intramolecular variants. This is perhaps best 
exemplified in our recently completed first- 
and second-generation chemoenzymatic 
syntheses of platencin (51),49,50 a compound 
isolated from Streptomyces platensis MA7327 
that acts as a potent and dual inhibitor of 
FabH and FabF, key enzymes associated with 
fatty acid biosynthesis in bacteria (Figure 
10).51  By virtue of its novel structure and 
modes of action, platencin is regarded as an 
important new lead in the development of 
urgently needed, next-generation anti-
bacterial agents.52  
In our first generation synthesis of 
compound 51 (Scheme 8),49 the acetonide 
derivative, 52, of the cis-1,2-dihydrocatechol 2 
(X = I) was engaged in a Stille cross-coupling 
reaction with the Z-configured 
alkenylstannane 53 to give the tetra-ene 54. 
Substrate 53 was prepared in a 
straightforward manner with the 
stereochemistry at the quaternary carbon 
centre being controlled through the agency of 
a chiral auxiliary. 
While compound 54 failed to engage in 
an intramolecular Diels-Alder (IMDA) 
reaction, the readily derived ketone 55 did so 
when heated in refluxing toluene and thus 
affording, in stereochemically pure form, 
adduct 56 embodying the tricarbocyclic core 
of platencin.  Over a further thirteen steps 
compound 56 could be converted into (–)-
platencin (51).  
Some of these steps were needed to deal 
with functional group incompatibilities, an 
issue that has been addressed, albeit in a 
modest way, through our recently disclosed 
second-generation synthesis.50 In a devel- 
oping collaboration with the Hudlicky group 
at Brock University (Canada), efforts are now 
focussed on a third-generation approach. 
 
 
 
 
 
Figure 10 
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Scheme 8 
 
Conclusions 
Enzymes have an almost unparalleled 
capacity to transform simple organic 
substrates into synthetically more valuable 
ones, especially enantiomerically pure 
compounds (EPCs).  Through the use of 
various genetic engineering, gene shuffling 
and directed evolution techniques the 
opportunities to expand upon the existing 
“library” of metabolites seem almost infinite.  
Furthermore, pathway-engineering techniques 
provide a capacity to produce (mutant) 
organisms that effect, through the 
orchestrated action of a series of enzymes, 
multistep transformations.  The conversion 
of m-ethyltoluene (33) into compound 3435 is 
a case in point and wherein both mono-
oxygenases and dioxygenases act in concert to 
produce a potentially high-value metabolite.  
When combined with the power of chemical 
synthesis (as manifest in the techniques of 
chemoenzymatic synthesis), such bio-
transformations provide a powerful tool kit 
for preparing a wide range of compounds of 
biological relevance.  Ironically, perhaps, 
while microbiologists have a remarkable 
capacity to generate a diversity of low 
molecular weight metabolites (and often at 
multi-kilogram or larger scale) and synthesis 
chemists have an almost insatiable appetite 
for new synthons, the often siloed nature of 
academic research activities results in less than 
desirable overlap of the relevant sets of 
expertise.  Changing this situation can only 
benefit both disciplines. 
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ABSTRACT: Syntheses of certain di- and mono-oxygenated derivatives (e.g., 2 and 3, respectively) and analogues (e.g., 4, a D-
ring monoseco-analogue of 2) of both the (−)- and (+)-enantiomeric forms of the alkaloid galanthamine [(−)-1] are reported.
All have been assessed for their capacities to inhibit acetylcholine esterase but, in contrast to the predictions from docking
studies, none bind strongly to this enzyme.
■ INTRODUCTION
The alkaloid (−)-galanthamine [(−)-1] (Figure 1) has been
isolated from a range of plant sources and is currently used in
the clinic for the symptomatic treatment of mild to moderate
forms of Alzheimer’s disease.1 It exerts its beneficial effects by
crossing the blood-brain barrier and then, in part at least,
inhibiting acetylcholine esterase (AChE). It also acts as an
allosteric modulator of the nicotinic acetylcholine receptor.1,2
The non-natural enantiomer of compound 1, namely ent-1 or
(+)-galanthamine, has also been shown to accumulate in brain
tissue but does so through nonspecific binding.3
Currently, (−)-galanthamine is produced industrially by
extraction from various plants sources, most notably the red
spider lily (Lycoris radia), the wild daffodil (Narcissus
pseudonarcissus), the summer snowflake (Leucojum aestivum),
and the Caucasian snowdrop (Galanthus woronowii).1 However,
both the increasing demands for the natural product and the
erosion of habitat of at least some of the producing plants has
prompted investigations into other methods for obtaining it or
for identifying analogues with improved efficacy. As part of such
efforts, galanthamine has been the subject of a significant
number of total synthesis studies with the first of these being
reported by Barton and Kirby4 and involving mimicking of the
proposed biogenesis. Substantial refinements of this process
have been reported in the interim,5 and one of these has
formed the basis of a pilot-plant scale synthesis of the alkaloid5a
although it is not clear if this contributes significantly to the
commercial production of the alkaloid. Magnus and co-workers
have described6 a related and highly effective approach.
Intramolecular Heck reactions have provided another means
for assembling the tetracyclic framework of galanthamine,7
including those accomplished in an enantioselective manner,
while various chirons (corresponding to the A-ring) have been
employed for the assembly in either enantiomeric form of the
alkaloid.8,9a New routes to (−)-galanthamine continue to be
reported,1e including approaches from our group.9
The identification and biological evaluation of analogues of
galanthamine has been another focus of significant activity10
that is now greatly assisted by data derived from high-resolution
X-ray analysis of the alkaloid bound to the active site of
acetylcholine esterase.11 Biomimetic diversity-oriented syn-
Received: May 3, 2017
Published: July 3, 2017
Figure 1. Structure of the alkaloid (−)-galanthamine.
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thesis, sophisticated QSAR analyses, multicomponent-coupling
chemistries, as well as more conventional studies have all
revealed active compounds.12 The screening of natural products
for relevant activities remains an ongoing area of investigation
and has also resulted in the isolation of new inhibitors of the
title enzyme.13
As part of an ongoing program to establish concise routes to
the tetracyclic framework of galanthamine,1e,9 we now report
chemoenzymatic syntheses of two oxygenated derivatives, 2
and 3, as well as analogues 4−9 of the natural or (−)-form of
the alkaloid (Figure 2).14
Syntheses of the enantiomers of the first five of these
derivatives/analogues, namely compounds ent-2 to ent-6, are
also described. As detailed below, and contrary to the
predictions arising from molecular docking studies, none of
these is an effective inhibitor of acetylcholine esterase.
Our motivation for undertaking the studies described herein
was that the introduction of additional functionalities within the
galanthamine framework could increase water solubility and/or
provide the means for conjugating the drug with various groups
including peptide fragments10f or other entities (e.g. mem-
antine)10d and thus allow for the development of a multi-
targeted therapeutic approach.10d In principle, then, the
attachment of such moieties could provide new inhibitors (or
even just prodrug forms10e of galanthamine) that are superior
to existing therapies. As revealed below, the nature of our
synthetic strategy is such that additionally oxygenated forms of
the galanthamine A-ring were likely to be the most readily
accessible. Accordingly, and because this region of alkaloid has
not been “explored” previously, such derivatives became a
major focus of the work detailed below.
■ RESULTS AND DISCUSSION
Chemical Synthesis Studies. The reaction sequence used
to assemble ABC-ring substructures of (−)-galanthamine is
shown in Scheme 1 and employs the readily available L-tartaric
acid (10) as starting material. Thus, as specified in a recent
publication,15 compound 10 can be converted over 11 steps,
involving reduction, Grignard addition, and ring-closing
metatheses as key transformations, into the 1,2-diacetal
annulated bromocyclohexene 11. Coupling of compound 11
with the readily available16 aryl boronic acid ester 12 proceeded
under conventional conditions to give the anticipated arylated
cyclohexene 13 (68%). Following protocols established during
the course of our syntheses of the ribisins,17 this last compound
was engaged in an intramolecular Mitsunobu reaction using
triphenylphosphine in conjunction with di-iso-propyl azodicar-
boxylate (DIAD) wherein the phenolic hydroxyl group served
as the internal nucleophile and so affording the acid-sensitive
isobenzofuran 14 (33%). As demonstrated through work in the
enantiomeric series (see below), if appropriate account is taken
of this acid-sensitivity, then the Mitsunobu reaction can be a
high yielding one. Despite concerns about the potential for
competing isomerization of compound 14 to its more
conjugated (fully aromatic) counterpart, upon subjecting it to
conditions previously employed for effecting the Eschenmos-
er−Claisen rearrangement of allylic alcohols,18 amide 15 was
produced in 84% yield. The structure of this compound
followed not only from the derived NMR, IR, and mass spectral
Figure 2. Galanthamine derivatives/analogues 2−9 targeted for synthesis.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b01062
J. Org. Chem. 2017, 82, 7869−7886
7870
80
data but also from a single-crystal X-ray analysis of its
enantiomer (see below). Compound 15 embodies both the
targeted ABC-ring substructure of (−)-galanthamine and the
associated quaternary carbon. In anticipation of installing the
final D-ring of the title alkaloid, the amide residue within
compound 15 was reduced using LiBHEt3 and 1° alcohol 16
thereby obtained in 92% yield. Oxidation of compound 16
under conditions defined by Bobbitt and Bailey19 then gave
acid 17 (76%), which represents the key precursor to the
targeted galanthamine derivatives/analogues 2−6.
The straightforward manipulations of acid 17 leading to the
targeted (−)-galanthamine derivatives/analogues 2, 3, 5, and 6
are shown in Scheme 2. Thus, coupling of compound 17 and
methylamine, using 1,1′-carbonyldiimidazole (CDI) for activa-
tion of the acid, afforded amide 5 (79%), and on exposure of
the latter to modified Pictet−Spengler conditions7c,20 involving
paraformaldehyde in the presence of trifluoroacetic acid (TFA),
tetracyclic lactam 2 (47%) was formed as a result of
concomitant cleavage of the Ley acetal moiety. Upon treatment
with sodium bis(2-methoxyethoxy)aluminum dihydride, com-
pound 2 was reduced to azepine 3 (44%), and hydrolysis of the
1,2-diacetal residue within compound 5 using aqueous
trifluoroacetic acid (TFA) afforded diol 6 (66%). Compound
6 can be considered as a hybrid of the title alkaloid and the
neurologically active natural product ribisin D.17,21
The synthesis of compound 4, a monoseco derivative of 5R-
hydroxy-(−)-galanthamine (3), simply involved (Scheme 3)
acid-catalyzed hydrolysis of precursor 15 under conventional
conditions. This reaction proceeded in 88% yield.
All of the spectral data obtained on targeted compounds 2−6
were in complete accordance with the assigned structures but
final confirmation of that of the first (i.e., 2) followed from a
single-crystal X-ray analysis of its enantiomer (see below).
In an effort to establish a more meaningful SAR profile for
the above-mentioned analogues, the enantiomerically related
derivatives/analogues ent-2 to ent-6 (Figure 3) were sought.
Scheme 1. Synthesis of Key Acid 17 Embodying the ABC-Ring Substructure and Associated Quaternary Carbon of
(−)-Galanthamine
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Although the routes defined above could simply be adapted for
this purpose by starting with D- rather than L-taratric acid, we
were able to establish a shorter pathway by starting with an
enzymatically derived chiron that is readily available in the
required enantiomeric form (but less so in the opposite one
required to prepare the derivatives/analogues just described).
The synthesis of the enantiomeric series of compounds
started, as shown in Scheme 4, with the enzymatically derived
and enantiomerically pure cis-1,2-dihydrocatechol 1822 that was
converted into the corresponding and well-known23 acetonide
19 under standard conditions. Immediate treatment of the last
compound with m-chloroperbenzoic acid (m-CPBA) then
afforded, in a completely regio- and stereo-selective fashion,
epoxide 2023 (93% from 18). Reaction of compound 20 with a
large excess of p-methoxybenzylalcohol (p-MBnOH) in the
presence of boron trifluoride etherate (BF3·Et2O) resulted in
selective nucleophilic opening of the epoxide ring at the allylic
Scheme 2. Conversion of Acid 17 into the (−)-Galanthamine Derivatives/Analogues 2, 3, 5, and 6
Scheme 3. Hydrolysis of Biacetal 15 Leading to Compound 4
Figure 3. Enantiomeric series of derivatives/analogues.
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carbon,24 but the protected bromoconduritol thus formed was
not isolated. Rather, it was simply allowed to react with
methanol in the presence of pyridinium tosylate (PPTS) and
thereby affording triol 21 (71%). Treatment of a methanolic
solution of this last compound with 2,2,3,3-tetramethoxybutane
(2,2,3,3-TMB) in the presence of p-toluenesulfonic acid
monohydrate (p-TsOH·H2O) then resulted in the selective
formation of the “Ley”-acetal25 ent-11 (85%) and so establish-
ing an “enantiomeric overlap” with the synthetic sequence
leading to the original sets of analogues.
During the conversion, 21 → ent-11 acetal formation is
presumed to take place prior to cleavage of the PMB-ether unit
because the reverse order of events would lead to an
intermediate conduritol embodying two adjacent trans-diol
moieties and the formation of two isomeric Ley-type acetals
would therefore be expected. Indeed, when the tetra-ol derived
from hydrolysis of compound 21 was subjected to reaction with
2,2,3,3-TMB in the presence of p-TsOH·H2O then an ∼1:1
mixture of the two possible bis-acetals is formed.
Scheme 4. Synthesis of Bromoconduritol ent-11 from the Enzymatically-Derived and Homochiral cis-1,2-Dihydrocatechol
Scheme 5. Synthesis of Key Acid ent-17 from Bromoconduritol ent-11
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As shown in Scheme 5, and as was the case in the
enantiomeric series, compound ent-11 could be engaged in a
Suzuki−Miyaura cross-coupling reaction26 with arylboronic
acid ester 12, thus affording the anticipated product ent-13
(71%) that participated in an intramolecular Mitsunobu
reaction to give compound ent-14 (96%). Allylic alcohol ent-
14 underwent an Eschenmoser−Claisen rearrangement reac-
tion on thermolysis with the dimethyl acetal of N,N-
dimethylacetamide in refluxing toluene and thereby affording
N,N-dimethylamide ent-15 (86%). The structure of this last
Scheme 6. Synthesis of Aryl Boronate Ester 27
Scheme 7. Synthesis of Analogue 7
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compound was confirmed by a single-crystal X-ray analysis,
details of which are provided in the Experimental Section and
the Supporting Information (SI). Reduction of compound ent-
15 with lithium triethylborohydride and oxidation of the
resulting 1° alcohol ent-16 (quant.) using the Bobbitt−Bailey
protocol19 then gave acid ent-17 (80%).
Following precisely the same reaction sequences as detailed
above in Schemes 2 and 3, compound ent-17 was converted
into target derivatives ent-2 to ent-6 (Figure 3) with the
structure of the first of these being confirmed by single-crystal
X-ray analysis. The monoseco analogue of compound ent-2,
namely amide ent-4, was readily obtained in 77% yield by
simply treating bis-acetal ent-15 with aqueous trifluoroacetic
acid (compare to Scheme 3).
As part of an effort to develop galanthamine derivatives
containing additional functionality in the aromatic C-ring,
especially ones capable of conjugation with motifs that might
bind to the so-called peripheral and anionic binding site of
acetylcholine esterase,27 we sought to exploit the synthetic
chemistry detailed above for this purpose. As such, the relevant
arylboronate acid ester (representing a synthon for the C-ring)
was required and the route used to obtain this is shown in
Scheme 6. Thus, vanillin (22) was converted, under established
conditions, into its bromo-derivative 2328 (90%), and the
aldehydic residue within the latter then protected as the
corresponding ethylene acetal using standard conditions and
thus affording compound 24 in 55% yield. The readily derived
MOM-ether 25 (70%) of the last compound was subjected to a
metalation/borylation protocol, and the intermediate boronic
acid 26 obtained on hydrolytic work up was reacted with
sodium iodide/trimethylsilyl chloride (to cleave the MOM
ether) and then pinacol and thus affording the hitherto
unreported ester 27 (45% from 25). The structure of this last
compound was confirmed by single-crystal X-ray analysis (see
Experimental Section and SI for details).
In the opening stages of attempts to exploit ester 27 in the
production of galanthamine analogues related to those
described above, epoxide 19 (Scheme 7) was subjected to
hydrolytic cleavage, thus affording previously reported29 trans-
diol 28 (68%). The allylic hydroxyl group of diol 28 was
selectively protected through its reaction with tri-iso-propylsilyl
trifluoromethanesulfonate (TIPS-OTf) in the presence of 2,6-
lutidine and thus producing allylic ether 29 (88%).30 The
location of the TIPS group within this product was established
using COSY experiments. Upon treating compound 29 with
methyl iodide in the presence of sodium hydride, bis-ether 30
(49%) rather than the anticipated regioisomer was obtained.
Because the illustrated locations of the ether residues within
compound 30 (that thwart the application of the anticipated
Eschenmoser−Claisen rearrangement) were not appreciated
until an X-ray analysis was carried out on a derivative, this was
carried forward by first treating it with TBAF and thus affording
homoallylic alcohol 31 (98%). Compound 31 was engaged in a
Suzuki−Miyaura cross-coupling reaction with ester 27 to give
Scheme 8. Synthesis of Analogue 8
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the arylated and crystalline cyclohexene 32 (45%), the
illustrated structure of which was established by single-crystal
X-ray analysis. Acid-catalyzed hydrolysis of the acetonide
residue within the last compound then gave triol 33 (81%).
Even though the position of the methoxy group within
compound 33 precluded the application of the type of EC
rearrangement used earlier, it was subjected to an intra-
molecular Mitsunobu reaction so as to produce a system,
namely compound 7 (85%), that embodies the ABC-ring
ensemble associated with (−)-galanthamine.
The synthesis of analogue 8 is shown in Scheme 8 and
involved, as the initial step, the regio- and diastereo-selective cis-
dihydroxylation of diene 19. Selective silylation of the allylic
hydroxyl group within the resulting and previously repor-
ted17b,31 diol 34 (62%) was readily achieved using TIPS-OTf in
the presence of 2,6-lutidine, and the product ether 35 (88%)
was subjected to O-methylation using methyl iodide/base.
Treatment of product bis-ether 36 (92%) with TBAF
resulted in cleavage of the O-TIPS bond and formation of
alcohol 37 (88%) that could be cross-coupled with boronate
ester 27 under Suzuki−Miyaura conditions and thus affording
the anticipated product 38 (55%). Contrary to expectations,
however, the allylic alcohol residue within compound 38 failed
to engage in an Eschenmoser−Claisen rearrangement upon
treatment with N,N-dimethylacetamide dimethyl acetal. Rather,
the replacement of the associated allylic hydroxyl group with an
N,N-dimethylacetamide residue took place to give, in a
stereoselective manner and after accompanying O-methylation
of the phenolic hydroxyl group, amide 39 (40%). This was
contaminated by small amounts (7%) of its chromato-
graphically inseparable C5 epimer. “Thwarted E-C rearrange-
ments” of this type have been reported previously32 and in this
instance the process may be driven by electron-rich arene
residues facilitating ionization of the intermediate mixed acetal
with the ensuing and extensively stabilized cation then
undergoing nucleophilic capture by 1-methoxy-N,N-dimethy-
lethen-1-amine that is itself generated through thermal cracking
of the starting dimethyl acetal. The basic structure of product
39 follows from the observation that the diastereotopic
methylene hydrogens of the acetamide side-chain both show
vicinal couplings to the adjacent allylic hydrogen. The
illustrated configuration of the C5 acetamide residue is assigned
on the basis that this would be introduced preferentially during
the course of the nucleophilic capture process mentioned above
from that face of the intermediate cation opposite to the
sterically demanding and nearby acetonide residue. Hydrolysis
of this acetonide residue within compound 33 under standard
conditions then gave analogue 8 in 69% yield.
The synthesis of final galanthamine analogue 9 followed a
very similar route to that used in preparing congener 8. The
reaction sequence involved is shown in Scheme 9. Thus,
reaction of epoxide 19 with acetic acid in the presence of a
mineral acid gave the previously reported trans-diol mono-
acetate 409a (81%), the free hydroxyl of which was protected as
Scheme 9. Synthesis of Analogue 9
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.7b01062
J. Org. Chem. 2017, 82, 7869−7886
7876
86
the corresponding MOM ether using standard protocols and
thus affording compound 419a in 90% yield.
Cleavage of the acetate unit with the last compound could be
effected under conventional conditions, and the resulting allylic
alcohol 429a (95%) then cross-coupled with boronate ester 27
in the usual manner to give product 43 (49%). As was the case
with congener 32 (Scheme 8), upon subjecting compound 43
to conditions often used to effect the EC rearrangement, this
substrate also engaged in both an allylic substitution reaction
and O-methylation of the phenolic hydroxyl of the precursor.
As a consequence, a chromatographically inseparable and 3:1
mixture of amide 44 and its β-epimer (35% combined yield)
was formed. The salient spectral features of compound 44
resembled those of congener 33. Hydrolysis of the mixture of
acetonide 44 and its C5-epimer under conventional conditions
then gave, after chromatographic purification, diol 9 (69%)
that, like the other galanthamine derivatives/analogues, was
subjected to molecular docking studies and evaluation as a
potential inhibitor of acetylcholine esterase. Details are
presented in the following section.
Biological Evaluation and Molecular Docking Studies.
The above-mentioned derivatives/analogues of (−)- and
(+)-galanthamine were each evaluated for their ability to
inhibit AChE using a modified method involving addition of
DMSO so as to ensure dissolution of these otherwise rather
insoluble compounds.33 The inhibitory effect of DMSO itself
on the AChE was taken into account by subtracting a control
measurement for obtaining the IC50 values of the tested
materials. A summary of the inhibition data thus obtained is
shown in Table 1. These assays reveal that only one of the
compounds, namely derivative 3, showed a measurable IC50
value (of 420 μM) compared to the positive control
(−)-galanthamine [(−)-1] which had an IC50 value of 0.9
μM. Clearly, then, and regardless of the absolute stereo-
chemistries of the systems involved, none of the above-
mentioned derivatives/analogues are strong inhibitors of AChE.
Analysis of these inhibition data was undertaken through
molecular docking simulations and using the structure of
(−)-galanthamine bound to human AChE.34 Crystallographic
studies have revealed that (−)-galanthamine binds into the
active site of AChE with the tetrahydroazepine or D-ring
assuming a boat-like conformation and the associated N-methyl
group in a pseudoequatorial orientation spanning the acyl- and
choline-binding sites.35 Docking simulations, using AUTO-
DOCK, matched the solved structure (see Figure 4A) with the
key interactions between AChE and (−)-galanthamine being
evident, thus suggesting that docking simulations of this type
can provide the correct orientation of binding for the
compounds. Surprisingly, with the exception of compounds 5
and ent-5, 8 and 9, for which no bound structures could be
obtained (in the case of the first two of these compounds, this
may be a consequence of their significantly greater size), the
derivatives all had significant docking binding energies, albeit
weaker than (−)-galanthamine (see right-hand column, Table
1). This highlights some of the known limitations in the
prediction of binding affinity by docking programs.36−38 The
docking studies do, however, reveal the likely structural basis
for the reduced affinity of these analogues. For example, the
configuration of compound 3 matches the orientation of
(−)-galanthamine, except that the additional (C5) hydroxyl
moiety is positioned toward tryptophan 84 and thus produces a
distortion in the shape of the A-ring. This most likely results in
destabilization of the π−π stacking interaction between the
indole ring of Trp84 and this ring (A)39 with this loss of
interaction impairing the compound’s capacity to inhibit AChE.
The (+)-enantiomer, ent-3, of compound 3 also has a
hydroxyl positioned toward Trp84, again disrupting the
stabilizing cyclohexene−indole interactions, although on this
occasion it is the same hydroxyl moiety that is present in
galanthamine, potentially explaining, in part at least, why
(+)-galanthamine derivatives are not potent inhibitors of
AChE.
■ CONCLUSIONS
The synthetic chemistry studies detailed above have established
that the ABC-ring system of galanthamine is readily obtained
through the Suzuki−Miyaura cross-coupling of o-hydroxyar-
ylboronates with conduritols incorporating a brominated
double-bond and then engaging the products of such processes
in an intramolecular Mitsunobu reaction. Furthermore, most of
the polyhydroxylated tetrahydrodibenzofurans arising from
such a reaction sequence engage in a thermally promoted
Eschenmoser−Claisen-type rearrangement reaction upon treat-
ment with N,N-dimethylacetamide dimethyl acetal in refluxing
toluene. The angularly substituted tetrahydrodibenzofurans
thus formed, which embody the quaternary carbon center
associated with the title alkaloid and represent monoseco
analogues of the same, can then be elaborated, using Pictet−
Spengler chemistry, to give oxygenated derivatives of galanth-
amine, certain variants of which have recently been isolated
Table 1. Outcomes of Evaluating Galanthamine Derivatives
and Analogues as Inhibitors of AChE and Their Calculated
Docking Binding Energies (BEs)
entry compd IC50 (μM) docking BE (kcal)
1 2 >500 −8.9
2 ent-2 >500 −9.6
3 3 420 ± 57 −8.4
4 ent-3 >500 −9.5
5 4 >500 −6.0
6 ent-4 >500 −9.1
7 5 >500
8 ent-5 >500
9 6 >500 −6.3
10 ent-6 >500 −9.2
11 7 >500 −7.8
12 8 >500
13 9 >500
14 1 (+ve control) 0.9 ± 0.2 −10.2
Figure 4. Overlap of (−)-galanthamine (1) (blue) and the docked
derivatives 3 (A, purple) and ent-3 (B, peach) in the active site of
AChE.
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from Chinese medicinal plants.40 Interestingly, these new
natural products were also poor inhibitors of AChE.
The biological evaluation of the galanthamine derivatives and
analogues obtained by the pathways described above reveals the
finely tuned nature of the interactions of the parent alkaloid
with the target enzyme AChE. In particular, structurally
“modest” changes to the galanthamine framework, as embodied
in the oxygenated derivatives 2, ent-2, 3, and ent-3, can
completely disrupt binding such that the compounds are
rendered inactive. These studies have also revealed that the
computational prediction of the likely binding affinity of
galanthamine analogues to AChE is fraught.
■ EXPERIMENTAL SECTION
General Protocols. Unless otherwise specified, proton (1H) and
carbon (13C) NMR spectra were recorded at room temperature in
base-filtered CDCl3 on a spectrometer operating at 400 MHz for
proton and 100 MHz for carbon nuclei. The signal due to residual
CHCl3 appearing at δH 7.26 and the central resonance of the CDCl3
“triplet” appearing at δC 77.0 were used to reference
1H and 13C NMR
spectra, respectively. 1H NMR data are recorded as follows: chemical
shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral]
where multiplicity is defined as s = singlet; d = doublet; t = triplet; q =
quartet; m = multiplet or combinations of the above. Infrared spectra
(νmax) were recorded on an FTIR spectrometer. Samples were
analyzed as thin films or finely divided solids. Low-resolution ESI mass
spectra were recorded on a single quadrupole mass spectrometer
interfaced with a liquid chromatograph, whereas high-resolution
measurements were conducted on a time-of-flight instrument. Low-
and high-resolution EI mass spectra were recorded on a magnetic-
sector machine. Melting points were measured on an automated
melting point system and are uncorrected. Analytical thin layer
chromatography (TLC) was performed on aluminum-backed 0.2 mm
thick silica gel 60 F254 plates. Eluted plates were visualized using a 254
nm UV lamp and/or by treatment with a suitable dip followed by
heating. These dips included phosphomolybdic acid:ceric sulfate:sul-
furic acid (concd):water (37.5 g: 7.5 g: 37.5 g: 720 mL), potassium
permanganate:potassium carbonate:5% w/v aq. sodium hydroxide
solution:water (3 g: 20 g: 5 mL: 300 mL)), p-anisaldehyde or
vanillin:sulfuric acid (concd):ethanol (15 g: 2.5 mL: 250 mL). Flash
chromatographic separations were carried out following protocols
defined by Still et al.41 with silica gel 60 (40−63 μm) as the stationary
phase and using the AR- or HPLC-grade solvents indicated. The
melting points of solids purified by such means were recorded directly
(i.e., after they had crystallized from the concentrated chromatographic
fractions). Starting materials, reagents, drying agents, and other
inorganic salts were generally commercially available and used as
supplied. THF, methanol, and CH2Cl2 were dried using a solvent
purification system that is based upon a technology originally
described by Grubbs et al.42
Specific Chemical Transformations (2R,3R,4aS,5S,8R,8aS)-6-(2-
Hydroxy-3-methoxy-phenyl)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-di -ol (13) and
Enantiomer ent-13. A magnetically stirred solution of bis-acetal
1115 (805 mg, 2.37 mmol), ester 12 (720 mg, 2.88 mmol), and
triethylamine (3 mL) in THF/water (20 mL of a 9:1 v/v mixture) was
subjected to sonication under an atmosphere of nitrogen for 0.5 h.
PdCl2dppf·CH2Cl2 (140 mg, 0.191 mmol) was then added, and the
ensuing mixture was heated under reflux for 2 h before being cooled
and quenched with phosphate buffer (5 mL of a 1 M aqueous solution
at pH 7). The mixture thus obtained was cooled to 0 °C, treated with
methanol/30% aq hydrogen peroxide (10 mL of a 1:1 v/v mixture),
and then allowed to warm to room temperature over 1 h. The
resulting mixture was diluted with water (50 mL) and extracted with
ethyl acetate (5 × 20 mL). The combined organic phases were washed
with brine (2 × 20 mL) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The ensuing thick orange oil
was triturated with diethyl ether (5 × 2 mL), and the resulting yellow
solid was subjected to flash column chromatography (silica, 4:15:1 v/v
ethyl acetate/hexane/methanol →12:7:1 v/v ethyl acetate/hexane/
methanol gradient elution). Concentration of the appropriate fractions
(Rf = 0.3 in 10:9:1 v/v/v ethyl acetate/hexane/methanol) afforded
phenol 13 (618 mg, 68%) as a white powder: mp 202−210 °C; [α]20D
−93.8 (c 0.1, methanol); 1H NMR (400 MHz, CD3OD) δ 6.89 (dd, J
= 7.5 and 1.8 Hz, 1H), 6.83−6.73 (complex m, 2H), 5.76 (d, J = 2.5
Hz, 1H), 4.60 (d, J = 3.7 Hz, 1H), 4.23 (dd, J = 8.0 and 2.5 Hz, 1H),
4.09 (dd, J = 11.0 and 8.0 Hz, 1H), 3.85 (s, 3H), 3.69 (dd, J = 11.0 and
3.7 Hz, 1H), 3.34 (s, 3H), 3.28 (s, 3H), 1.34 (s, 3H), 1.33 (s, 3H)
(signals due to hydroxyl protons not observed); 13C NMR (100 MHz,
CD3OD) δ 149.0, 145.0, 138.9, 132.9, 128.6, 123.6, 120.3, 112.2,
100.7, 100.3, 71.4, 70.7, 69.7, 69.0, 56.6, 48.3, 48.2, 18.1(5), 18.1(0);
IR νmax 3456, 3283, 2941, 1589, 1468, 1218, 1129, 1119, 914, 594
cm−1; MS (ESI, +ve) m/z 788 ([(2 M + Na)+, 80%], 405 [(M + Na)+,
100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H26NaO8
405.1525, found 405.1526.
Compound ent-13 was prepared in an analogous fashion from ent-
11 (2.04 g, 5.34 mmol) to give 1.60 g (71%) of product; [α]20D +86.4
(c 0.1, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 13.
(2R,3R,4aS,5R,11aR,11bS)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,4a,5,11a,11b-hexahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-5-ol (14) and Enantiomer ent-14. A magnetically stirred
solution of phenol 13 (605 mg, 1.58 mmol) and PPh3 (456 mg, 1.74
mmol) in THF (70 mL) maintained at −5 °C was treated dropwise
over 0.5 h with di-iso-propyl azodicarboxylate (364 μL, 1.74 mmol).
The resulting solution was stirred at −5 °C for 4 h and then allowed to
warm to room temperature over 1 h before being concentrated under
reduced pressure. The orange oil thus obtained was subjected to two
successive flash chromatographic separations (silica, hexane → 1:1 v/v
ethyl acetate/hexane gradient elution), and concentration of
appropriate fractions (Rf = 0.7, 2:1 v/v ethyl acetate/hexane) afforded
allylic alcohol 14 (193 mg, 33%) as a white foam; [α]20D −157 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.99 (dd, J = 7.5 and 1.2 Hz,
1H), 6.89 (apparent t, J = 7.5 Hz, 1H), 6.82 (dd, J = 8.1 and 1.2 Hz,
1H), 5.81 (m, 1H), 5.14 (dt, J = 9.0 and 3.6 Hz, 1H), 4.67−4.61
(complex m, 1H), 4.04 (dd, J = 10.5 and 9.0 Hz, 1H), 3.93 (dd, J =
10.5 and 7.7 Hz, 1H), 3.88 (s, 3H), 3.34 (s, 6H), 2.34 (d, J = 4.8 Hz,
1H), 1.36(3) (s, 3H), 1.35(9) (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 151.6, 145.4, 139.1, 125.7, 122.1, 116.2, 113.6, 113.5, 99.2, 98.9, 84.0,
74.1, 71.3, 70.1, 56.0, 48.4, 48.0, 17.7, 17.6; IR νmax 3486, 2959, 2897,
1614, 1597, 1494, 1445, 1133, 1114, 1098, 1035, 1015, 786 cm−1; MS
(ESI, +ve) m/z 752 [(2 M + Na)+, 25%], 387 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C19H24NaO7 387.1420,
found 387.1423.
Compound ent-14 was prepared in an analogous fashion from ent-
13 (345 mg, 0.90 mmol) to give 314 mg (96%) of product; [α]20D
+102 (c 1.0, CHCl3). All the other spectral data acquired on this
material were identical with those reported above for compound 14.
N,N-Dimethyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-
2,3-dimethyl-2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (15) and Enantiomer ent-15. A
magnetically stirred solution of allylic alcohol 14 (180 mg, 0.494
mmol) in toluene (20 mL) maintained at 22 °C was treated with N,N-
dimethylacetamide dimethyl acetal (900 μL, 4.9 mmol), and the
resulting solution was heated under reflux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was triturated with diethyl ether. The resulting
waxy solid was subjected to flash chromatography (silica, 20:79:1 v/v
ethyl acetate/hexane/methanol → 60:39:1 v/v ethyl acetate/hexane/
methanol gradient elution), and concentration of appropriate fractions
(Rf = 0.2 in 2:1 v/v ethyl acetate/hexane) afforded amide 15 (178 mg
84%) as a white foam; [α]20D −89.9 (c 1.0, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.83 (m, 1H), 6.75 (d, J = 7.8 Hz, 1H), 6.72 (d, J =
7.6 Hz, 1H), 6.02 (dd, J = 10.0 and 2.7 Hz, 1H), 5.74 (dd, J = 10.0 and
2.0 Hz, 1H), 5.04 (d, J = 9.6 Hz, 1H), 4.55 (dt, J = 9.6 and 2.0 Hz,
1H), 3.85 (s, 3H), 3.76 (t, J = 9.6 Hz, 1H), 3.30 (s, 3H), 3.16 (s, 3H),
2.89 (s, 3H), 2.78 (s, 3H), 2.71 (d, J = 15.8 Hz, 1H), 2.61 (d, J = 15.8
Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
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169.0, 145.6(4), 145.5(6), 134.2, 128.9, 126.9, 121.5, 115.3, 112.0,
99.8, 87.1, 70.5, 65.9, 56.1, 51.0, 48.1, 47.4, 42.5, 37.3, 35.3, 17.7(4),
17.7(0) (one signal obscured or overlapping); IR νmax 2954, 2889,
1651, 1491, 1459, 1380, 1276, 1115, 1061, 1000, 954, 739 cm−1; MS
(ESI, +ve) m/z 456 [(M + Na)+, 100%], 201 (35); HRMS (ESI, +ve)
m/z (M + Na)+ calcd for C23H31NNaO7 456.1998, found 456.2000.
Compound ent-15 was prepared in an analogous fashion from ent-
14 (234 mg, 0.64 mmol) to give 238 mg (86%) of product as a white
foam. A small sample was crystallized (diethyl ether/methanol/
hexane) to give a white, crystalline solid; mp 160−165 °C (dec);
[α]20D +87.1 (c 1.0, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
15.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)ethan-1-ol (16) and Enantiomer ent-16. A magnetically
stirred solution of amide 15 (146 mg, 0.337 mmol) in THF (17 mL)
maintained at 0 °C was treated dropwise with lithium triethylborohy-
dride (1.7 mL of a 1 M solution in THF, 1.7 mmol). The resulting
mixture was warmed to room temperature over 2 h, recooled to 0 °C,
quenched with methanol (2 mL), and then treated with silica (200 mg
of flash chromatographic-grade material) before being subjected to
flash chromatography (silica, 1:4 v/v ethyl acetate/hexane → 1:1 v/v
ethyl acetate/hexane gradient elution). Concentration of relevant
fractions (Rf = 0.6, 2:1 v/v ethyl acetate/hexane) afforded compound
16 (122 mg, 92%) as a white foam; [α]20D −131.9 (c 1.8, CHCl3); 1H
NMR (400 MHz, CDCl3) δ 6.84 (apparent t, J = 7.8 Hz, 1H), 6.74
(m, 1H), 6.69 (dd, J = 7.5 and 1.2 Hz, 1H), 5.91 (broad d, J = 10.0 Hz,
1H), 5.70 (broad d, J = 10.0 Hz, 1H), 4.89 (d, J = 9.6 Hz, 1H), 4.31
(ddd, J = 9.6, 2.7, and 1.5 Hz, 1H), 3.84 (s, 3H), 3.72 (t, J = 9.6 Hz,
1H), 3.67−3.57 (complex m, 2H), 3.28 (s, 3H), 3.17 (s, 3H), 1.96 (dt,
J = 13.7 and 6.7 Hz, 1H), 1.85 (dt, J = 13.7 and 6.4 Hz, 1H), 1.40
(triplet, J = 5.2 Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H); 13C NMR (100
MHz, CDCl3) δ 145.7, 145.4, 133.6, 130.1, 126.4, 121.8, 114.9, 112.0,
99.9, 99.7, 86.9, 70.8, 65.4, 59.3, 56.1, 51.7, 48.0, 47.5, 43.5, 17.7, 17.6;
IR νmax 3508, 2948, 2837, 1619, 1588, 1491, 1459, 1281, 1130, 1116,
1036, 753, 736 cm−1; MS (ESI, +ve) m/z 415 [(M + Na)+, 100%];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C21H28NaO7 415.1733,
found 415.1733.
Compound ent-16 was prepared in an analogous fashion from ent-
15 (177 mg, 0.408 mmol) to give 160 mg (quantitative) of product;
[α]20D +108 (c 0.9, CHCl3). All of the other spectral data acquired on
this material were identical with those reported above for compound
16.
2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-Trimethoxy-2,3-dimethyl-
2,3,11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]benzofuran-6a-
(4aH)-yl)acetic Acid (17) and Enantiomer ent-17. A magnetically
stirred solution of alcohol 16 (122 mg, 0.310 mmol) in acetonitrile/
water (9:1 v/v, 2.3 mL) maintained at room temperature was treated
in one portion with 4-(acetylamino)-2,2,6,6-tetramethyl-1-oxo-piper-
idinium tetrafluoroborate (280 mg, 0.93 mmol). The resulting dark-
brown solution was stirred at 22 °C for 48 h (by which time it was a
pale-yellow color) and then poured into water (3 mL) and extracted
with diethyl ether (5 × 4 mL). The combined organic extracts were
washed with HCl (2 × 1 mL of a 1 M aqueous solution) and brine (2
× 5 mL) before being dried (Na2SO4), filtered, and concentrated
under reduced pressure. The residue thus obtained was subjected to
flash chromatography (silica, CH2Cl2 → 1:19 v/v methanol/CH2Cl2
gradient elution) and concentration of appropriate fractions (Rf = 0.2
in 1:19 v/v methanol/CH2Cl2) afforded acid 17 (96 mg, 76%) as a
clear, colorless gum; [α]20D −88.5 (c 0.6, CHCl3); 1H NMR (400
MHz, CDCl3) δ 6.85 (m, 1H), 6.76 (d, J = 7.4 Hz, 1H), 6.74 (d, J =
7.4 Hz, 1H), 5.96 (dd, J = 10.0 and 2.6 Hz, 1H), 5.77 (d, J = 10.0 Hz,
1H), 5.17 (d, J = 9.7 Hz, 1H), 4.40 (d, J = 9.7 Hz, 1H), 3.85 (s, 3H),
3.75 (t, J = 9.7 Hz, 1H), 3.29 (s, 3H), 3.17 (s, 3H), 2.76 (d, J = 15.6
Hz, 1H), 2.63 (d, J = 15.6 Hz, 1H), 1.36 (s, 3H), 1.28 (s, 3H) (signal
due to carboxylic acid group proton not observed); 13C NMR (100
MHz, CDCl3) δ 174.8, 145.6, 132.9, 128.1, 127.9, 121.9, 115.0, 112.3,
99.9, 99.8, 86.0, 70.5, 65.5, 56.1, 50.9, 48.0, 47.5, 44.0, 17.7 (signals
due to two carbons obscured or overlapping); IR νmax 2950, 1710,
1712, 1619, 1491, 1459, 1284, 1128, 1116, 1034, 960, 732 cm−1; MS
(ESI, +ve) m/z 429 [(M + Na)+, 100%]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C21H26NaO8 429.1525, found 429.1524.
Compound ent-17 was prepared in an analogous fashion from ent-
16 (150 mg, 0.382 mmol) to give 115 mg (80%) of product; [α]20D
+95.7 (c 1.2, CHCl3). All of the other spectral data acquired on this
material were identical with those reported above for compound 17.
N-Methyl-2-((2R,3R,4aS,6aS,11aR,11bR)-2,3,10-trimethoxy-2,3-
dimethyl-2,3,-11a,11b-tetrahydrobenzo[b][1,4]dioxino[2,3-g]-
benzofuran-6a(4aH)-yl)acetamide (5) and Enantiomer ent-5. A
magnetically stirred solution of acid 17 (93 mg, 0.23 mmol) in THF
(12 mL) maintained at room temperature was treated with 1,1′-
carbonyldiimidazole (49 mg, 0.30 mmol). The resulting solution was
heated under reflux for 1 h before being cooled to room temperature
and then placed in an ice bath at 0 °C. Methylamine (700 μL of a 2 M
solution in THF, 1.4 mmol) was then added dropwise, and the ensuing
solution was maintained at 0 °C for 3 h before being warmed to 22 °C
and stirred at this temperature for another 8 h. After this time, the
reaction mixture was diluted with ethyl acetate (40 mL) and washed
with NH4Cl (3 × 15 mL of a saturated aqueous solution). The
combined aqueous phases were extracted with ethyl acetate (3 × 10
mL), and the combined organic phases were washed with brine (2 ×
10 mL) before being dried (Na2SO4), filtered, and concentrated under
reduced pressure. The residue thus obtained was subjected to flash
chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/methanol →
8:11:1 v/v ethyl acetate/hexane/methanol gradient elution) and
concentration of appropriate fractions (Rf = 0.3 in 10:9:1 v/v ethyl
acetate/hexane/methanol) gave amide 5 (76 mg, 79%) as a clear,
colorless oil; [α]20D −102.1 (c 1.2, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 6.81 (m, 1H), 6.72 (dd, J = 8.0 and 1.2 Hz, 1H), 6.68 (dd, J
= 7.5 and 1.2 Hz, 1H), 6.09 (dd, J = 10.0 and 2.6 Hz, 1H), 5.72 (dd, J
= 10.0 and 1.5 Hz, 1H), 5.36 (broad q, J = 4.8 Hz, 1H), 4.97 (d, J = 9.7
Hz, 1H), 4.37 (ddd, J = 9.7, 2.6, and 1.5 Hz, 1H), 3.81 (s, 3H), 3.71 (t,
J = 9.7 Hz, 1H), 3.27 (s, 3H), 3.13 (s, 3H), 2.71 (d, J = 4.8 Hz, 3H),
2.51 (d, J = 14.0 Hz, 1H), 2.42 (d, J = 14.0 Hz, 1H), 1.32 (s, 3H), 1.26
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 169.5, 145.5, 133.4, 128.7,
126.9, 121.6, 115.2, 112.1, 99.8, 99.7, 86.9, 70.3, 65.5, 56.0, 51.2, 48.0,
47.4, 46.8, 26.2, 17.7, 17.6 (signal due to one carbon obscured or
overlapping); IR νmax 3317, 2952, 2921, 1646, 1548, 1491, 1457, 1377,
1197, 1114, 1034, 999, 955, 735 cm−1; MS (ESI, +ve) m/z 442 [(M +
Na)+, 100%]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C22H29NNaO7 442.1842, found 442.1842.
Compound ent-5 was prepared in an analogous fashion from ent-17
(115 mg, 0.28 mmol) to give 91 mg (79%) of product; [α]20D +89.1 (c
1.3, CHCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 5.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a(5aH)-yl)-N-methylacetamide (6) and
Enantiomer ent-6. A round-bottomed flask charged with a magnetic
stirrer bar and amide 5 (16.7 mg, 0.04 mmol) was treated sequentially
with water (250 μL) and trifluoroacetic acid (250 μL) and the ensuing
mixture stirred at 22 °C for 0.5 h; then, the volatiles were removed
under reduced pressure. The residue thus obtained was subject to flash
chromatography (silica, 5:4:1 v/v ethyl acetate/hexane/methanol) and
concentration of appropriate fractions (Rf = 0.3 in 8:1:1 v/v ethyl
acetate/hexane/methanol) afforded diol 6 (8.1 mg, 66%) as a white
foam; [α]20D −11 (c 0.4, methanol); 1H NMR [400 MHz, (CD3)2CO]
δ 7.04 (broad s, 1H), 6.84−6.74 (complex m, 3H), 6.00 (dd, J = 10.1
and 2.3 Hz, 1H), 5.67 (dd, J = 10.1 and 1.5 Hz, 1H), 5.25 (d, J = 8.7
Hz, 1H), 4.75 (broad s, 1H), 4.22 (partially obscured and broad s,
1H), 4.18 (d, J = 8.7 Hz, 1H), 3.82 (s, 3H), 3.40 (t, J = 8.7 Hz, 1H),
2.63 (d, J = 4.6 Hz, 3H), 2.48 (d, J = 13.9 Hz, 1H), 2.41 (d, J = 13.9
Hz, 1H); 13C NMR [100 MHz, (CD3)2CO] δ 170.7, 146.9, 146.2,
135.5, 131.6, 128.5, 122.1, 116.1, 113.3, 90.4, 75.8, 69.9, 56.4, 51.6,
46.8, 25.9; IR νmax 3315, 2943, 1642, 1491, 1272, 1199, 1179, 1132,
1064, 945, 723 cm−1; MS (ESI, +ve) m/z 634 [(2 M + Na)+, 40], 328
[(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M + Na)+ calcd for
C16H19NNaO5 328.1161, found 328.1158.
Compound ent-6 was prepared in an analogous fashion from ent-5
(16.7 mg, 0.04 mmol) to give 11.8 mg (97%) of product; [α]20D +16.7
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(c 1.0, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 6.
(4aR,5R,6S,8aS)-5,6-Dihydroxy-3-methoxy-11-methyl-4a,5,11,12-
tetrahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-10(9H)-one (2)
and Enantiomer ent-2. A magnetically stirred solution of amide 5
(56 mg, 0.133 mmol) in acetonitrile (14 mL) was treated sequentially
with paraformaldehyde (20 mg, 0.67 mmol) and trifluoroacetic acid
(63 μL, 0.82 mmol). The resulting solution was stirred at room
temperature for 8 h and then quenched with phosphate buffer (15 mL
of a 1 M aqueous solution at pH 7) and extracted with CH2Cl2 (3 ×
10 mL). The combined organic extracts were washed with brine (1 × 5
mL) and dried (Na2SO4) before being filtered and then concentrated
under reduced pressure. The residue thus obtained was subjected to
flash chromatography (silica, 4:15:1 v/v ethyl acetate/hexane/
methanol → 8:1:1 v/v ethyl acetate/hexane/methanol gradient
elution) and concentration of the appropriate fractions (Rf = 0.4 in
8:1:1 v/v ethyl acetate/hexane/methanol) afforded lactam 2 (19.7 mg,
47%) as a white, amorphous solid; [α]20D −139 (c 0.4, methanol). 1H
NMR (400 MHz, CDCl3) δ 6.71 (apparent s, 2H), 5.97 (dd, J = 10.2
and 4.7 Hz, 1H), 5.58 (d, J = 10.2 Hz, 1H), 4.78−4.73 (complex m,
1H), 4.67−4.63 (complex m, 1H), 4.53 (d, J = 16.0 Hz, 1H), 4.32 (d, J
= 16.0 Hz, 1H), 4.12 (m, 1H), 3.85 (s, 3H), 3.18 (d, J = 14.2 Hz, 1H),
3.07 (d, J = 14.2 Hz, 1H), 3.04 (s, 3H) (signals due to hydroxyl group
protons not observed); 13C NMR (100 MHz, CDCl3) δ 171.8, 145.9,
144.8, 131.9, 128.7, 125.7, 125.1, 120.4, 111.9, 88.4, 68.5, 67.0, 56.1,
52.1, 43.2, 42.3, 35.9; IR νmax 3357, 2924, 1623, 1508, 1438, 1280,
1101, 1070, 1031, 971, 880, 793 cm−1; MS (ESI, +ve) m/z 657 [(2 M
+ Na)+, 40%], 340 [(M + Na)+, 100]; HRMS (ESI, +ve) m/z (M +
Na)+ calcd for C17H19NNaO5 340.1161, found 340.1159.
Compound ent-2 was prepared in an analogous fashion from ent-5
(20 mg, 0.048 mmol) to give 9.5 mg (63%) of product as a white,
amorphous solid. A small sample was recrystallized (diethyl ether) to
give a white, crystalline solid; mp 135−140 °C; [α]20D +127 (c 0.4,
methanol). All of the other spectral data acquired on this material were
identical with those reported above for compound 2.
(4aR,5R,6S,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahy-
dro-6H-benzo[2,3]-benzofuro[4,3-cd]azepine-5,6-diol (3) and
Enantiomer ent-3. A magnetically stirred solution of lactam 2 (9.5
mg, 0.03 mmol) in THF (5 mL) maintained at room temperature was
treated with NaAlH2(OCH2CH2OCH3) 2 (60 μL of a 60% w/v
solution in toluene, 0.184 mmol) and the ensuing mixture heated
under reflux for 24 h after which time it was cooled to 0 °C (ice-bath),
quenched with potassium sodium tartrate (2 mL of a saturated
aqueous solution), diluted with water (10 mL) and then extracted with
CHCl3 (3 × 5 mL). The combined organic extracts were washed with
brine (1 × 2 mL) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to flash chromatography (silica, 1:19 v/v NH3 saturated
methanol/CHCl3 → 1:9 v/v NH3 saturated methanol/CHCl3 gradient
elution) and concentration of appropriate fractions (Rf = 0.2 in 1:9 v/v
NH3 saturated methanol/CHCl3) afforded amine 3 (4.0 mg, 44%) as a
white, amorphous solid; [α]20D −86.6 (c 0.3, CDCl3); 1H NMR (400
MHz, CDCl3) δ 6.66 (d, J = 8.2 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H),
6.23 (d, J = 10.2 Hz, 1H), 5.93 (dd, J = 10.2 and 3.8 Hz, 1H), 4.57 (d,
J = 4.6 Hz, 1H), 4.30 (m, 1H), 4.19−4.09 (complex m, 2H), 3.84 (s,
3H), 3.63 (m, 1H), 3.27 (m, 1H), 2.98 (broad d, J = 14.8 Hz, 1H),
2.34 (s, 3H), 2.18 (m, 1H), 1.81 (dd, J = 13.4 and 2.2 Hz, 1H) (signals
due to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ 145.4, 144.0, 132.3, 129.1, 128.1, 126.6, 122.4, 111.1, 90.9,
72.4, 67.6, 60.1, 55.9, 54.2, 49.8, 42.0, 36.0; IR νmax 3345, 2921, 1626,
1596, 1507, 1439, 1282, 1041, 948, 793, 726 cm−1; MS (ESI, +ve) m/z
629 [(2 M + Na)+, 30%], 326 [(M + Na)+, 100], 304 [(M + H)+, 7];
HRMS (ESI, +ve) m/z (M + H)+ calcd for C17H22NO4 304.1549,
found 304.1544.
Compound ent-3 was prepared in an analogous fashion from ent-2
(9.5 mg, 0.030 mmol) to give 4.0 mg (44%) of product, [α]20D +60.5
(c 0.4, CDCl3). All of the other spectral data acquired on this material
were identical with those reported above for compound 3.
2 - ( ( 5aR , 6R , 7 S , 9aS ) - 6 , 7 -D i h yd ro x y - 4 -me thoxy - 6 , 7 -
dihydrodibenzo[b,d]furan-9a-(5aH)-yl)-N,N-dimethylacetamide (4)
and Enantiomer ent-4. Amide 15 (15 mg, 0.035 mmol) was treated
trifluoroacetic acid/water (200 μL of a 1:1 v/v mixture), and the
resulting mixture was stirred at 22 °C for 0.5 h; then, the volatiles were
removed under reduced pressure. The residue thus obtained was
subjected to flash chromatography (silica, 1:19 v/v methanol/
CH2Cl2), and concentration of the relevant fractions (Rf = 0.1)
afforded diol 4 (9.8 mg, 88%) as a clear, colorless oil; [α]20D +5.7 (c
0.9, CH3OH);
1H NMR (400 MHz, CDCl3) δ 6.86 (m, 1H), 6.78−
6.73 (complex m, 2H), 5.98 (d, J = 9.9 Hz, 1H), 5.83 (d, J = 9.9 Hz,
1H), 5.01 (d, J = 7.5 Hz, 1H), 4.45 (broad s, 1H), 3.85 (s, 3H), 3.71
(m, 1H), 2.88 (s, 3H), 2.81 (s, 3H), 2.79 (m, 1H), 2.58 (d, J = 15.8
Hz, 1H) (signals due to hydroxyl protons not observed); 13C NMR
(100 MHz, CDCl3) δ 169.7, 145.5, 145.3, 134.1, 129.4, 128.5, 122.0,
115.4, 111.9, 90.5, 74.4, 69.2, 56.1, 50.1, 42.7, 37.5, 35.6; IR νmax 3389,
2927, 1616, 1489, 1457, 1402, 1271, 1093, 1058, 941, 749, 731 cm−1;
MS (ESI, +ve) m/z 661 [(2 M + Na)+, 40%], 342 [(M + Na)+, 100];
HRMS (ESI, +ve) m/z (M + Na)+ calcd for C17H21NNaO5 342.1317,
found 342.1311.
Compound ent-4 was prepared in an analogous fashion from ent-15
(23.7 mg, 0.055 mmol) to give 13.4 mg (77%) of product; [α]20D −8.2
(c 1.3, methanol). All of the other spectral data acquired on this
material were identical with those reported above for compound 4.
(1S,2S,3S,6S)-4-Bromo-6-((4-methoxybenzyl)oxy)cyclohex-4-ene-
1,2,3-triol (21). Step i. BF3·OEt2 (100 μL of a 10% v/v solution in
CH2Cl2) was added dropwise over 0.25 h to a magnetically stirred
solution of epoxide 2023 (2.00 g, 8.09 mmol) and p-methoxybenzyl
alcohol (23.8 g, 175 mmol) in dry CH2Cl2 (80 mL) maintained at −20
°C. The resulting solution was allowed to warm to −10 °C over 2 h
after which time a second aliquot of BF3·OEt2 (150 μL of a 10% v/v
solution in CH2Cl2) was added dropwise over 0.25 h. The reaction
mixture thus formed was warmed to 22 °C over 12 h then quenched
with phosphate buffer (3 mL of a 1 M aqueous solution at pH 7), and
the solvent was then removed under reduced pressure. The residue
thus obtained, which was comprised of a mixture of the desired PMB-
ether and p-methoxybenzyl alcohol, was submitted directly to step ii as
detailed immediately below.
Step ii. A magnetically stirred solution of the material obtained from
step i in methanol (160 mL) was treated with pyridinium p-
toluenesulfonate (2.03 g, 8.09 mmol) and the mixture so-formed was
heated at 50 °C for 48 h; then, it was cooled to 22 °C and treated with
NaHCO3 (500 mg), and the solvent was removed under reduced
pressure. The residue thus obtained was treated with ethyl acetate
(200 mL) and then water (100 mL), and the separated aqueous layer
was extracted with ethyl acetate (4 × 50 mL). The combined organic
phases were washed with brine (1 × 30 mL) and then dried (Na2SO4),
filtered, and concentrated under reduced pressure. The resulting
yellow oil was subjected to flash column chromatography (silica,
CH2Cl2 → 1:19 v/v methanol/CH2Cl2 gradient elution), and
concentration of appropriate fractions (Rf = 0.2 in 1:19 v/v
methanol/CH2Cl2) afforded triol 21 (1.98 g, 71% from 20) as a
white foam; [α]20D +132.1 (c 1.1, CHCl3);
1H NMR [400 MHz,
(CD3)2CO] δ 7.32 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.14
(d, J = 2.4 Hz, 1H), 4.67 (s, 2H), 4.58 (d, J = 5.1 Hz, 1H), 4.27−4.20
(complex m, 2H), 4.03 (broad s, 1H), 3.86 (dd, J = 7.4 and 2.0 Hz,
1H), 3.82 (broad d, J = 9.7 Hz, 1H), 3.78 (s, 3H), 3.54 (m, 1H); 13C
NMR [100 MHz, (CD3)2CO] δ 160.2, 132.8, 131.8, 130.2, 124.8,
114.4, 80.8, 74.1, 72.3(2), 72.2(5), 71.8, 55.5; IR (KBr) νmax 3437,
2918, 2848, 1732, 1449, 1368, 1241, 1072, 1026 cm−1; MS (ESI, +ve)
m/z 369 and 367 [(M + Na)+, 100 and 98%]; HRMS (ESI, +ve) m/z
(M + Na)+ calcd for C14H17
79BrNaO5 367.0155, found 367.0157.
(2S,3S,4aR,5S,8S,8aR)-6-Bromo-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-diol (ent-11). A
magnetically stirred solution of triol 21 (2.57 g, 7.44 mmol), 2,2,3,3-
tetramethoxybutane (1.91 g, 10.7 mmol), and trimethyl orthoformate
(3.40 mL, 31.1 mmol) in dry methanol (50 mL) was treated with p-
TsOH·H2O (73 mg, 5 mol %). The resulting mixture was heated
under reflux for 24 h, cooled to 22 °C, and treated with NaHCO3
(2.00 g), and the solvent was removed under reduced pressure. The
residue thus obtained was treated with ethyl acetate (100 mL) and
then NaHCO3 (30 mL of a saturated aqueous solution). The separated
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organic phase was washed with NaHCO3 (1 × 30 mL of a saturated
aqueous solution) and water (1 × 30 mL), and then the combined
aqueous layers were extracted with ethyl acetate (3 × 30 mL). The
combined organic phases were washed with brine (2 × 20 mL) and
then dried (Na2SO4), filtered, and concentrated under reduced
pressure. The resulting thick, orange oil was subjected to flash column
chromatography (silica, 1:20 v/v methanol/CH2Cl2 elution), and
concentration of appropriate fractions (Rf = 0.3) afforded bis-acetal
ent-11 (2.14 g, 85%) as a white foam; [α]20D +72.6 (c 1.1, CHCl3)
{lit.15 (for 11); [α]20D −76.5 (c 1.0, CHCl3)}; 1H NMR (400 MHz,
CD3OD) δ 6.05 (d, J = 2.5 Hz, 1H), 4.22 (d, J = 4.1 Hz, 1H), 4.06
(dd, J = 7.9 and 2.5 Hz, 1H), 3.87 (dd, J = 11.1 and 7.9 Hz, 1H), 3.63
(dd, J = 11.1 and 4.1 Hz, 1H), 3.30 (s, 3H), 3.25 (s, 3H), 1.32 (s, 3H),
1.29 (s, 3H) (signals due to hydroxyl group protons not observed);
13C NMR (100 MHz, CD3OD) δ 135.2, 124.0, 100.8, 100.2, 73.1,
71.8, 69.8, 69.2, 48.3, 48.2, 18.1, 18.0; IR (KBr) νmax 3160, 2940, 1636,
1454, 1375, 1136, 1077, 1031, 980, 915 cm−1; MS (ESI, +ve) m/z 363
and 361 [(M + Na)+, 95 and 100%]; HRMS (ESI, +ve) (M+Na)+
calcd for C12H19
79BrNaO6 361.0263, found 361.0263.
3-Bromo-4-hydroxy-5-methoxybenzaldehyde (23). A magneti-
cally stirred solution of vanillin (22) (4.00 g, 26.3 mmol) in acetic
acid (10 mL) was treated with molecular bromine (1.34 mL, 0.03
mol), and the ensuing mixture was stirred at 22 °C for 3 h during
which time a precipitate appeared. The reaction mixture was quenched
with water (30 mL), and the precipitate was filtered off, washed with
water (1 × 50 mL) and then methanol (1 × 20 mL) before being dried
under vacuum to afford compound 2328 (5.40 g, 90%) as a white,
crystalline solid; mp 164 °C (lit.28 mp 160−162 °C); 1H NMR
(CDCl3, 400 MHz) δ 9.79 (s, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.36 (d, J
= 1.7 Hz, 1H), 6.52 (s, 1H), 3.99 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 189.6, 148.9, 147.7, 130.1, 130.0, 108.2, 108.0, 56.6; IR νmax
3305, 2980, 1674, 1590, 1463, 1290, 1157, 1047, 680 cm−1; MS (ESI,
+ ev) m/z 255 and 253 [(M+Na)+, 100 and 99%]; HRMS (ESI, +ve)
(M+Na)+ calcd for C8H7
79BrNaO3 252.9476, found 252.9479.
2-Bromo-4-(1,3-dioxolan-2-yl)-6-methoxyphenol (24). Com-
pound 23 (5.00 g, 21.8 mmol), toluene (120 mL), p-TsOH·H2O
(39 mg, 0.21 mmol) and ethylene glycol (3.60 mL, 65.2 mmol) were
placed in a round-bottom flask fitted with a Dean−Stark trap and
condenser. The ensuing mixture was heated under reflux for 5 h before
being cooled, quenched with NaHCO3 (100 mL of a saturated
solution), and extracted with ethyl acetate (1 × 100 mL). The organic
phase was dried (Na2SO4), filtered, and concentrated under reduced
pressure, and the light-yellow oil thus obtained was subjected flash
chromatography (silica, 5:1 v/v hexane/ethyl acetate elution).
Concentration of the relevant fractions (Rf = 0.4 in 1:9 v/v ethyl
acetate/hexane) gave compound 24 (3.30 g, 55%) as a light-yellow oil.
1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 1.5 Hz, 1H), 6.94 (d, J =
1.5 Hz, 1H), 5.97 (s, 1H), 5.71 (s, 1H), 4.14−4.11 (complex m, 2H),
4.04−3.98 (complex m, 2H), 3.92 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 147.2, 143.8, 130.7, 123.2, 108.0, 107.9, 102.9, 65.2, 56.4; IR
νmax 3358, 2963, 2887, 1684, 1603, 1589, 1503, 1466, 1426, 1280,
1181, 1090, 1044 cm−1; MS (ESI, +ve) m/z 299 and 297 [(M+Na)+,
92 and 100%] 277 and 275 [(M+H)+, 45 and 40]; HRMS (ESI, +ve)
(M+H)+ calcd for C10H12
79BrO4 274.9919, found 274.9921.
2-(3-Bromo-5-methoxy-4-(methoxymethoxy)phenyl)-1,3-dioxo-
lane (25). A magnetically stirred mixture of phenol 24 (3.23 g, 11.79
mmol) in dry THF (30 mL) maintained at 0 °C was treated with NaH
(564 mg of a 60% suspension in oil, 14.2 mmol). After 0.5 h, the
reaction mixture was treated with chloromethyl methyl ether (980 μL,
12.9 mmol) and then stirred at 22 °C for 18 h before being quenched
with water (100 mL; CAUTION! possibility of hydrogen gas
evolution). The separated aqueous layer was extracted with diethyl
ether (3 × 30 mL), and the combined organic phases were washed
with brine (1 × 30 mL) and then dried (Na2SO4), filtered, and
concentrated under reduced pressure. The residue thus obtained was
subjected to flash chromatography (silica, 1:4 v/v ethyl acetate/hexane
elution) and gave, after concentration of the relevant fractions (Rf =
0.5 in 1:3 v/v ethyl acetate/hexane), bromide 25 (2.65 g, 70%) as a
clear, colorless oil; 1H NMR (CDCl3, 400 MHz) δ 7.28 (d, J = 1.9 Hz,
1H), 6.98 (d, J = 1.9 Hz, 1H), 5.74 (s, 1H), 5.17 (s, 2H), 4.13−4.01
(complex m, 4H), 3.86 (s, 3H), 3.64 (s, 3H); 13C NMR (CDCl3, 100
MHz) δ 153.3, 143.9, 135.1, 123.1, 117.6, 109.6, 102.6, 98.6, 65.3,
58.0, 56.1; IR νmax 2941, 2891, 2839, 1696, 1570, 1484, 1463, 1416,
1384, 1274, 1157, 1081, 1043, 942, 854 cm−1; MS (EI, 70 eV) m/z
320 and 318 (M+•, 99 and 100%), 289 and 287 (55 and 53), 239 (85),
166 (25); HRMS (EI, 70 eV) M+• calcd for C12H15
79BrO5 318.0103,
found 318.0104.
4-Hydroxy-3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)benzaldehyde (27). Step i. A magnetically stirred mixture of
bromide 25 (1.30 g, 4.15 mmol) in dry THF (15 mL) maintained at
−78 °C was treated with n-BuLi (3.1 mL of a 1.6 M solution in THF,
5.0 mmol). After 1 h, the reaction mixture was treated with tri-iso-
propyl borate (1.9 mL, 8.3 mmol) and then stirred at 22 °C for 15 h
before being quenched with HCl (10 mL of a 10% w/v aqueous
solution). The separated aqueous layer was extracted with ethyl acetate
(3 × 50 mL), and the combined organic phases were washed with
brine (1 × 50 mL) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The residue thus obtained, and
which is presumed to contain boronic acid 26, was subjected directly
to step ii of the reaction sequence.
Step ii. A magnetically stirred mixture of the product obtained from
step i in dry acetonitrile (40 mL) maintained at 0 °C was treated with
sodium iodide (0.62 g, 14.5 mmol) and chlorotrimethylsilane (530 μL,
14.5 mmol). The resulting solution was warmed to 22 °C over 4 h and
then treated with Na2S2O3 (20 mL of a saturated aqueous solution).
The separated aqueous layer was extracted with ethyl acetate (3 × 20
mL), and the combined organic phases were washed with brine (1 ×
20 mL) before being dried (Na2SO4), filtered, and concentrated under
reduced pressure. The residue thus obtained was immediately
subjected to step iii of the reaction sequence.
Step iii. A magnetically stirred suspension of the product obtained
from step ii in benzene (30 mL) was treated with pinacol (990 mg,
8.40 mmol), and the solution thus obtained was heated under reflux
for 2 h in an apparatus fitted with a Dean−Stark trap and a condenser.
The cooled reaction mixture was treated with water (20 mL), and the
separated aqueous layer was extracted with ethyl acetate (3 × 20 mL).
The combined organic phases were then washed with brine (1 × 50
mL) before being dried (Na2SO4), filtered, and concentrated under
reduced pressure. The residue thus obtained was subjected to flash
chromatography (silica, 2:3 v/v diethyl ether/hexane elution) to
afford, after concentration of the relevant fractions (Rf = 0.4), boronic
ester 27 (520 mg, 45% from 25) as a white, crystalline solid; mp 73
°C; 1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 8.33 (s, 1H), 7.72 (d,
J = 1.9 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 3.93 (s, 3H), 1.38 (s, 12H);
13C NMR (CDCl3, 100 MHz) δ 190.9, 158.6, 148.3, 133.8, 129.6,
111.7, 85.1, 56.0, 24.8; IR νmax 3407, 2992, 2931, 2830, 2797, 2714,
1683, 1620, 1587, 1467, 1388, 1372, 1298, 1256, 1140, 1056, 980, 846,
674 cm−1; MS (EI, 70 eV) m/z 278 (M+•, 38%), 221 (100), 178 (51),
177 (30); HRMS (EI, 70 eV) M+• calcd for C14H19BO5 278.1326,
found 278.1326.
(3aS,4S,5S,7aS)-7-Bromo-2,2-dimethyl-5-((triiso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (29). Tri-iso-propylsilyl
trifluoromethanesulfonate (1.95 mL, 7.3 mmol) was added dropwise
to a magnetically stirred solution of compound 2829 (1.40 g, 5.3
mmol) and 2,6-lutidine (2.5 mL, 21.5 mmol) in CH2Cl2 (30 mL)
maintained at −78 °C under a nitrogen atmosphere. The ensuing
mixture was allowed to warm to 22 °C over 3 h and then treated with
NH4Cl (60 mL of a saturated aqueous solution). The separated
aqueous phase was extracted with CH2Cl2 (1 × 20 mL), and the
combined organic phases were dried (MgSO4), filtered, and
concentrated under reduced pressure. The resulting light yellow oil
was subjected to flash chromatography (silica, 3:100 v/v ethyl acetate/
hexane elution) and gave, after concentration of the appropriate
fractions (Rf = 0.3 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
an ∼6:1 mixture of compound 29 and its regioisomeric silyl ether
(1.95 g, 88% combined yield) as a light-yellow oil; 1H NMR (400
MHz, CDCl3) δ 6.42 (s, 1H), 4.66 (d, J = 6.6 Hz, 1H), 4.17 (m, 1H),
4.11 (m, 1H), 3.55 (t, J = 8.7 Hz, 1H), 2.45 (s, 1H), 1.54 (s, 3H), 1.40
(s, 3H), 1.15−1.04 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ 144.5, 110.2, 92.2, 79.3, 77.0, 74.5, 73.6, 28.0, 25.7, 18.0(1), 17.9(9),
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12.4; IR νmax 3469, 2943, 2893, 2866, 1635, 1463, 1382, 1248, 1070,
1019, 997, 882, 866, 828 cm−1; MS (ESI, +ve) m/z 445 and 443 [(M
+Na)+, 100 and 97%]; HRMS (ESI, +ve) (M + Na)+ calcd for
C18H33
79BrNaO4Si 443.1229, found 443.1232.
(((3aR,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-4-yl)oxy)tri-iso-propylsilane (30).
Sodium hydride (342 mg of a 60% dispersion in mineral oil, 8.6
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 29 and its regioisomer (1.20 g, 2.9 mmol) and
iodomethane (391 μL, 6.3 mmol) in dry THF (20 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (70 mL)
(CAUTION! possibility of hydrogen evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 30 mL), and
the combined organic phases were then dried (MgSO4), filtered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to flash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/ hexane), an ∼5:1
mixture of compound 30 and its regioisomer (612 mg, 49% combined
yield) as a yellowish oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.16 (m, 1H), 4.63 (m, 1H), 4.47 (m, 1H), 4.36 (m, 1H),
3.86 (m, 1H), 3.41 (s, 3H), 1.42 (s, 3H), 1.40 (s, 3H), 1.12−0.95
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 129.4, 122.3, 110.0, 77.3, 77.2(3), 77.2(2), 69.9, 57.3,
27.5, 26.2, 18.0(2), 17.9(5), 12.5; IR νmax 2939, 2892, 2866, 1645,
1463, 1381, 1234, 1163, 1078, 1039, 1011, 941, 882, 815, 680 cm−1;
MS (ESI, +ve) m/z 459 and 457 [(M+Na)+, 98 and 96%], 355 (100),
347 and 345 (67 and 65); HRMS (ESI, +ve) (M+Na)+ calcd for
C19H35
79BrNaO4Si 457.1386, found 457.1389.
(3aS,4R,5S,7aS)-7-Bromo-5-methoxy-2,2-dimethyl-3a,4,5,7a-tet-
rahydrobenzo-[d][1,3]dioxol-4-ol (31). A magnetically stirred sol-
ution of an ∼5:1 mixture of compound 30 and its regioisomer (600
mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a nitrogen
atmosphere was treated with tetra-n-butylammonium fluoride (2 mL
of 1.0 M solution in THF, 2.0 mmol). After 2 h, the reaction mixture
was concentrated under reduced pressure, and the residue so-formed
was subjected to flash chromatography (silica, 1:2 v/v ethyl acetate/
hexane elution) to provide, after concentration of the appropriate
fractions (Rf = 0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane),
compound 31 (377 mg, 98%) as a light-yellow oil; [α]20D −15.7 (c 2.4,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 6.28 (s, 1H), 4.68 (d, J = 6.5
Hz, 1H), 4.15 (m, 1H), 3.66 (m, 2H), 3.48 (s, 3H), 2.64 (broad s,
1H), 1.55 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3) δ
132.2, 118.8, 111.0, 80.3, 77.5, 77.2, 72.5, 57.5, 28.1, 25.9; IR νmax
3453, 2987, 2934, 2826, 1646, 1457, 1381, 1217, 1164, 1074, 869
cm−1; MS (EI, 70 eV) m/z 280 and 278 (M+•, both 3%), 265 and 263
(both 35%), 101 (100); HRMS (EI, 70 eV) M+• calcd for
C10H15
79BrO4 278.0154, found 278.0148.
4-Hydroxy-3-((3aR,6S,7R,7aS)-7-hydroxy-6-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (32). A magnetically stirred solution of compound 31 (150
mg, 0.54 mmol), ester 27 (180 mg, 0.65 mmol), PdCl2dppf·CH2Cl2
(31.5 mg, 0.04 mmol), and triethylamine (3 mL) in THF/water (18
mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and then
heated under reflux for 2 h before being cooled, poured into water (50
mL), and extracted with ethyl acetate (3 × 30 mL). The combined
organic phases were washed with brine (1 × 40 mL) and then dried
(Na2SO4), filtered, and concentrated under reduced pressure. The
ensuing light-yellow oil was subjected to flash chromatography (silica,
1:4 v/v ethyl acetate/hexane elution), and concentration of the
relevant fractions (Rf = 0.5 in 1:3 v/v ethyl acetate/hexane) afforded
phenol 32 (85 mg, 45%) as a white, crystalline solid; mp 129 °C,
[α]20D +16.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.83 (s,
1H), 7.45 (d, J = 1.8 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.09 (s, 1H),
6.19 (d, J = 1.3 Hz, 1H), 5.17 (d, J = 6.4 Hz, 1H), 4.27 (dd, J = 8.9 and
6.4 Hz, 1H), 3.98 (s, 3H), 3.86 (m, 1H), 3.79 (m, 1H), 3.54 (s, 3H),
2.71 (broad s, 1H), 1.53 (s, 3H), 1.40 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 190.9, 149.2, 147.7, 132.3, 131.7, 129.2, 128.2, 125.1, 110.7,
108.4, 79.9, 77.7, 73.9, 72.9, 57.5, 56.4, 28.2, 26.0; IR νmax 3400, 2986,
2935, 2830, 1681, 1588, 1488, 1455, 1432, 1373, 1301, 1254, 1217,
1148, 1067, 990, 863, 732 cm−1; MS (EI, 70 eV) m/z 350 (M+•, 5%),
292 (53), 260 (55), 232 (100), 231 (72), 218 (53), 203 (39), 189
(33); HRMS (EI, 70 eV) M+• calcd for C18H22O7 350.1366, found
350.1369.
(2′R,3′R,4′S,5′S)-2′ ,3′ ,4′ ,6-Tetrahydroxy-5,5′-dimethoxy-
2′,3′,4′,5′-tetrahydro-[1,1′-biphenyl]-3-carbaldehyde (33). Com-
pound 32 (60 mg, 0.17 mmol) was treated with acetic acid/water
(10 mL of a 2:1 v/v mixture), and the resulting mixture was stirred at
22 °C for 18 h and then cooled and concentrated under reduced
pressure. Subjection of the residue thus obtained to flash
chromatography (silica, 1:8:1 v/v/v methanol/ethyl acetate/hexane
elution) gave, after concentration of the appropriate fractions (Rf =
0.4), compound 33 (43 mg, 81%) as a white powder; mp 191 °C;
[α]20D +7.5 (c 0.1, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ 9.83
(s, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.39 (d, J = 1.9 Hz, 1H), 6.03 (d, J =
2.5 Hz, 1H), 4.63 (d, J = 3.8 Hz, 1H), 3.97 (m, 1H), 3.92 (s, 3H), 3.84
(dd, J = 7.6 and 2.5 Hz, 1H), 3.62 (dd, J = 10.3 and 3.8 Hz, 1H), 3.49
(s, 3H), 2.83 (broad, s, 3H) (signal due to a hydroxyl group proton
not observed); 13C NMR [100 MHz, (CD3)2CO] δ 191.3, 151.3,
149.5, 137.4, 132.1, 129.9, 128.6, 128.4, 110.1, 82.9, 72.7, 71.8, 70.2,
57.6, 56.6; IR νmax 3346, 2926, 2839, 2821, 1678, 1586, 1454, 1429,
1383, 1298, 1257, 1145, 1106, 1070, 943, 858, 696 cm−1; MS (ESI,
+ve) m/z 643 [(2M + Na)+, 35%], 333 [(M + Na)+, 100]; HRMS
(ESI, +ve) (M+Na)+ calcd for C15H18NaO7 333.0950, found 333.0952.
(5aS,6S,7S,8S)-6,7-Dihydroxy-4,8-dimethoxy-5a,6,7,8-
tetrahydrodibenzo[b,d]-furan-2-carbaldehyde (7). A magnetically
stirred solution of phenol 33 (40 mg, 0.13 mmol) in THF (12 mL)
was treated with Ph3P (40 mg, 0.15 mmol), cooled to 0 °C, and
treated dropwise with a solution of di-iso-propyl azodicarboxylate (25
μL, 0.13 mmol) in THF (1 mL). The reaction mixture thus obtained
was stirred at 0 °C for 2 h and then concentrated under reduced
pressure, and the ensuing light-yellow oil was subjected to flash
chromatography (silica, 3:97 v/v methanol/CH2Cl2 elution). Con-
centration of the relevant fractions (Rf = 0.4 in 0.5:9.5 v/v methanol/
CH2Cl2) afforded benzofuran 7 (32 mg, 85%) as a clear, light-yellow
oil; [α]20D +92.0 (c 0.2, CHCl3);
1H NMR [400 MHz, (CD3)2CO] δ
9.87 (s, 1H), 7.69 (d, J = 1.5 Hz, 1H), 7.44 (d, J = 1.5 Hz, 1H), 6.19 (t,
J = 3.6 Hz, 1H), 5.09 (m, 1H), 4.94 (s, 1H), 4.48 (broad s, 1H), 4.09
(m, 1H), 3.95 (s, 3H), 3.81−3.77 (complex m, 2H), 3.49 (s, 3H); 13C
NMR [100 MHz, (CD3)2CO] δ 191.1, 157.6, 146.9, 138.0, 133.1,
127.7, 118.2, 117.6, 114.0, 89.1, 83.8, 77.3, 75.6, 57.5, 56.6; IR νmax
3339, 2926, 2892, 2853, 2823, 1686, 1604, 1590, 1437, 1337, 1313,
1185, 1119, 1092, 1069, 997, 920, 721, 694 cm−1; MS (ESI, +ve) m/z
607 [(2M + Na)+, 40%], 315 [(M + Na)+, 100], 293 (23), 195 (30);
HRMS (ESI, +ve) (M + Na)+ calcd for C15H16NaO6 315.0845, found
315.0847.
(3aS,4S,5R,7aS)-7-Bromo-2,2-dimethyl-5-((tri-iso-propylsilyl)oxy)-
3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-4-ol (35). Tri-iso-propylsilyl
trifluoromethanesulfonate (620 μL, 2.3 mmol) was added dropwise to
a magnetically stirred solution of compound 3431 (500 mg, 1.9 mmol)
and 2,6-lutidine (880 μL, 7.6 mmol) in CH2Cl2 (15 mL) maintained at
−78 °C under a nitrogen atmosphere. The ensuing mixture was
allowed to warm to 22 °C over 3 h and then treated with NH4Cl (30
mL of a saturated aqueous solution). The separated aqueous phase was
extracted with CH2Cl2 (1 × 10 mL), and the combined organic phases
were dried (MgSO4), filtered, and concentrated under reduced
pressure. The resulting light-yellow oil was subjected to flash
chromatography (silica, 3:100 v/v ethyl acetate/hexane elution) and
gave, after concentration of the appropriate fractions (Rf = 0.3 in
0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼6:1 mixture of
ether 35 and its regioisomer (700 mg, 88% combined yield) as a light-
yellow oil. 1H NMR (400 MHz, CDCl3) δ (major regioisomer) 6.00
(m, 1H), 4.62 (dd, J = 5.2 and 1.5 Hz, 1H), 4.49 (m, 2H), 4.24 (m,
1H), 2.67 (d, J = 1.5 Hz, 1H), 1.40 (s, 3H), 1.39 (s, 3H), 1.12−0.99
(complex m, 21H); 13C NMR (100 MHz, CDCl3) δ (major
regioisomer) 130.8, 123.5, 110.0, 75.9, 75.7, 69.3, 68.3, 27.5, 26.2,
17.9(4), 17.9(3), 12.2; IR νmax 3560, 2943, 2893, 2867, 1645, 1463,
1382, 1370, 1340, 1236, 1080, 1055, 882, 863, 682 cm−1; MS (EI, 70
eV) m/z 423 and 421 [(M+ H)+, 10 and 9%], 407 and 405 [(M −
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CH3•)+, 7 and 6], 321 and 319 (100 and 97); HRMS (EI, 70 eV) (M
− CH3•)+ calcd for C17H3079BrO4Si 405.1097, found 405.1096.
(((3aS,4S,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]diox-ol-5-yl)oxy)tri-iso-propylsilane (36).
Sodium hydride (172 mg of a 60% dispersion in mineral oil, 4.3
mmol) was added to a magnetically stirred solution of an ∼6:1 mixture
of compound 35 and its regioisomer (600 mg, 1.4 mmol) and
iodomethane (267 μL, 4.3 mmol) in dry THF (15 mL) maintained at
0 °C under a nitrogen atmosphere. Stirring was continued for 2 h at 22
°C, and then the reaction mixture was treated with ice-water (30 mL)
(CAUTION! possibility of hydrogen gas evolution). The separated
aqueous phase was extracted with ethyl acetate (1 × 15 mL), and the
combined organic phases were then dried (MgSO4), filtered, and
concentrated under reduced pressure. The ensuing light-yellow oil was
subjected to flash chromatography (silica, 1:50 v/v ethyl acetate/
hexane elution) to give, after concentration of the appropriate fractions
(Rf = 0.4 in 0.5:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane), an ∼5:1
mixture of compound 36 and its regioisomer (570 mg, 92% combined
yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3) δ (major
regioisomer) 6.15 (d, J = 3.0 Hz, 1H), 4.62 (m, 1H), 4.56 (m, 1H),
4.44 (t, J = 5.4 Hz, 1H), 3.70 (m, 1H), 3.54 (s, 3H), 1.41 (s, 3H), 1.38
(s, 3H), 1.10−0.98 (complex m, 21H); 13C NMR (100 MHz, CDCl3)
δ (major regioisomer) 133.1, 122.2, 109.9, 80.3, 76.9, 75.1, 68.2, 59.7,
27.5, 26.0, 17.9(8), 17.9(6), 12.2; IR νmax 2941, 2887, 2865, 1649,
1460, 1383, 1335, 1241, 1197, 1138, 1121, 1079, 1040, 956, 880, 858,
680 cm−1; MS (ESI, +ve) m/z 459 and 457 [(M + Na)+, 83 and 81%],
437 and 435 (88 and 86), 205 and 203 (97 and 100); HRMS (ESI,
+ve) (M + Na)+ calcd for C19H35
79BrNaO4Si 457.1386, found
457.1375.
(3aS,4R,5R,7aS)-7-Bromo-4-methoxy-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]-dioxol-5-ol (37). A magnetically stirred
solution of an ∼5:1 mixture of compound 36 and its regioisomer
(600 mg, 1.4 mmol) in THF (10 mL) maintained at 22 °C under a
nitrogen atmosphere was treated with tetra-n-butylammonium fluoride
(2 mL of 1.0 M solution in THF, 4.1 mmol). After 2 h, the reaction
mixture was concentrated under reduced pressure, and the residue so-
formed was subjected to flash chromatography (silica, 1:2 v/v ethyl
acetate/hexane elution). Concentration of the relevant fractions (Rf =
0.4 in 4:2.5:5.5 v/v/v ethyl acetate/CH2Cl2/hexane) gave compound
37 (338 mg, 88%) as a white powder; mp 61 °C; [α]20D +15.3 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3, 400 MHz) δ 6.15 (d, J = 3.0
Hz, 1H), 4.59 (m, 1H), 4.53 (t, J = 5.1 Hz, 1H), 4.33 (complex m,
1H), 3.76 (t, J = 4.4 Hz, 1H), 3.54 (s, 3H), 2.55 (broad s, 1H), 1.42 (s,
3H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 132.0, 123.2,
110.3, 78.7, 76.2, 73.9, 66.3, 59.2, 27.6, 26.2; IR νmax 3453, 2987, 2935,
2900, 2831, 1646, 1457, 1381, 1372, 1231, 1109, 1077, 1041, 964, 868
cm−1; MS (EI, 70 eV) (EI, 70 eV) 280 and 278 (M+•, both 1%), 265
and 263 (74 and 76), 177 and 175 (13 and 15), 124 (28), 115 (100);
HRMS M+• calcd for C10H15
79BrO4 278.0154, found 278.0153.
4-Hydroxy-3-((3aR,6R,7R,7aR)-6-hydroxy-7-methoxy-2,2-dimeth-
yl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-methoxybenzal-
dehyde (38). A magnetically stirred solution of compound 37 (116
mg, 0.42 mmol), boronate ester 27 (139 mg, 0.50 mmol), PdCl2dppf·
CH2Cl2 (25 mg, 0.03 mmol), and triethylamine (2 mL) in THF/water
(15 mL of a 9:1 v/v mixture) was purged with nitrogen for 0.5 h and
then heated under reflux for 3 h before being cooled, poured into
water (40 mL), and extracted with ethyl acetate (3 × 20 mL). The
combined organic phases were washed with brine (1 × 30 mL) and
then dried (Na2SO4), filtered, and concentrated under reduced
pressure. The ensuing light-yellow oil was subjected to flash
chromatography (silica, 1:4 v/v ethyl acetate/hexane elution), and
concentration of the relevant fractions (Rf = 0.5 in 1:3 v/v ethyl
acetate/hexane) gave phenol 38 (80 mg, 55%) as a light-yellow oil;
[α]20D +7.0 (c 0.2, CHCl3);
1H NMR (400 MHz, CDCl3) δ 9.82 (s,
1H), 7.39 (d, J = 1.5 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H), 6.10 (d, J = 3.3
Hz, 1H), 5.15 (d, J = 5.8 Hz, 1H), 4.64 (t, J = 5.5 Hz, 1H), 4.52 (m,
1H), 3.96 (s, 3H), 3.79 (t, J = 4.6 Hz, 1H), 3.59 (s, 3H), 2.65 (broad
d, J = 8.3 Hz, 1H), 1.46 (s, 3H), 1.40 (s, 3H) (signal due to hydroxyl
group proton not observed); 13C NMR (100 MHz, CDCl3) δ 190.8,
149.4, 147.9, 134.8, 132.0, 129.2, 128.3, 125.9, 109.8, 108.4, 79.7, 73.6,
73.3, 65.0, 59.1, 56.3, 27.6, 25.9; IR νmax 3368, 2985, 2936, 1681, 1588,
1456, 1432, 1297, 1149, 1120, 1071, 913, 873 cm−1; MS (EI, 70 eV)
m/z 350 (M+•, 4%), 274 (41), 115 (100); HRMS (EI, 70 eV) M+•
calcd for C18H22O7 350.1366, found 350.1370.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-me-
thoxy-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-yl)-
N,N-dimethylacetamide (39). A magnetically stirred solution of
compound 38 (60 mg, 0.17 mmol) in toluene (10 mL) was treated
with N,N-dimethylacetamide dimethyl acetal (126 μL, 0.87 mmol),
and the ensuing mixture was heated under reflux for 18 h. The cooled
reaction mixture was concentrated under reduced pressure, and the
residue thus obtained was subjected to flash chromatography (silica,
4:1 v/v ethyl acetate/hexane elution). Concentration of the
appropriate fractions (Rf = 0.3 in 5:1 v/v ethyl acetate/hexane) then
gave an ∼5:1 mixture of amide 39 and its β-epimer (30 mg, 40%
combined yield) as a clear, colorless oil; 1H NMR (400 MHz, CDCl3)
δ (major epimer) 9.87 (s, 1H), 7.39−7.36 (complex m, 2H), 6.01 (d, J
= 4.6 Hz, 1H), 5.20 (d, J = 6.7 Hz, 1H), 4.41 (t, J = 6.7 Hz, 1H), 3.91
(s, 3H), 3.86 (s, 3H), 3.65−3.59 (complex m, 1H), 3.48 (s, 3H), 3.34
(m, 1H), 3.01 (s, 3H), 2.94 (s, 3H), 2.73 (dd, J = 15.9 and 5.1 Hz,
1H), 2.27 (dd, J = 15.9 and 9.4 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H);
13C NMR (100 MHz, CDCl3) δ (major epimer) 191.2, 171.3, 153.3,
152.1, 134.6, 133.9, 133.1, 132.3, 127.5, 109.6, 109.0, 79.7, 74.4, 73.6,
60.8, 58.1, 56.0, 37.3, 35.5, 33.7, 33.4, 27.9, 25.7; IR νmax 2982, 2932,
2857, 2831, 1691, 1646, 1578, 1458, 1421, 1384, 1240, 1142, 1034,
1002, 913, 863, 733 cm−1; MS (ESI, +ve) m/z 456 [(M + Na)+, 78%],
434 (100), 376 (21); HRMS (ESI, +ve) (M + Na)+ calcd for
C23H31NNaO7 456.1998, found 456.1996.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′,4-trimethoxy-
3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dimethylacetamide (8).
An ∼5:1 mixture of compound 39 and its β-epimer (16 mg, 0.04
mmol) was treated with acetic acid/water (10 mL of a 2:1 v/v
mixture), and the resulting solution was heated at 50 °C for 22 h and
then cooled to 22 °C and concentrated under reduced pressure.
Subjection of the residue thus obtained to flash chromatography
(silica, 1:8:1 v/v methanol/ethyl acetate/hexane elution) gave, after
concentration of the appropriate fractions (Rf = 0.4 in 1:9 v/v
methanol/ethyl acetate), an ∼6:1 mixture of compound 8 and its β-
epimer (10 mg, 69% combined yield) as a light-yellow oil; 1H NMR
(400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.39 (complex m,
2H), 5.99 (m, 1H), 4.71 (m, 1H), 4.01 (dd, J = 9.2 and 4.0 Hz, 1H),
3.92 (s, 3H), 3.87 (s, 3H), 3.80 (m, 1H), 3.50 (m, 1H), 3.46 (s, 3H),
3.02 (s, 3H), 2.95 (s, 3H), 2.85 (broad s, 1H), 2.74 (dd, J = 15.9 and
5.0 Hz, 1H), 2.20 (dd, J = 15.9 and 9.0 Hz, 1H) (signal due to a
hydroxyl group proton not observed); 13C NMR (CDCl3, 100 MHz) δ
(major epimer) 191.1, 171.4, 153.2, 151.7, 135.1, 134.9, 133.3, 132.4,
127.5, 109.8, 77.7, 69.0, 68.5, 61.0, 57.9, 56.0, 37.3, 35.6, 34.3, 32.4; IR
νmax 3395, 2957, 2935, 2828, 1688, 1627, 1463, 1420, 1387, 1260,
1128, 1105, 1089, 797 cm−1; MS (ESI, +ve) m/z 787 [(2M + H)+,
30%], 416 [(M + Na)+, 100], 394 (92), 376 (20); HRMS (ESI, +ve)
(M + Na)+ calcd for C20H27NNaO7 416.1685, found 416.1685.
4-Hydroxy-3-((3aR,6S,7R,7aR)-6-hydroxy-7-(methoxymethoxy)-
2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-5-me-
thoxybenzaldehyde (43). A magnetically stirred solution of
compound 429a (100 mg, 0.33 mmol), boronate ester 27 (108 mg,
0.39 mmol), PdCl2dppf·CH2Cl2 (19 mg, 0.02 mmol), and triethyl-
amine (3 mL) in THF/water (18 mL of a 9:1 v/v mixture) was purged
with nitrogen for 0.5 h and then heated under reflux for 2 h before
being cooled, poured into water (50 mL), and extracted with ethyl
acetate (3 × 30 mL). The combined organic phases were washed with
brine (1 × 40 mL) and then dried (Na2SO4), filtered, and
concentrated under reduced pressure. The ensuing light-yellow oil
was subjected to flash chromatography (silica, 1:1 v/v ethyl acetate/
hexane elution), and concentration of the relevant fractions (Rf = 0.3
in 1:3 v/v ethyl acetate/hexane) then gave phenol 43 (60 mg, 49%) as
a light-yellow oil; [α]20D +18.4 (c 0.9, CHCl3);
1H NMR (400 MHz,
CDCl3) δ 9.82 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.6 Hz,
1H), 7.07 (s, 1H), 6.16 (d, J = 2.2 Hz, 1H), 5.21 (d, J = 6.2 Hz, 1H),
4.90 (d, J = 6.8 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 4.36 (dd, J = 8.4 and
6.2 Hz, 1H), 4.27 (broad d, J = 8.1 Hz, 1H), 4.08 (d, J = 3.3 Hz, 1H),
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3.97 (s, 3H), 3.67 (m, 1H), 3.50 (s, 3H), 1.51 (s, 3H), 1.40 (s, 3H);
13C NMR (100 MHz, CDCl3) δ 190.8, 149.2, 147.6, 133.6, 131.8,
129.2, 128.5, 125.0, 110.5, 108.1, 98.0, 83.2, 76.5, 74.0, 69.4, 56.4, 55.9,
28.2, 26.0; IR νmax 3370, 2985, 2948, 2936, 1683, 1588, 1488, 1456,
1432, 1372, 1300, 1250, 1217, 1149, 1105, 1058, 1037, 996, 866, 732
cm−1; MS (EI, +ve) m/z 380 (M+•, 2%), 362 (12), 260 (59), 259 (54),
231 (100), 218 (48); HRMS (EI, +ve) M+• calcd for C19H24O8
380.1471, found 380.1478.
2-((3aS,4R,5R,7aR)-7-(5-Formyl-2,3-dimethoxyphenyl)-4-(me-
thoxymethoxy)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]-
dioxol-5-yl)-N,N-dimethylacetamide (44). A magnetically stirred
solution of compound 43 (33 mg, 0.09 mmol) in toluene (10 mL)
was treated with N,N-dimethylacetamide dimethyl acetal (64 μL, 0.44
mmol), and the ensuing mixture was heated under reflux for 18 h. The
cooled reaction mixture was concentrated under reduced pressure, and
subjection of the ensuing residue to flash chromatography (silica,
9.5:0.5 v/v ethyl acetate/hexane elution) gave, after concentration of
the appropriate fractions (Rf = 0.4 in ethyl acetate), an ∼3:1 mixture of
amide 44 and its β-epimer (14 mg, 35% combined yield) as a clear,
colorless oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s,
1H), 7.38 (m, 2H), 5.98 (d, J = 4.3 Hz, 1H), 5.22 (d, J = 6.0 Hz, 1H),
4.77 (m, 2H), 4.46 (t, J = 6.5 Hz, 1H), 4.04 (dd, J = 6.9 and 4.5 Hz,
1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.43 (s, 3H), 3.30 (m, 1H), 3.01 (s,
3H), 2.94 (s, 3H), 2.75 (dd, J = 15.8 and 5.1 Hz, 1H), 2.33 (dd, J =
15.8 and 9.5 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H); 13C NMR (mixture
of epimers) (100 MHz, CDCl3) δ 191.3, 171.2, 153.3, 152.0, 134.6,
134.0, 133.0, 132.3, 129.3, 127.7, 113.8, 109.6, 109.2, 100.0, 96.5, 76.2,
75.0, 74.1, 73.8, 60.8, 56.0, 55.7, 37.2, 35.5, 34.2, 33.8, 28.0, 27.9, 26.0;
IR νmax 2982, 2933, 2843, 1692, 1647, 1579, 1455, 1384, 1243, 1145,
1070, 1037, 918, 863 cm−1; MS (ESI, +ve) m/z 486 [(M + Na)+,
100%], 464 (3), 60 (10); HRMS (ESI, +ve) (M + Na)+ calcd for
C24H33NNaO8 486.2104, found 486.2105.
2-((3R,4R,5R,6R)-5′-Formyl-5,6-dihydroxy-2′,3′-dimethoxy-4-(me-
thoxymethoxy)-3,4,5,6-tetrahydro[1,1′-biphenyl]-3-yl)-N,N-dime-
thylacetamide (9). Compound 44 (8 mg, 0.02 mmol) was treated
with acetic acid/water (10 mL of a 2:1 v/v mixture), and the resulting
solution was heated at 50 °C for 22 h and then cooled and
concentrated under reduced pressure. Subjection of the residue thus
obtained to flash chromatography (silica, 1:8:1 v/v methanol/ethyl
acetate/hexane elution) gave, after concentration of the appropriate
fractions (Rf = 0.4 in 1:9 v/v methanol/ethyl acetate), an ∼6.5:1
mixture of compound 9 and its β-epimer (5 mg, 69%) as a light-yellow
oil; 1H NMR (400 MHz, CDCl3) δ (major epimer) 9.87 (s, 1H), 7.38
(m, 2H), 5.97 (d, J = 4.4 Hz, 1H), 4.76−4.71 (complex m, 3H), 4.14
(dd, J = 9.1 and 5.7 Hz, 1H), 4.01 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H),
3.45 (s, 3H), 3.34 (broad s, 1H), 3.02 (s, 3H), 2.94 (s, 3H), 2.84 (dd, J
= 15.9 and 5.2 Hz, 1H), 2.25 (dd, J = 15.9 and 8.9 Hz, 1H) (signal due
to hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ (major epimer) 191.2, 171.4, 153.2, 151.7, 135.2, 135.0,
133.3, 132.5, 127.4, 109.8, 97.5, 76.9, 69.2, 68.9, 61.0, 56.0(1), 55.9(6),
37.3, 35.8, 35.6, 33.2; IR νmax 3384, 2919, 2848, 1688, 1630, 1579,
1463, 1419, 1387, 1329, 1292, 1245, 1147, 1130, 1037, 917, 862 cm−1;
MS (ESI, +ve) m/z 446 [(M + Na)+, 68%], 424 (100); HRMS (ESI,
+ve) (M + Na)+ calcd for C21H29NNaO8 446.1791, found 446.1780.
Crystallographic Studies. Crystallographic Data. Compound
ent-2. C17H19NO5, M = 317.34, T = 150 K, orthorhombic, space group
P212121, Z = 4, a = 6.58612(5) Å, b = 9.28140(8) Å, c = 23.3001(2) Å;
V = 1424.30(2) Å3, Dx = 1.480 g cm
−3, 2794 unique data (2θmax =
144.6°), R = 0.027 [for 2725 reflections with I > 2.0σ(I)]; Rw = 0.072
(all data), S = 1.01.
Compound ent-15. C23H31NO7, M = 433.50, T = 150 K,
monoclinic, space group P21, Z = 2, a = 10.14845(9) Å, b =
10.61199(7) Å, c = 10.80864(10) Å; β = 106.8796(9)°; V =
1113.89(2) Å3, Dx = 1.292 g cm
−3, 3907 unique data (2θmax = 144.8°),
R = 0.026 [for 3843 reflections with I > 2.0σ(I)]; Rw = 0.067 (all
data), S = 1.03.
Compound 27. C14H19BO5, M = 278.11, T = 150 K, orthorhombic,
space group Pbam, Z = 8, a = 23.0535(6) Å, b = 18.2756(6) Å, c =
6.8183(2) Å; V = 2872.66(15) Å3, Dx = 1.286 g cm
−3, 3098 unique
data (2θmax = 145.2°), R = 0.084 [for 2982 reflections with I >
2.0σ(I)]; Rw = 0.191 (all data), S = 1.06.
Compound 32. C18H22O7, M = 359.38, T = 150 K, monoclinic,
space group P21, Z = 4, a = 7.3153(1) Å, b = 31.4358(3) Å, c =
7.8245(1) Å; β = 94.8743(8)°; V = 1792.83(4) Å3, Dx = 1.331 g cm
−3,
7018 unique data (2θmax = 145°), R = 0.030 [for 6919 reflections with
I > 2.0σ(I)]; Rw = 0.080 (all data), S = 0.99.
Structure Determination. Diffraction images for compounds ent-2,
ent-15, 27, and 32 were all measured on a diffractometer (Mo Kα,
mirror monochromator, λ = 0.71073 Å or, for 32, Cu Kα mirror
monochromator, λ = 1.54184 Å) fitted with an area detector, and the
data were extracted using the DENZO/Scalepack package.43 The
structure solutions for all four compounds were solved by direct
methods (SIR92)44 and then refined using the CRYSTALS program
package.45 Atomic coordinates, bond lengths and angles, and
displacement parameters have been deposited at the Cambridge
Crystallographic Data Centre (CCDC nos. 1517512, 1517513,
1517514 and 1517515). These data can be obtained free-of-charge
via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@
ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: + 44
1223 336033.
AChE Inhibition Testing. The galanthamine derivatives/ana-
logues described above were tested for inhibition against AChE as
described by Sangnoi et al.46 Thus, the compounds were dissolved in
DMSO and made up to concentrations ranging from 5 mM to 3.05
μM by serial dilution with DMSO. Then, 2.5 μL of a solution of each
compound was added to a solution of 5,5′-dithiobis(2-nitrobenzoic
acid) (125 μL of a 1.5 mM aqueous solution), tris(hydroxymethyl)-
aminomethane buffer (72.5 μL of a 15 mM solution at pH 8.0), and
acetylthiocholine iodide (25 μL of a 150 μM aqueous solution) in
water. Enzyme activity was followed after the addition of AChE (25 μL
of 0.03 μM solution of Electrophorus electricus, Type V−S, EC 3.1.1.7)
by measuring the absorption at 412 nm using a microplate
spectrophotometer. Assays were repeated in triplicate, and the
hydrolysis rate was calculated during the data from the absorptions
observed over the first 2 min. Standard commercially available graphic
software was used to calculate the tabulated IC50 values.
Molecular Docking Studies. The three-dimensional coordinates
of each compound were generated with the PRODRG server (http://
davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg).47 Galanthamine and the
above-mentioned derivatives/analogues were docked into the structure
of human acetylcholine esterase (4EY6) using Autodock Vina v1.1.2
after removal of galanthamine from the active site gorge.48
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Abstract – Compound ent-1 as well as certain related homochiral and 
polyfunctionalized cyclohexenes have been prepared from the 1,2-diacetal 4 that 
is itself readily derived from L-tartaric acid (3). Grignard addition and 
ring-closing metathesis processes constitute the key steps associated with the 
reaction sequences involved. This work provides a method for obtaining a range 
of potentially useful cyclohexenone-containing chirons that are enantiomerically 
related to those that have been prepared from the homochiral 
cis-1,2-dihydrocatechol 2, the product of the microbial biotransformation of 
bromobenzene.
INTRODUCTION 
In connection with a study focused on acetylcholine esterase (AChE) inhibitors, we prepared, over five 
steps, the polyfunctionalized and homochiral -bromocyclohexenone 1 from the enantiomerically pure 
cis-1,2-dihydrocatechol 2.1 Compound 2 is the product of the microbial dihydroxylation of bromobenzene, 
a transformation that can be achieved particularly effectively with a genetically-engineered strain of E. 
coli that over-expresses the enzyme toluene dioxygenase (TDO).2 In order to fully explore the biological 
profiles of the AChE inhibitors in question, we required the enantiomer of compound 1, namely ent-1. 
While a logical precursor to this brominated cyclohexene is the cis-1,2-dihydrocatechol ent-2, the latter is 
not as readily accessible, especially in homochiral form, as congener 2.3 Accordingly, we sought another 
means for obtaining chiron ent-1 as well as related systems that could serve as valuable building blocks 
for the synthesis of various polyoxygenated cyclohexenes and their saturated counterparts. 
167
The groups of Madsen,4 Sulikowski5 and Yan6 have each demonstrated that the acetonide derived from 
D- or L-tartaric acid can be elaborated, via manipulation of the derived ester residues using reduction,
vinyl Grignard addition and then ring-closing metathesis (RCM) steps, into various conduritols or amino
pseudosugars. Prasad has described7 closely related chemistries. The RCM products so formed
incorporate rather unstable acetonide-protected cyclohex-4-ene-trans-1,2-diol moieties. On the other hand,
and during the course of establishing a total synthesis the macrolide antascomicin B (a potential
immunosuppressive agent), Ley8 and co-workers used a butanediacetal-protected dimethyl tartrate to
construct, via a late-stage RCM, a complex cyclohexene annulated to a 1,4-dioxane and that embodies a
stable masked trans-1,2-diol moiety. Herein we report on the exploitation of these types of protocols in
the synthesis of the target chiron ent-1 as well as a range of analogues that are likely to be of value in the
synthesis of a variety of biologically active systems.
RESULTS AND DISCUSSION 
The preparation of a series of poly-oxygenated and homochiral cyclohexenes from L-tartaric acid (3) is 
shown in Scheme 1 and started with the formation, under standard and operationally simple conditions, of 
diacetal diester 4 (72%). Reduction of the latter compound to the corresponding dialdehyde was achieved 
using di-iso-butylaluminium hydride (DIBAl-H) in toluene at –78 °C and this was immediately reacted 
with vinylmagnesium bromide5 to give the bis-olefin 5 as an inseparable mixture of diastereoisomers in 
88% combined yield. This mixture was treated with the Grubbs’-II catalyst in dichloromethane and so 
effecting a RCM reaction and thus forming a ca. 10:6:3 mixture of the three possible stereoisomeric 
forms of the anticipated cyclohexene 6 in 99% combined yield. 
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Scheme 1 
 
This mixture of cyclohexenes, which was characterized as such, was subjected to a two-fold oxidation 
with the Dess-Martin periodinane (DMP) and so affording the corresponding enedione 7 in 88% yield. 
 
While enedione 7 was prone to two-fold enolization and concomitant formation of the isomeric 
hydroquinone,9 this C2-symmetric compound could be stereoselectively reduced to the -hydroxyenone 8 
(94%) under Luche-type conditions. Confirmation of the stereochemical outcome associated with this 
conversion, which involves axial delivery of hydride,10 was achieved through the single-crystal X-ray 
analysis of a halogenated derivative. Specifically, successive treatment of compound 8 with molecular 
 
 
Figure 1. ORTEP derived from the single-crystal X-ray analysis of compound 9 (CCDC No. 1491822). 
Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen atoms are drawn as circles 
with small radii. 
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bromine then triethylamine at 0 °C11 afforded the crystalline -bromoenone 9 (79% yield) that was 
subjected to such an analysis. The derived ORTEP is shown in Figure 1 while other results of this 
analysis are provided in the Experimental Section. 
 
The completion of the synthesis of the target synthon ent-1 followed the pathway shown in Scheme 2 and 
involved the conversion of the -hydroxyenone 9 into the corresponding acetate, 10 (97%), under 
standard conditions. Luche reduction of compound 10 afforded a diastereoisomeric and 
chromatographically separable mixture of compounds 11 (7%) and 12 (79%). Subjection of the latter 
product to a Mitsunobu reaction, using p-methoxybenzoic acid as nucleophile and the 
N,N,N’,N’-tetramethylazodicarboxamide (TMAD)/tri-n-butylphosphine reagent combination,12 then 
afforded ester 13 (79%). Finally, cleavage of this ester using potassium hydroxide in methanol gave the 
target ent-1 in 96% yield. 
 
 
Scheme 2 
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The minor product, 11, derived from the reduction of -bromoenone 10 was readily and nearly 
quantitatively converted into compound ent-1 through treatment (Scheme 3) with potassium carbonate in 
methanol. All the spectral data acquired on compound ent-1 were consistent with the assigned structure 
and matched those recorded1 on its enantiomer (viz. 1) save for the specific rotation that was of similar 
magnitude but opposite in sign {viz. –76.5 (c 1.0 in CHCl3) for ent-1 vs +72.6 (c 1.1 in CHCl3) for 1}. 
Given this relationship and that the structure of compound 1 has been established through the 
single-crystal X-ray analysis of a derivative,1 the illustrated stereochemical array within compound ent-1 
is secure. 
 
 
Scheme 3 
 
Considering the ready availability of both D- and L-tartaric acid and the demonstrated utility of 
polyoxygenated and halogenated cyclohexenes in the synthesis,2 the simple protocols defined above 
should provide a useful new means for the assembly of biologically active systems, especially various 
conduritols and related compounds.15 Work directed towards such ends is now underway in our 
laboratories. Results will be reported in due course. 
EXPERIMENTAL 
General Experimental Procedures 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at 18 °C in 
base-filtered CDCl3 on a Varian spectrometer operating at 400 MHz for proton and 100 MHz for carbon 
nuclei. For 1H NMR spectra, signals arising from the residual protio-forms of the solvent were used as the 
internal standards. 1H NMR data are presented as follows: chemical shift ( ) [multiplicity, coupling 
constant(s) J (Hz), relative integral] where multiplicity is defined as: s = singlet; d = doublet; t = triplet; q 
= quartet; m = multiplet or combinations of the above. The signal due to residual CHCl3 appearing at H 
7.26 and the central resonance of the CDCl3 “triplet” appearing at C 77.1(6) were used to reference 1H 
and 13C NMR spectra, respectively. Infrared spectra ( max) were recorded on a Perkin–Elmer UTAR Two 
FTIR Spectrometer. Samples were analyzed as either thin films or finely divided solids. Low-resolution 
ESI mass spectra were recorded on a Micromass LC-ZMD single quadrupole liquid chromatograph-mass 
spectrometer while high-resolution measurements were conducted on an LCT Premier time-of-flight 
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instrument. Low- and high-resolution EI mass spectra were recorded on an Autospec Premier Micromass 
magnetic-sector machine. Optical rotations were recorded in CHCl3 at 20 °C on a Perkin Elmer Model 
343 Polarimeter. Melting points were measured on an Optimelt™ automated melting point system and are 
uncorrected. Analytical thin layer chromatography (TLC) was performed on aluminium-backed 0.2 mm 
thick silica gel 60 F254 plates as supplied by Merck. Eluted plates were visualized using a 254 nm UV 
lamp and/or by treatment with a suitable dip followed by heating. These dips included phosphomolybdic 
acid : ceric sulfate : sulfuric acid (conc.) : water (37.5 g : 7.5 g : 37.5 g : 720 mL) or potassium 
permanganate : potassium carbonate : 5% sodium hydroxide aqueous solution : water (3 g : 20 g : 5 mL : 
300 mL). Flash chromatographic separations were carried out following protocols defined by Still et al.13 
with silica gel 60 (40–63 μm) as the stationary phase and using the AR- or HPLC-grade solvents 
indicated. Starting materials and reagents were generally available from the Sigma–Aldrich, Merck, TCI, 
Strem or Lancaster Chemical Companies and were used as supplied. Drying agents and other inorganic 
salts were purchased from the AJAX, BDH or Unilab Chemical Companies. Diethyl ether, 
N,N-dimethylformamide (DMF), CH2Cl2 and EtOAc were dried using a Glass Contour solvent 
purification system that is based upon a technology originally described by Grubbs et al.14 Where 
necessary, reactions were performed under an inert atmosphere. 
 
Specific Experimental Procedures and Product Characterization 
Dimethyl (2R,3R,5R,6R)-5,6-dimethoxy-5,6-dimethyl-1,4-dioxane-2,3-dicarboxylate (4) 
Using a modification of a procedure reported16 by Maycock and co-workers, a magnetically stirred 
solution of L–tartaric acid (11.87 g, 79.09 mmol), 2,3-butanedione (7.25 mL, 80 mmol) and trimethyl 
orthoformate (50 mL, 466 mmol) in dry MeOH (100 mL) was treated with p-toluenesulfonic acid 
monohydrate (710 mg, 5 mol%). The resulting solution was heated under reflux for 24 h and the ensuing 
deep-red mixture then cooled to room temperature and neutralized with NaHCO3 (4.00 g). Stirring was 
continued for 0.5 h then the reaction mixture was concentrated under reduced pressure. The residue thus 
obtained was diluted with EtOAc (100 mL) then NaHCO3 (30 mL of a saturated aqueous solution) added 
and the separated organic phase washed with NaHCO3 (1  30 mL of a saturated aqueous solution) then 
water (1  30 mL). The combined aqueous layers were extracted with EtOAc (3  30 mL) and the 
combined organic phases then washed with brine (2  20 mL) before being dried (Na2SO4), filtered and 
concentrated under reduced pressure. The yellow solid thus obtained was recrystallized (hexane/EtOAc) 
and the resulting solid collected and washed successively with ice-cold hexane and ice-cold EtOAc to 
give bis-ester 416,17 (16.73 g, 72%) as an off-white, crystalline solid, mp 107–108 ºC (lit.17 mp 106–
108 °C), [ ]D –135.7 (c 1.1, CHCl3) {lit.17 [ ]D –139.6 (c 1.0, CHCl3)} [Found: (M + K)+, 331.0777. 
C12H20KO8 requires (M + K)+, 331.0795]. 1H NMR (CDCl3, 400 MHz) H 4.54 (s, 2H), 3.77 (s, 6H), 3.32 
172
(s, 6H), 1.36 (s, 6H); 13C NMR (CDCl3, 100 MHz) C 168.6, 99.4, 68.9, 52.7, 48.6, 17.5; IR (solid) max 
2992, 1736, 1443, 1377, 1282, 1202, 1139, 1110, 1026, 898, 886, 810, 744 cm–1; MS (ESI, +ve) m/z 315 
[(M + Na)+, 100%]. 
1,1'-((2S,3S,5R,6R)-5,6-Dimethoxy-5,6-dimethyl-1,4-dioxane-2,3-diyl)bis(prop-2-en-1-ol) (5) 
A magnetically stirred solution of bis-ester 4 (3.10 g, 10.63 mmol) in dry toluene (30 mL) was cooled to  
–78 ºC then DIBAl-H (22.3 mL of a 1 M solution in toluene, 22.3 mmol) added, via syringe-pump, over 
0.75 h. The ensuing mixture was stirred at –78 ºC for 2 h then vinylmagnesium bromide (74.4 mL of a 1 
M solution in THF, 74.4 mmol) was added dropwise over 0.5 h. The solution thus formed was stirred at  
–78 ºC for 0.5 h then allowed to warm to room temperature. After 16 h the reaction mixture was cooled to 
0 ºC, quenched with Rochelle salt (100 mL of a saturated solution: CAUTION slow addition required) 
then re-warmed to room temperature and stirring continued for 3 h. The resulting biphasic mixture was 
transferred to a separating funnel and the organic layer separated then washed with water (1  100 mL). 
The combined aqueous layers were extracted with EtOAc (3  30 mL) and the combined organic phases 
then washed with brine (3  30 mL) before being dried (Na2SO4), filtered and concentrated under reduced 
pressure. The ensuing thick, orange oil was subjected to flash column chromatography (silica, hexane  
1:1 v/v EtOAc/hexane gradient elution) and concentration of appropriate fractions (Rf = 0.5 in 1:1 v/v 
EtOAc/hexane) afforded bis-allylic alcohol 5 (2.69 g, 88%) as a clear, colorless oil and a mixture of 
diastereoisomers [Found: (M + Na)+, 311.1465. C14H24NaO6 requires (M + Na)+, 311.1471]. 1H NMR 
(CDCl3, 400 MHz) H (mixture of three diastereoisomers) 6.12–5.94 (complex m, 2H), 5.40–5.15 (series 
of m, 4H), 4.31–4.17 (complex m, 2H), 4.03–3.65 (series of m, 2H), 3.24–3.19 (4  s, 6H), 2.70–2.30 
(series of m, 2H), 1.28–1.27 (3  s, 6H); 13C NMR (CDCl3, 100 MHz) C (mixture of three 
diastereoisomers) 138.1, 138.0, 136.7(2), 136.6(8), 117.2, 116.8, 116.1, 115.8, 99.0, 98.9, 98.8(1), 98.7(9), 
72.6, 72.3, 72.1, 71.6, 71.3, 70.5, 48.1(0), 48.0(6), 17.6(1), 17.5(9), 17.5; IR (film) max 3407, 2991, 2949, 
2833, 1375, 1121, 1036, 997, 921, 852 cm–1; MS (ESI, +ve) m/z 311 [(M + Na)+, 100%]. 
(2R,3R,4aS,8aS)-2,3-Dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-5,8-diol 
(6) 
A solution of the bis-allylic alcohol 5 (2.67 g, 9.25 mmol) in CH2Cl2 (200 mL) was sonicated under an 
atmosphere of nitrogen for 0.5 h then Grubbs’-II catalyst (157 mg, 2 mol%) was added in one portion. 
The ensuing mixture was heated under reflux for 1.5 h then cooled to room temperature and the solvent 
removed under reduced pressure. The resulting brown solid was subjected to flash column 
chromatography (silica, 1:1 v/v EtOAc/hexane  EtOAc gradient elution) and concentration of 
appropriate fractions (Rf = 0.3 in 2:1 v/v EtOAc/hexane) afforded cyclohexene 6 (2.39 g, 99%) as a white, 
amorphous solid and a mixture of diastereoisomers [Found: (M + Na)+, 283.1165. C12H20NaO6 requires 
(M + Na)+, 283.1158]. 1H NMR (CDCl3, 400 MHz) H (mixture of three diastereoisomers) 6.07–5.62 
173
(series of m, 2H), 4.51–4.20 (complex m, 2H), 4.10–3.57 (series of m, 2H), 3.49 (broad m, 1H), 3.36–
3.24 (4  s, 6H), 2.64–2.09 (series of broad m, 1H), 1.39–1.28 (4  s, 6H). 13C NMR (CDCl3, 100 MHz) 
C 132.9, 130.0, 129.3, 126.6, 100.0, 99.8, 99.3, 99.1, 72.5, 70.6, 70.3, 69.7, 67.9, 65.9, 65.5, 65.3, 48.3, 
48.2, 48.1(3), 48.0(7), 17.9(4), 17.9(0), 17.8(2), 17.8(0); IR (solid) max 3313, 2948, 1465, 1373, 1204, 
1117, 1030, 971, 915, 886, 847 cm–1; MS (ESI, +ve) m/z 283 [(M + Na)+, 100%]. 
(2R,3R,4aR,8aR)-2,3-Dimethoxy-2,3-dimethyl-2,3,4a,8a-tetrahydrobenzo[b][1,4]dioxine-5,8-dione 
(7) 
Dess-Martin periodane (23.80 g, 53.31 mmol) was added, in portions, to a magnetically stirred solution of 
compound 6 (4.63 g, 17.78 mmol) in CH2Cl2 (25 mL) maintained at 0 ºC. After addition was complete 
(0.25 h) the cooling bath was removed and the reaction mixture was stirred at room temperature for 2 h 
before being concentrated under reduced pressure at 20 ºC. The residue thus obtained was subjected to 
rapid flash chromatography (silica, 2:8 v/v pentane/Et2O elution) and concentration of the relevant 
fractions (Rf = 0.7 in 1:2 v/v CH2Cl2/Et2O) at 20 ºC afforded enedione 7 (4.01 g, 88%) as a bright yellow, 
crystalline solid, mp 115–117 ºC (dec.), [ ]D –121.0 (c 0.9 in CHCl3) [Found: (M + Na)+, 279.0850. 
C12H16NaO6 requires (M + Na)+, 279.0845]. 1H NMR (CDCl3, 400 MHz) H 6.84 (s, 2H), 4.73 (s, 2H), 
3.26 (s, 6H), 1.41 (s, 6H); 13C NMR (CDCl3, 100 MHz) C 192.1, 140.1, 100.6, 73.9, 48.7, 17.6; IR 
(solid) max 2954, 2849, 1699, 1380, 1133, 1113, 1027, 823, 543 cm–1; MS (ESI, +ve) m/z 343 [(M + 2  
CH3OH + Na)+, 100%], 311 [(M + CH3OH + Na)+, 50], 279 [(M + Na)+, 10]. 
(2R,3R,4aR,8R,8aS)-8-Hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,8,8a-tetrahydrobenzo[b][1,4]dioxin-  
5(4aH)-one (8) 
Sodium borohydride (770 mg, 20.35 mmol) was added, in portions over 0.08 h, to a magnetically stirred 
solution of CeCl3 2O (7.60 g, 20.40 mmol) in MeOH (50 mL) maintained at 0 ºC. The ensuing mixture 
was stirred at this temperature for 0.25 h then transferred to a pressure-equalized dropping funnel and 
added dropwise to a magnetically solution of endione 7 (4.01 g, 15.67 mmol) in MeOH (150 mL) that had 
been cooled to –78 ºC. After 1.5 h further portions of NaBH4 (5  10 mg, 1.32 mmol) were slowly added 
until the yellow reaction mixture became colorless and at which point it was quenched with acetone (20 
mL). NH4Cl (100 mL of a saturated aqueous solution) was added to the reaction mixture so-formed that 
was then allowed to warm to room temperature. The ensuing mixture was concentrated under reduced 
pressure and the residue thus obtained diluted with EtOAc (100 mL) and water (50 mL). The separated 
aqueous layer was extracted with EtOAc (3  50 mL) and the combined organic phases then washed with 
brine (2  50 mL) before being dried (Na2SO4), filtered and concentrated under reduced pressure. The 
residue thus generated was subjected to flash column chromatography (silica, CH2Cl2  1:2 v/v 
Et2O/CH2Cl2 gradient elution) and concentration of appropriate fractions (Rf = 0.2 in 1:1 v/v 
EtOAc/hexane) afforded enone 8 (3.79 g, 94%) as a clear, colorless oil, [ ]D –215.0 (c 0.5, CHCl3) 
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[Found: (M + Na)+, 281.1006. C12H18NaO6 requires (M + Na)+, 281.1001]. 1H NMR (CDCl3, 400 MHz) 
H 6.85 (dd, J = 10.5 and 2.0 Hz, 1H), 6.07 (dd, J = 10.5 and 2.6 Hz, 1H), 4.67 (m, 1H), 4.25 (d, J = 11.4 
Hz, 1H), 3.96 (dd, J = 11.4 and 8.7 Hz, 1H), 3.31 (s, 3H), 3.28 (s, 3H), 2.55 (d, J = 3.9 Hz, 1H), 1.42 (s, 
3H), 1.36 (s, 3H); 13C NMR (CDCl3, 100 MHz) C 193.5, 148.6, 128.4, 100.3, 99.4, 74.3, 72.3, 70.1, 48.7, 
48.2, 17.7(3), 17.6(6); IR (film) max 3452, 2958, 1683, 1379, 1118, 1028, 967, 947, 881, 806, 634, 585, 
540 cm–1; MS (ESI, +ve) m/z 281 [(M + Na)+, 100%]. 
(2R,3R,4aR,8R,8aS)-6-Bromo-8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,8,8a-tetrahydrobenzo[b][1, 
4]dioxin-5(4aH)-one (9) 
Molecular bromine (400 μL of a 10% v/v solution in CH2Cl2, 0.79 mmol) was added, dropwise, to a 
magnetically stirred solution of enone 8 (185 mg, 0.72 mmol) in CH2Cl2 maintained at –5 ºC. The 
resulting solution was stirred at this temperature for 1 h then triethylamine (300 μL, 2.15 mmol) added 
dropwise. The cooling bath was then removed and the reaction mixture stirred at room temperature for 16 
h before being quenched with sodium sulfite (2 mL of a saturated aqueous solution). The separated 
organic layer was washed successively with sodium sulfite (3  5 mL of a saturated aqueous solution) and 
NH4Cl (3  5 mL of an aqueous solution) then the combined aqueous washings were extracted with 
EtOAc (3  10 mL). The combined organic phases were washed with brine (2  10 mL) before being 
dried (Na2SO4), filtered and concentrated under reduced pressure. The ensuing residue was subjected to 
flash column chromatography (silica, CH2Cl2  1:9 v/v Et2O/CH2Cl2 gradient elution) and concentration 
of appropriate fractions (Rf = 0.2 in 1:9 v/v Et2O/CH2Cl2) afforded bromoenone 9 (190 mg, 79 %) as a 
white, crystalline solid, mp 178–181 °C, [ ]D –146.6 (c 0.5, CHCl3) [Found: (M + Na)+, 359.0100. 
C12H1779BrNaO6 requires (M + Na)+, 359.0106]. 1H NMR (CDCl3, 400 MHz) H 7.29 (d, J = 2.3 Hz, 1H), 
4.63 (ddd, J = 8.6, 4.1 and 2.3 Hz, 1H), 4.28 (d, J = 11.4 Hz, 1H), 3.98 (dd, J = 11.4 and 8.6 Hz, 1H), 
3.31 (s, 3H), 3.28 (s, 3H), 2.57 (d, J = 4.1 Hz, 1H), 1.42 (s, 3H), 1.35 (s, 3H); 13C NMR (CDCl3, 100 
MHz) C 186.3, 148.6, 123.2, 100.5, 99.3, 73.6, 71.6, 70.5, 48.8, 48.3, 17.6(3), 17.5(9); IR (solid) max 
3480, 2945, 1712, 1601, 1450, 1373, 1334, 1279, 1205, 1141, 1110, 1023, 907, 888, 870, 858, 606, 782, 
663, 606, 517, 440 cm–1; MS (ESI, +ve) m/z 361 and 359 [(M + Na)+, 98 and 100%, respectively]. 
(2R,3R,4aS,5R,8aR)-7-Bromo-2,3-dimethoxy-2,3-dimethyl-8-oxo-2,3,4a,5,8,8a-hexahydrobenzo[b][1,
4]dioxin-5-yl acetate (10) 
Acetic anhydride (120 μL, 1.25 mmol) was added to a magnetically stirred solution of bromoenone 9 
(140 mg, 0.416 mmol) in pyridine (5 mL). Stirring was continued at room temperature for 1 h then the 
reaction mixture was concentrated under reduced pressure to afford acetate 10 (153 mg, 97%) as a white 
foam, [ ]D –366.5 (c 0.6, CHCl3) [Found: (M + Na)+, 401.0217. C14H1979BrNaO7 requires (M + Na)+, 
401.0212]. 1H NMR (CDCl3, 400 MHz) H 7.13 (d, J = 2.4 Hz, 1H), 5.67 (dd, J = 8.9 and 2.4 Hz, 1H), 
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4.39 (d, J = 11.2 Hz, 1H), 4.18 (dd, J = 11.2 and 8.9 Hz, 1H), 3.29 (s, 3H), 3.25 (s, 3H), 2.16 (s, 3H), 1.40 
(s, 3H), 1.31 (s, 3H); 13C NMR (CDCl3, 100 MHz) C 185.9, 170.1, 144.8, 124.3, 100.5, 99.3, 71.7, 71.0, 
70.6, 48.7, 48.1, 20.9, 17.6, 17.5; IR (solid) max 2952, 1751, 1720, 1377, 1220, 1135, 1113, 1028, 979, 
918, 886, 853, 786, 662 cm–1; MS (ESI, +ve) m/z 467 and 465 [(M + 2  CH3OH + Na), 98 and 100%, 
respectively], 403 and 401 [(M + Na)+, 30 and 29, respectively]. 
(2R,3R,4aS,5R,8aR)-7-Bromo-2,3-dimethoxy-2,3-dimethyl-8-oxo-2,3,4a,5,8,8a-hexahydrobenzo[b][1,
4]dioxin-5-yl acetate (11) and (2R,3R,4aS,5R,8S,8aS)-7-Bromo-8-hydroxy-2,3-dimethoxy-2,3- 
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxin-5-yl acetate (12) 
Sodium borohydride (211 mg, 5.59 mmol) was added, in portions over 0.08 h, to a magnetically stirred 
solution of CeCl3 2O (1.09 g, 2.93 mmol) in MeOH (20 mL) maintained at 0 ºC. The ensuing mixture 
was stirred at this temperature for 0.25 h then transferred to a pressure-equalized dropping funnel and 
added dropwise to a magnetically solution of acetate 10 (1.06 g, 2.79 mmol) in MeOH (100 mL) 
maintained at –78 ºC. After 1 h the reaction mixture was allowed to warm to room temperature, quenched 
with water (5 mL) and concentrated under reduced pressure. The residue thus obtained was diluted with 
EtOAc (100 mL) and NH4Cl (50 mL of a saturated aqueous solution). The separated aqueous layer was 
extracted with EtOAc (3  50 mL) and the combined organic phases then washed with brine (2  50 mL) 
before being dried (Na2SO4), filtered and concentrated under reduced pressure. The residue thus obtained 
was subjected to flash column chromatography (silica, 1:19 v/v Et2O/CH2Cl2) to afford two fractions, A 
and B. 
Concentration of fraction A (Rf = 0.3 in 1:19 v/v Et2O/CH2Cl2) afforded compound 11 (76 mg, 7%) as a 
clear, colorless oil, [ ]D –160.0 (c 0.9, CHCl3) [Found: (M + Na)+, 403.0373. C14H2179BrNaO7 requires 
(M + Na)+, 403.0368]. 1H NMR (CDCl3, 400 MHz) H 6.12 (d, J = 2.5 Hz, 1H), 5.30 (dd, J = 8.4 and 2.5 
Hz, 1H), 4.35 (d, J = 4.0 Hz, 1H), 4.16 (dd, J = 11.0 and 8.4 Hz, 1H), 3.78 (dd, J = 11.0 and 4.0 Hz, 1H), 
3.27 (s, 3H), 3.26 (s, 3H), 2.74 (broad s, 1H), 2.09 (s, 3H), 1.33 (s, 3H), 1.29 (s, 3H); 13C NMR (CDCl3, 
100 MHz) C 170.5, 130.6, 123.8, 100.1, 99.3, 72.2, 72.1, 67.6, 65.1, 48.4, 48.0, 21.1, 17.8, 17.7; IR 
(film) max 3475, 2950, 1750, 1733, 1371, 1230, 1135, 1116, 1033, 970, 933, 886, 851, 732 cm–1; MS 
(ESI, +ve) m/z 405 and 403 [(M + Na)+, 100 and 98%, respectively]. 
Concentration of fraction B (Rf = 0.2 in 1:19 v/v Et2O/CH2Cl2) afforded compound 12 (840 mg, 79%) as 
a clear, colorless oil, [ ]D –204.7 (c 0.9, CHCl3) [Found: (M + Na)+, 403.0367. C14H2179BrNaO7 requires 
(M + Na)+, 403.0368]. 1H NMR (CDCl3, 400 MHz) H 6.04 (app. t, J = 2.1 Hz, 1H), 5.38 (m, 1H), 4.35 
(m, 1H), 3.90 (dd, J = 11.0 and 8.3 Hz, 1H), 3.81 (dd, J = 11.0 and 7.8 Hz, 1H), 3.31 (s, 3H), 3.27 (s, 3H), 
2.53 (s, 1H), 2.09 (s, 3H), 1.34 (s, 3H), 1.30 (s, 3H); 13C NMR (CDCl3, 100 MHz) C 170.3, 128.5, 127.1, 
99.4, 99.2, 72.1, 71.8, 71.4, 68.6, 48.2, 48.0, 21.1, 17.7, 17.6; IR (film) max 3474, 2919, 2850, 1737, 
1369, 1229, 1118, 1020, 969, 914, 886, 852, 795, 736 cm–1; MS (ESI, +ve) m/z 405 and 403 [(M + Na)+, 
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100 and 98%, respectively]. 
(2R,3R,4aR,5R,8R,8aS)-8-Acetoxy-6-bromo-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydro- 
benzo[b][1,4]dioxin-5-yl 4-methoxybenzoate (13) 
Tri-n-butylphosphine (520 μL, 2.08 mmol) was added to a magnetically stirred solution of allylic alcohol 
12 (397 mg, 1.04 mmol) and p-methoxybenzoic acid (316 mg, 2.08 mmol) in benzene (7 mL). The 
solution thus obtained was cooled to 0 ºC then N,N,N ,N -tetramethylazodicarboxamide (TMAD) (376 mg, 
2.08 mmol) was added in one portion. The ensuing mixture was stirred at 0 °C for 0.25 h then heated 
under reflux for 48 h. The cooled solution was filtered through a short pad of diatomaceous earth and the 
filtrate concentrated under reduced pressure. The residue thus obtained was subjected to flash column 
chromatography (silica, CH2Cl2  1:19 v/v Et2O/CH2Cl2 gradient elution) and concentration of 
appropriate fractions (Rf = 0.5 in 1:9 v/v Et2O/CH2Cl2) afforded ester 13 (422 mg, 79%) as a white, 
amorphous solid, [ ]D –28.3 (c 1.1, CHCl3) [Found: (M + Na)+, 537.0734. C22H2779BrNaO9 requires (M + 
Na)+, 537.0736]. 1H NMR (CDCl3, 400 MHz) H 8.05 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 8.9 Hz, 2H), 6.24 
(d, J = 2.5 Hz, 1H), 5.97 (d, J = 4.2 Hz, 1H), 5.37 (dd, J = 8.5 and 2.5 Hz, 1H), 4.28 (dd, J = 11.1 and 8.5 
Hz, 1H), 3.95 (dd, J = 11.1 and 4.2 Hz, 1H), 3.88 (s, 3H), 3.30 (s, 3H), 3.25 (s, 3H), 2.14 (s, 3H), 1.27 (s, 
3H), 1.10 (s, 3H); 13C NMR (CDCl3, 100 MHz) C 170.4, 165.8, 163.6, 132.6, 132.3, 122.5, 121.0, 113.7, 
99.6, 99.3, 72.2, 71.9, 66.7, 66.0, 55.6, 48.4, 47.9, 21.1, 17.7, 17.4; IR (film) max 2980, 1724, 1605, 1511, 
1372, 1254, 1226, 1166, 1117, 1083, 1051, 1028, 971, 933, 765, 699, 663, 611 cm–1; MS (ESI, +ve) m/z 
539 and 537 [(M + Na)+, 100 and 98%, respectively]. 
(2R,3R,4aS,5R,8R,8aS)-6-Bromo-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]-
dioxine-5,8-diol (ent-1) 
Method i (ex. Compound 13): Potassium hydroxide (60 mg, 1.07 mmol) was added to a magnetically 
stirred solution of compound 13 (103 mg, 0.20 mmol) in MeOH (10 mL) and the ensuing mixture stirred 
at room temperature for 48 h. The MeOH was then removed under reduced pressure and the residue thus 
obtained diluted with EtOAc (10 mL) and NH4Cl (10 mL of a saturated aqueous solution). The separated 
aqueous layer was extracted with EtOAc (3  5 mL) and the combined organic phases washed with brine 
(2  5 mL) before being dried (Na2SO4), filtered and concentrated under reduced pressure. The resulting 
white solid was subjected to flash column chromatography (silica,  1:24 v/v Et2O/CH2Cl2 gradient 
elution) and concentration of appropriate fractions (Rf = 0.3 in 1:19 v/v MeOH/CH2Cl2) afforded enediol 
ent-1 (65 mg, 96%) as a white foam, [ ]D –76.5 (c 1.0, CHCl3) [Found: (M + Na)+, 361.0260. 
C12H1979BrNaO6 requires (M + Na)+, 361.0263]. 1H NMR (CD3OD, 400 MHz) H 6.05 (d, J = 2.5 Hz, 
1H), 4.22 (d, J = 4.1 Hz, 1H), 4.06 (dd, J = 7.9 and 2.5 Hz, 1H), 3.87 (dd, J = 11.1 and 7.9 Hz, 1H), 3.63 
(dd, J = 11.1 and 4.1 Hz, 1H), 3.30 (s, 3H), 3.26 (s, 3H), 1.32 (s, 3H), 1.29 (s, 3H) (signals due to 
hydroxyl group protons not observed); 13C NMR (CD3OD, 100 MHz) C 135.3, 124.0, 100.8, 100.2, 73.1, 
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71.8, 69.9, 69.2, 48.3(1), 48.2(5), 18.1, 18.0; IR (film) max 3236, 3007, 2954, 2905, 2834, 1114, 1074, 
1054, 1030, 985, 912, 884, 852, 760, 665, 617, 599 cm–1; MS (ESI, +ve) m/z 363 and 361 [(M + Na)+, 98 
and 100%, respectively]. 
Method ii (ex. Compound 11): Potassium carbonate (50 mg, 0.36 mmol) was added to a magnetically 
stirred solution of ester 11 (76 mg, 0.20 mmol) in MeOH (10 mL) and the resulting mixture stirred at 
room temperature for 12 h then concentrated under reduced pressure. The residue thus obtained was 
diluted with EtOAc (10 mL) and water (10 mL) then the separated aqueous layer extracted with EtOAc (3 
 5 mL). The combined organic phases were washed with brine (2  5 mL) before being dried (Na2SO4), 
filtered and concentrated under reduced pressure to give enediol ent-1 (67 mg, 99%) as a white foam. 
This material was identical, in all respects, with that obtained by Method i. 
 
X-Ray Crystallographic Study 
Crystallographic Data 
Compound 9: C12H17BrO6, M = 337.17, T = 150 K, orthorhombic, space group P212121, Z = 4, a = 
6.8265(1), b = 11.4217(1), c = 17.8288(1) Å; V = 1390.12(1) Å3; Dx = 1.611 g cm–3; 2750 unique data 
(2 max 144.6°), R = 0.021 [for 2718 reflections with I > 2.0 (I)]; Rw = 0.052 (all data), S = 1.03. 
Structure Determination 
Images were measured on an Agilent SuperNova CCD diffractometer (CuK , mirror monochromator, 
 = 1.54184 Å) and data extracted using the CrysAlis package.18 Structure solution was by direct methods 
(SIR92).19 The structure of compound 9 was refined using the CRYSTALS program package.20 Atomic 
coordinates, bond lengths and angles, and displacement parameters have been deposited at the Cambridge 
Crystallographic Data Centre (CCDC no. 1491822). These data can be obtained free-of-charge via 
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by contacting The 
Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 
336033. 
 
Supplementary Material 
The 1H and 13C NMR spectra of compounds 4–13 and ent-1 are available on the Journal’s website. 
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ABSTRACT: A total synthesis of compound 3 from D-(−)-tartaric acid is
reported, thereby establishing that the structure, including relative stereo-
chemistry, originally assigned to the cyclic carbonate-containing natural
product aspergillusol B is correct.
In 2014 Rukachaisirikul and co-workers reported1 on theisolation and structural elucidation of a series of metabolites
from the culture broth of the fungus Aspergillus sp. PSU-
RSPG185 found in soil samples collected from Surat Thani
Province in Thailand. Among these were (+)-asperpentyn (1)2
and two novel cyclic carbonate-containing compounds, named
aspergillusols A and B, and to which structures 2 and 3,
respectively, were assigned.3,4
The following year we detailed5 the syntheses of compound 1
and the enantiomer, ent-2, of the structure assigned to the first of
these cyclic carbonates. The enzymatically derived and enanti-
omerically pure cis-1,2-dihydrocatechol 46 was used as the
starting material in this work, and by such means we were able to
confirm the structures of (+)-asperpentyn (1) and aspergillusol A
save for the absolute stereochemistry of the latter. This ambiguity
arose because of the significant difference in the specific rotation
recorded for the synthetically derived compound ent-2 {[α]D =
+192.5 (c 0.2, methanol} and that reported for the natural product
{[α]D = −4.6 (c 0.49, methanol}.
Recently, we reported7 procedures that allow for the con-
version of L-(+)-tartaric acid into a range of cyclohexene-based
chirons that are likely to have broad applications in chemical
synthesis. Of course, the enantiomeric forms of these chirons will
be available by using D-(−)-tartaric acid and in order to showcase
the utility of our protocols, we now report on their use to prepare,
for the first time, compound 3 in enantiomerically pure form
from this abundant and enantiomerically pure starting material.
■ RESULTS AND DISCUSSION
The synthetic route shown in Scheme 1 was used to convert
D-(−)-tartaric acid (5) into a series of chiral cyclohexenes, and
this parallels, exactly, the one employed to make the
enantiomeric systems. Thus, compound 5 was treated with a
mixture of diacetyl, trimethyl orthoformate, and catalytic
amounts of p-toluenesulfonic acid monohydrate in hot methanol
to give the Ley diacetal 6 in 72% yield. Treatment of a toluene
solution of the latter compound with 2 molar equiv of di-
isobutylaluminum hydride (DIBAl-H) at −78 °C and then with
7 molar equiv of vinylmagnesium bromide afforded, after
allowing the reaction mixture to warm to ambient temperatures,
a diastereoisomeric mixture of the anticipated bis-allylic alcohols
in 85% yield. This mixture was subjected to ring-closing
metathesis using Grubbs-II catalyst in dichloromethane at ca.
40 °C and by such means the analogous mixture of cyclohexene
diols 8 was obtained in 94% combined yield. Twofold oxidation
of this mixture using the Dess−Martin periodinane (DMP) in
dichloromethane at 0 °C afforded the corresponding enedione 9
(86% yield). Unsurprisingly, and in keeping with earlier
observations, compound 9 was prone to aromatization to the
isomeric hydroquinone through a 2-fold enolization process.
Accordingly, this centrosymmetric species was immediately
reduced with just over 1 molar equiv of the Luche reagent in
methanol at −78 °C, thereby delivering the γ-hydroxycyclohex-
enone 10 completely stereoselectively and in 84% yield.
All the of IR, NMR, and mass spectral data acquired on this
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last compound matched those reported7 for its enantiomer
derived from L-(+)-tartaric acid. Furthermore, the specific
rotation of compound 10 was of equal magnitude but opposite
sign to that recorded7 for its enantiomer (viz., ent-10).
The conversion the γ-hydroxycyclohexenone 10 into the
target cyclic carbonate 3 followed the reaction pathway shown
in Scheme 2. Thus, the former compound was engaged in a
Mitsunobu reaction using p-nitrobenzoic acid as nucleophile, and
the enone-ester 11 (99%) so-formed subjected to a Johnson
α-iodination reaction using molecular iodine and pyridine in
dichloromethane in the presence of a catalytic amound of
4-(N,N-dimethylamino)pyridine (DMAP). By such means
compound 12 (99%) was obtained. Luche reduction of enone
12 in methanol at −78 °C proceeded in a completely stereo-
selective manner and after the intermediate diol monoester
was saponified, using aqueous sodium hydroxide, diol 13 was
obtained in 87% yield. Cleavage of the Ley diacetal unit within
the last compound was achieved using a mixture of trifluoroacetic
Scheme 1. Elaboration of D-(−)-Tartaric Acid (5) to Homochiral Cyclohexenone Derivatives
Scheme 2. Conversion of Compound 10 into Cyclic Carbonate 3
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.7b00303
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acid (TFA) and water in dichloromethane at 22 °C and by such
means the iodocondurtitol 14 (95%) was obtained. Tetra-ol 14 is
a known compound but because the reported8 spectral data did
not match those we acquired on this material a single-crystal
X-ray analysis was carried out (Figure 1).9 This served to confirm
the illustrated structure (including absolute stereochemistry) for
compound 14 obtained by the present pathway. Following pro-
tocols established in our earlier studies,5,10 iodide 14was engaged
in a Sonogashira cross-coupling reaction with commercially avail-
able 2-methylbut-1-en-3-yne using copper(I) iodide, PdCl2(PPh3)2
and triethylamine in dimethylformamide (DMF). In this way
the rather insoluble dienyne 15 (80%) was obtained. In the final
step of the reaction sequence, compound 15 was treated with
bis(trichloromethyl)carbonate (triphosgene) in the presence
of triethylamine and using tetrahydrofuran (THF) as solvent.
Compound 3 was thereby obtained as a white powder in 26%
yield [56% based on recovered starting material (brsm)]. All the
spectral data acquired on this cyclic carbonate were in complete
accord with the assigned structure. Diol 3 was converted, under
standard conditions, into the crystalline bis p-nitrobenzoate 16
(87%). While the spectral data acquired on this derivative were
also in complete accord with the illustrated structure, all efforts to
secure a single-crystal X-ray analysis of this crystalline material
were unsuccessful.
A comparison of the spectral data derived from compound 3
with the equivalent data reported1 for aspergillusol B by
Rukachaisirikul and co-workers revealed a very good match
(see Table 1). Unfortunately, this group did not report a specific
rotation for the naturally derived material. Accordingly, while the
absolute stereochemistry of the synthetic material is as illustrated,
the corresponding configuration of the natural product cannot be
defined at the present time.
■ CONCLUSIONS
The studies reported herein not only serve to confirm the
structure assigned to aspergillusol B but also highlight the
capacities of our recently reported protocols7 to deliver a range of
synthetically useful homochiral polyoxygenated cyclohexenes in
either enantiomeric form from D- or L-tartaric acid, each of which
is an abundant material. Efforts to further demonstrate the utility
of such chirons are currently under way in our laboratories and
results will be reported in due course.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Unless otherwise specified,
proton (1H) and carbon (13C) NMR spectra were recorded at room
temperature in base-filtered CDCl3 on a Varian spectrometer operating
at 400 MHz for proton and 100 MHz for carbon nuclei. The signal due
to residual CHCl3 appearing at δH 7.26 and the central resonance of the
CDCl3 triplet appearing at δC 77.1(6) were used to reference
1H and 13C
NMR spectra, respectively. 1H NMR data are recorded as follows:
chemical shift (δ) [multiplicity, coupling constant(s) J (Hz), relative
integral] where multiplicity is defined as s = singlet; d = doublet;
t = triplet; q = quartet; m = multiplet or combinations of the above.
Infrared spectra (νmax) were recorded on a Perkin−Elmer 1800 Series
FTIR spectrometer. Samples were analyzed as either thin films or finely
divided solids. Low-resolution ESI mass spectra were recorded on a
single quadrupole liquid chromatograph−mass spectrometer, while
Figure 1. ORTEP derived from the single-crystal X-ray analysis of com-
pound 14 (CCDC 1533559) with labeling of selected atoms. Anisotropic
displacement ellipsoids display 30% probability levels. Hydrogen atoms
are drawn as circles with small radii, and the hydrogen-bonding linking the
two molecules in the unit cell is shown by a dotted line.
Table 1. Comparison of the 13C and 1H NMR Data Recorded for Synthetically Derived Compound 3 with Those Reported1 for
Aspergillusol B
13C NMR (δC)
1H NMR (δH)
aspergillusol Ba compound 3b aspergillusol Bc compound 3d
153.4 153.6 6.06, dd, J = 3.9 and 2.1 Hz, 1H 6.13, br s, 1H
130.2 130.3 5.36, quintet, J = 3.9, and 1.8 Hz, 1H 5.44, br s, 1H
125.7 125.7 5.34, quintet, J = 1.8 Hz, 1H 5.38, br s, 1H
124.5 124.5 5.15, ddd, J = 7.8, 3.9, and 2.1 Hz, 1H 5.21, dd, J = 7.5 and 3.4 Hz, 1H
124.3 124.3 4.64, dd, J = 8.7 and 7.8 Hz, 1H 4.71, apt t, J = 8.5 Hz, 1H
96.7 96.6 4.03, dt, J = 8.7 and 1.8 Hz, 1H 4.09, d, J = 8.4 Hz, 1H
82.5 82.6 4.19, m, 1H
77.3 77.4 3.76, t, J = 8.7 Hz, 1H 3.83, br t, J = 8.7 Hz, 1H
73.0 72.9e 1.88, t, J = 1.2 Hz, 3H 1.95, s, 3Hf
72.8 72.9e
69.0 69.0
23.0 23.1
aData obtained from ref 1, recorded in CDCl3 at 125 MHz.
bData recorded in CDCl3 containing 1% (H3C)4Si at 100 MHz.
cData obtained from
ref 1, recorded in CDCl3 at 500 MHz.
dData recorded in CDCl3 containing 1% (H3C)4Si at 400 MHz.
eWhen the 13C NMR spectrum of compound
3 was recorded in slightly acidic CDCl3, these signals appeared as distinct resonances at δC 73.2 and 73.0 ppm.
fSignals due to hydroxy group protons
not observed.
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high-resolution measurements were conducted on a time-of-flight
instrument. Low- and high-resolution EI mass spectra were recorded on
a magnetic-sector machine. Melting points were measured on an
Optimelt automated melting point system and are uncorrected.
Analytical thin-layer chromatography was performed on aluminum-
backed 0.2mm thick silica gel 60 F254 plates as supplied byMerck. Eluted
plates were visualized using a 254 nmUV lamp and/or by treatment with
a suitable dip followed by heating. These dips included phosphomo-
lybdic acid−ceric sulfate−sulfuric acid (conc)−water (37.5 g:7.5 g:37.5
g:720 mL) or potassium permanganate−potassium carbonate−5%
sodium hydroxide aqueous solution−water (3 g:20 g:5 mL:300 mL).
Flash chromatographic separations were carried out following protocols
defined by Still et al.11 with silica gel 60 (40−63 μm) as the stationary
phase and using the AR- or HPLC-grade solvents indicated. Starting
materials and reagents were generally available from Sigma−Aldrich,
Merck, TCI, Strem, or Lancaster Chemicals and were used as supplied.
Drying agents and other inorganic salts were purchased from AJAX,
BDH, or Unilab Chemicals. THF, methanol, and dichloromethane
were dried using a Glass Contour solvent purification system that is
based upon a technology originally described by Grubbs et al.12 Where
necessary, reactions were performed under a nitrogen atmosphere.
Synthesis of 1,1′-((2R,3R,5S,6S)-5,6-Dimethoxy-5,6-dimeth-
yl-1,4-dioxane-2,3-diyl)bis(prop-2-en-1-ol) (7). The previously
reported13 diester 6 (3.41 g, 11.7 mmol), which is readily derived
from D-tartaric acid (5), was treated, successively, with di-isobutylalu-
minum hydride in toluene and then with vinyl magnesium bromide as
described6 for the reaction of compound ent-6. By such means com-
pound 7 (2.87 g, 85%) was obtained as a mixture of three diastereo-
isomers. 7: clear, colorless oil; the 1H and 13C NMR spectral data
obtained on this material were identical with those reported7 for the
corresponding mixture of enantiomers.
Synthesis of (2S,3S,4aR,8aR)-2,3-Dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexa-hydrobenzo[b][1,4]dioxine-5,8-diol (8).
Compound 7 (5.50 g, 19.1 mmol) was subjected to ring-closing
metathesis using the Grubbs-II catalyst (in dichloromethane at 40 °C) in
the same manner as applied to its enantiomer (ent-7) and thereby
affording cyclohexene 8 (4.68 g, 94%) as a mixture of three
diastereoisomers. 8: white, amorphous solid; the 1H and 13C NMR
spectral data obtained on this material were identical with those
reported7 for the corresponding mixture of enantiomers.
Synthesis of (2S,3S,4aS,8aS)-2,3-Dimethoxy-2,3-dimethyl-
2,3,4a,8a-tetrahydrobenzo[b][1,4]dioxine-5,8-dione (9). Com-
pound 8 (1.26 g, 4.85 mmol) was subjected to 2-fold oxidation using
three molar equivalents of DMP in the same manner as employed for its
enantiomer (ent-8) and thus affording enedione 9 (1.07 g, 86%). 9: bright
yellow, crystalline solid, mp 162−165 °C, lit.7 mp (for enantiomer) 115−
117 °C (dec.); [α]D +115 (c 1.1 in CHCl3), lit.
7 [α]D (for enantiomer)
−121.0 (c 0.9 in CHCl3); the 1H and 13C NMR spectral data obtained on
this material were identical with those reported7 for its enantiomer.
Synthesis of (2S,3S,4aS,8S,8aR)-8-Hydroxy-2,3-dimethoxy-
2,3-dimethyl-2,3,8,8a-tetrahydrobenzo[b][1,4]dioxin-5(4aH)-
one (10).Compound 9 (1.74 g, 6.77 mmol) was subjected to reduction
under the same conditions as used for its enantiomer (ent-9), viz. using a
slight excess of the Luche reagent, thus producing γ-hydroxyenone 10
(1.47 g, 84%). 10: white and crystalline solid, mp 171−172 °C; [α]D
+225.5 (c 1.0 in CHCl3), lit.
7 [α]D (for enantiomer) −215.0 (c 0.5 in
CHCl3); the
1H and 13C NMR spectral data obtained on this material
were identical with those reported7 for its enantiomer.
Synthesis of (2S,3S,4aR,5R,8aS)-2,3-Dimethoxy-2,3-dimeth-
yl-8-oxo-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxin-5-yl 4-Ni-
trobenzoate (11). A magnetically stirred solution of compound 10
(480 mg, 1.86 mmol), triphenylphosphine (585 mg, 2.23 mmol), and
p-nitrobenzoic acid (373 mg, 2.23 mmol) in dry THF (40 mL) was
cooled to 0 °C then diethyl azodicarboxylate (DEAD) (360 μL, 2.23
mmol) was added over 0.25 h. The resulting solution was stirred at 0 °C
for 0.5 h before being allowed to warm to 22 °C then stirred at this
temperature for another 1.5 h. The solution thus obtained was
concentrated under reduced pressure and the light yellow solid thus
obtained was subjected to flash chromatography (silica, dichloro-
methane → 1:19 v/v diethyl ether/dichloromethane gradient elution).
Concentration of the relevant fractions (Rf = 0.3 in 1:19 v/v diethyl
ether/dichloromethane) afforded p-nitrobenzoate 11 (750 mg, 99%).
11: white, crystalline solid, mp 183−185 °C; [α]20D +156 (c 0.6,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 8.33 (m, 2H), 8.24 (m, 2H),
7.03 (dd, J = 10.1 and 5.8 Hz, 1H), 6.26 (d, J = 10.1 Hz, 1H), 5.83 (dd, J
= 5.8 and 3.8 Hz, 1H), 4.93 (d, J = 11.0 Hz, 1H), 4.24 (dd, J = 11.0 and
3.8 Hz, 1H), 3.37 (s, 3H), 3.27 (s, 3H), 1.43 (s, 3H), 1.25 (s, 3H); 13C
NMR (100 MHz, CDCl3) δ 193.5, 164.4, 150.9, 139.4, 135.5, 133.0,
131.1, 123.8, 100.5, 100.0, 70.3, 67.9, 67.3, 48.8, 48.4, 17.7, 17.6; IR νmax
2980, 1721, 1710, 1610, 1528, 1344, 1278, 1111, 1091, 1027, 721 cm−1;
MS (ESI, +ve) m/z 431 and 430 [(M + Na)+, 20 and 100%]; HRMS
calcd for C19H21NNaO9 430.1114, found 430.1118.
Synthesis of (2S,3S,4aR,5R,8aS)-7-Iodo-2,3-dimethoxy-2,3-
dimethyl-8-oxo-2,3,4a,-5,8,8a-hexahydrobenzo[b][1,4]dioxin-
5-yl 4-Nitrobenzoate (12). A solution of molecular iodine (415 mg,
1.64 mmol) in dichloromethane/pyridine (4 mL of a 1:1 v/v mixture)
was added over 0.25 h to a magnetically stirred solution of compound 11
(268 mg, 0.66 mmol) and DMAP (4 mg, 0.03 mmol) in dichloro-
methane/pyridine (10 mL of 7:3 v/v mixture) maintained at 0 °C. The
ensuing mixture was stirred for 16 h at 0 °C and after which time it was
allowed to warm to 22 °C. The resulting solution was diluted with ethyl
acetate (40 mL) and washed successively with HCl (2 × 10 mL of a 1 M
aqueous solution), water (1 × 10 mL) and Na2SO3 (2 × 10 mL of a
saturated aqueous solution). The combined aqueous phases were
extracted with ethyl acetate (3 × 10 mL), and combined organic phases
washed with brine (3 × 10 mL) then dried (Na2SO4), filtered, and
concentrated under reduced pressure. Heptane (20 mL) was added to
the ensuing residue and the mixture thus obtained concentrated under
reduced pressure (so as to remove any remaining traces of pyridine)
to give compound 12 (351 mg, 99%). 12: white foam; [α]20D −59.0
(c 0.9, CHCl3); Rf 0.6 in 1:19 v/v diethyl ether/dichloromethane;
1H
NMR (400 MHz, CDCl3) δ 8.33 (m, 2H), 8.23 (m, 2H), 7.81 (d, J =
6.2 Hz, 1H), 5.68 (dd, J = 6.2 and 3.9 Hz, 1H), 4.98 (d, J = 11.0 Hz, 1H),
4.24 (dd, J = 11.0 and 3.9 Hz, 1H), 3.37 (s, 3H), 3.26 (s, 3H), 1.42
(s, 3H), 1.24 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 187.4, 164.2,
150.9, 147.3, 135.2, 131.2, 123.8, 110.3, 100.6, 99.9, 69.5, 69.1, 66.8,
48.9, 48.5, 17.6, 17.5; IR νmax 2952, 1718, 1607, 1528, 1342, 1264, 1141,
1101, 1035, 719 cm−1; MS (ESI, +ve)m/z 588 [(M +methanol + Na)+,
70%], 557 and 556 [(M +Na)+, 25 and 100], 430 (50); HRMS calcd for
C19H20INNaO9 556.0080, found 556.0081.
Synthesis of (2S,3S,4aR,5R,8R,8aR)-6-Iodo-2,3-dimethoxy-
2,3-dimethyl-2,3,4a,- 5,8,8a -hexahydrobenzo[b][1,4]dioxine-
5,8-diol (13). Sodium borohydride (15 mg, 0.40 mmol) was added, in
portions over 0.08 h, to a magnetically stirred solution of enone 12
(100mg, 0.19mmol) and CeCl3·7H2O (70mg, 0.19mmol) inmethanol
(5 mL) maintained at −78 °C. After 0.5 h the reaction mixture was
allowed to warm to 22 °C and water (0.5 mL) then added dropwise.
When evolution of hydrogen gas had subsided (ca. 0.25 h), NaOH
(0.5 mL of a 1 M aqueous solution) was added to the reaction mixture
and the resulting solution stirred for 2 h at 22 °C then diluted with ethyl
acetate (20 mL) and washed with NaHCO3 (2 × 5 mL of a saturated
aqueous solution). The combined aqueous washings were extracted
with ethyl acetate (3 × 5 mL) and then combined organic layers then
washed with brine (3× 5 mL) before being dried (Na2SO4), filtered and
concentrated under reduced pressure. The residue thus obtained was
subjected to flash column chromatography (silica, dichloromethane →
1:9 v/v methanol/dichloromethane gradient elution) and concen-
tration of the relevant fractions (Rf = 0.2 in 1:19 v/v methanol/
dichloromethane) afforded compound 13 (62 mg, 87%). 13: white,
amorphous solid; [α]20D +85.8 (c 0.4, CHCl3);
1H NMR (400 MHz,
CDCl3) δ 6.62 (dd, J = 5.8 and 1.8 Hz, 1H), 4.17−4.04 (complex m,
3H), 3.68 (dd, J = 10.8 and 4.1 Hz, 1H), 3.30 (s, 3H), 3.27 (s, 3H), 2.57
(br d, J = 1.7 Hz, 1H), 2.47 (d, J = 4.5 Hz, 1H), 1.34 (s, 6H); 13C NMR
(100 MHz, CDCl3) δ 137.1, 109.5, 99.8, 99.4, 74.5, 68.2, 67.5(1),
67.4(9), 48.3, 48.2, 17.9, 17.7; IR νmax 3429, 2949, 1376, 1115, 1028,
919, 849, 815, 656 cm−1; MS (ESI, +ve) m/z 409 [(M + Na)+, 100%];
HRMS calcd for C12H19INaO6 409.0124, found 409.0123.
Synthesis of (1R,2R,3S,4R)-5-Iodocyclohex-5-ene-1,2,3,4-tet-
raol (14). Water (200 μL) then trifluoroacetic acid (200 μL) were
added successively to a magnetically stirred solution of compound 13
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(66 mg, 0.17 mmol) in dichloromethane (3 mL) maintained under a
stream of nitrogen at 22 °C. The mixture thus obtained was allowed to
evaporate to dryness (ca. 0.25 h), the ensuing residue diluted with
dichloromethane (3 mL) and the resulting solution again treated with
water (200 μL) then trifluoroacetic acid (200 μL). After evaporation to
dryness (ca. 0.25 h) the residue was subjected to flash chromatography
(silica, 10:9:1 v/v hexane/ethyl acetate/methanol→ 1:8:1 v/v hexane/
ethyl acetate/methanol gradient elution). Concentration of the
relevant fractions (Rf = 0.3 in 1:8:1 v/v hexane/ethyl acetate/methanol)
afforded compound 14 (44 mg, 95%). 14: white, crystalline solid, mp =
139−141 °C (from ethyl acetate−hexane), lit. mp8 145−149 (from
acetone/methanol); [α]20D −39.5 (c 0.6, methanol), lit.
8 [α]20D −45
(c 0.5, methanol); 1HNMR (400MHz, CD3OD) δ 6.54 (dd, J = 5.3 and
1.2 Hz, 1H), 4.05 (dd, J = 5.4 and 4.1 Hz, 1H), 3.82−3.77 (complex m,
2H), 3.55 (m, 1H) (signals due to hydroxy group protons not
observed); 13C NMR (100 MHz, CD3OD) δ 139.5, 109.8, 78.5, 73.4,
72.1, 69.7; IR νmax 3279, 2907, 1618, 1264, 1089, 1066, 1046, 1019, 821
cm−1; MS (ESI, +ve) m/z 295 [(M + Na)+, 100%]; HRMS calcd for
C6H9INaO4 294.9443, found 294.9443.
Synthesis of (1R,2R,3R,4S)-5-(3-Methylbut-3-en-1-yn-1-yl)-
cyclohex-5-ene-1,2,3,4-tetraol (15). A magnetically stirred mixture
of iodide 14 (34 mg, 0.125 mmol) and triethylamine (2 mL) in DMF
(1 mL) maintained at 22 °C was degassed by sonication under an
atmosphere of nitrogen for 0.5 h, then treated with CuI (5 mg, 0.046
mmol), PdCl2(Ph3P)2 (21 mg, 0.030 mmol) and 2-methyl-1-buten-3-
yne (150 μL, 1.58 mmol). The resulting solution was stirred at 22 °C for
4 h and then the volatiles were removed under reduced pressure. The
residue thus obtained was dissolved in THF (1 mL) and subjected to
flash column chromatography (silica, 45:50:5 v/v hexane/ethyl acetate/
methanol → 23:70:7 v/v hexane/ethyl acetate/methanol gradient
elution). Concentration of the relevant fractions (Rf = 0.3 in 1:8:1 v/v
hexane/ethyl acetate/methanol) afforded compound 15 (50 mg, 80%).
15: white, amorphous solid; [α]20D −57.1 (c 0.6, methanol); 1H NMR
(400 MHz, CD3OD) δ 6.06 (dd, J = 5.2 and 1.8 Hz, 1H), 5.30 (m, 1H),
5.27 (m, 1H), 4.23 (app t, J = 4.4 Hz, 1H), 3.85 (dd, J = 7.2 and 1.8 Hz,
1H), 3.71 (dd, J = 9.8 and 7.2 Hz, 1H), 3.49 (dd, J = 9.8 and 4.4 Hz, 1H),
1.91 (app t, J = 1.3 Hz, 3H) (signals due to hydroxy group protons not
observed); 13C NMR (100 MHz, CD3OD) δ 134.1, 128.3(3), 128.3(1)
122.5, 92.5, 87.5, 74.4, 73.4, 72.1, 67.6, 23.5; IR νmax 3249, 2883, 1664,
1630, 1608, 1429, 1258, 1092, 1051, 898, 633 cm−1; MS (ESI, +ve) m/z
443 [(2 M + Na)+, 50%], 233 [(M + Na)+, 100]; HRMS calcd for
C11H14NaO4 233.0790, found 233.0790.
Synthesis of (3aS,4R,5S,7aR)-4,5-Dihydroxy-6-(3-methylbut-
3-en-1-yn-1-yl)-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-2-one
(3). A magnetically stirred solution of tetraol 15 (37 mg, 0.18 mmol) in
THF (2 mL) maintained at −78 °C was treated with triethylamine
(90 μL, 0.65 mmol) and then with a solution of triphosgene (27 mg
0.09mmol) in THF (1mL). The resulting mixture was stirred at−78 °C
for 0.5 h then allowed to warm to 0 °C and stirred at this temperature
for another 0.5 h. The suspension thus obtained was poured into ice-
cold NH4Cl (10 mL of a saturated aqueous solution) and extracted with
ethyl acetate (3 × 5 mL). The combined organic phases were dried
(Na2SO4), filtered and concentrated under reduced pressure and the
residue thus obtained was subjected to flash chromatography (silica,
hexane→ 65:35 v/v hexane/ethyl acetate gradient elution) to afford two
fractions, A and B. Concentration of fraction A (Rf = 0.3 in 10:9:1 v/v
hexane/ethyl acetate/methanol) afforded compound 3 (11 mg, 26% or
56% brsm). Concentration of fraction B (Rf = 0.1 in 10:9:1 v/v hexane/
ethyl acetate/methanol) afforded the starting material 15 (20 mg, 54%
recovery). The 1H and 13C NMR spectral data obtained on this material
were identical with those derived from an authentic sample. 3: white
powder, mp 115−117 °C (dec); [α]20D −12 (c 0.5, CDCl3); 1H NMR
(400 MHz, CDCl3) see Table 1;
13C NMR (100 MHz, CDCl3) see
Table 1; IR νmax 3412, 2957, 2922, 2199, 1791, 1628, 1357, 1169, 1046,
889, 772, 727 cm−1; MS (ESI, +ve) m/z 495 [(2 M + Na)+, 70%], 259
[(M + Na)+, 100], 102 (75); HRMS calcd for C12H12NaO5 259.0582,
found 259.0583.
Synthesis of (3aR,4R,5S,7aR)-6-(3-Methylbut-3-en-1-yn-1-yl)-
2-oxo-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxole-4,5-diyl Bis(4-
nitrobenzoate) (16). A magnetically stirred solution of compound 3
(5.1 mg, 0.022 mmol) and triethylamine (100 μL, 0.72 mmol) in dry
dichloromethane (2 mL) maintained at 0 °C was treated sequentially
with p-nitrobenzoyl chloride (16 mg, 0.086 mmol) and DMAP (one
crystal, ca. 0.1 mg). The ensuing mixture was allowed to warm to 22 °C,
stirred at this temperature for 4 h then diluted with diethyl ether (5 mL)
and quenched with phosphate buffer (5 mL of a 1 M, pH 7 aqueous
solution). The separated aqueous layer was extracted with diethyl ether
(3× 1mL) and the combined organic phases were then dried (Na2SO4),
filtered and concentrated under reduced pressure. The light yellow
residue thus obtained was subjected to flash chromatography (silica, 7:3
v/v hexane/ethyl acetate elution) and concentration of the relevant
fractions (Rf = 0.6) gave compound 16 (10 mg, 87%). 16: white,
amorphous solid; [α]20D +77.7 (c 0.5, CDCl3);
1H NMR (400 MHz,
CDCl3) δ 8.30−8.25 (complex m, 4H), 8.21−8.17 (complex m, 2H),
8.17−8.13 (complex m, 2H), 6.39 (dd, J = 4.1 and 1.8 Hz, 1H), 5.99
(ddd, J = 8.0, 1.8, and 1.3 Hz, 1H), 5.83 (dd, J = 8.1 and 8.0Hz, 1H), 5.43
(ddd, J = 7.9, 4.1, and 1.3 Hz, 1H), 5.22 (app p, J = 1.3 Hz, 1H), 5.12
(br t, J = 1.3 Hz, 1H), 5.09 (dd, J = 8.1 and 7.9 Hz, 1H), 1.67 (app t, J =
1.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 163.8, 163.4, 152.5, 151.2,
133.9, 133.8, 131.2(4), 131.1(9), 126.9, 126.2, 125.4, 125.1, 123.9(4),
123.9(2), 97.2, 82.4, 74.2, 72.3, 71.0, 68.9, 22.7 (one signal obscured or
overlapping); IR νmax 3932, 2852, 1809, 1732, 1607, 1524, 1347, 1259,
1095, 1051, 907, 716 cm−1; MS (ESI, +ve) m/z 557 [(M + Na)+, 100],
337(70); HRMS calcd for C26H18N2NaO11 557.0803, found 557.0808.
Crystallographic Studies. Crystallographic Data.Compound 14:
C6H9IO4,M = 272.03, T = 150 K, monoclinic, space group P21, Z = 4, a
= 9.4654(3) Å, b = 7.09196(19) Å, c = 13.2976(5) Å; V = 835.51(5) Å3,
Dx = 2.163 g cm
−3, 3355 unique data (2θmax = 147.8°), R = 0.081
[for 3304 reflections with I > 2.0σ(I)]; Rw = 0.225 (all data), S = 1.05.
Structure Determination. Diffraction images for compound 14 were
measured on a diffractometer (Cu Kα, mirror monochromator, λ =
1.54184 Å) fitted with an area detector, and the data extracted using the
DENZO/Scalepack package.14 The structure solution was solved by
direct methods (SIR92),15 then refined using the CRYSTALS program
package.16 Atomic coordinates, bond lengths and angles, and displace-
ment parameters have been deposited at the Cambridge Crystallo-
graphic Data Centre (CCDC no. 1533559). These data can be obtained
free-of-charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing
data_request@ccdc.cam.ac.uk, or by contacting The Cambridge
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ,
UK; fax: +44 1223 336033.
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75, 223−229. (c) Johnson, R. A. Org. React. 2004, 63, 117−264.
(d) Hudlicky, T.; Reed, J. W. Synlett 2009, 2009, 685−703. (e) Bon, D.
J.-Y. D.; Lee, B.; Banwell, M. G.; Cade, I. A. Chim. Oggi 2012, 30 (No. 5,
Chiral Technologies Supplement), 22−27.
(7) Buckler, J. N.; Schwartz, B. D.; Banwell, M. G. Heterocycles 2017,
95, 290−303.
(8) Boyd, D. R.; Sharma, N. D.; Llamas, N. M.; Malone, J. F.; O’Dowd,
C. R.; Allen, C. C. R. Org. Biomol. Chem. 2005, 3, 1953−1963.
(9) Details of this analysis are provided in the Supporting Information.
(10) Taher, E. S.; Guest, P.; Benton, A.; Ma, X.; Banwell, M. G.; Wilis,
A. C.; Seiser, T.; Newton, T.W.; Hutzler, J. J. Org. Chem. 2017, 82, 211−
233.
(11) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923−
2925.
(12) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.;
Timmers, F. J. Organometallics 1996, 15, 1518−1520.
(13) (a) Brittain, D. E. A.; Griffith-Jones, C. M.; Linder, M. R.; Smith,
M. D.; McCusker, C.; Barlow, J. S.; Akiyama, R.; Yasuda, K.; Ley, S. V.
Angew. Chem., Int. Ed. 2005, 44, 2732−2737. (b) Maycock, C. D.;
Ventura, M. R. Tetrahedron: Asymmetry 2012, 23, 1262−1271.
(14) Otwinowski, Z.; Minor, W. DENZO−SMN Processing of X-ray
diffraction data collected in oscillation mode. InMethods in Enzymology,
Vol. 276: Macromolecular Crystallography, Part A; Carter, C. W., Jr.;
Sweet, R. M., Eds.; Academic Press: New York, 1997; pp 307−326.
(15) SIR92. Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi,
A.; Burla, M. C.; Polidori, G.; Camalli, M. J. Appl. Crystallogr. 1994, 27,
435−436.
(16) Betteridge, P. W.; Carruthers, J. R.; Cooper, R. I.; Prout, K.;
Watkin, D. J. J. Appl. Crystallogr. 2003, 36, 1487.
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.7b00303
J. Nat. Prod. 2017, 80, 2088−2093
2093
212
S
SUPPORTING INFORMATION FOR: 
 
A Total Synthesis of the Cyclic Carbonate-containing Natural Product 
Aspergillusol B from D-(–)-Tartaric Acid   
 
Joshua N. Buckler, Tamaryn Meek, Martin G. Banwell* and Paul D. Carr 
 
 
Research School of Chemistry, Institute of Advanced Studies, The Australian National 
University, Canberra, ACT 2601, Australia 
 
 
Martin.Banwell@anu.edu.au 
 
CONTENTS                    PAGE 
  
1H and 13C NMR spectra of compounds 3 and 11 - 16     S2 
 
 
 
213
S
400 MHz 1H NMR Spectrum of Compound 3 (recorded in CDCl3 
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400 MHz 1H NMR Spectrum of Compound 11 (recorded in CDCl3) 
 
100 MHz 13C NMR Spectrum of Compound 11 (recorded in CDCl3) 
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400 MHz 1H NMR Spectrum of Compound 12 (recorded in CDCl3) 
 
100 MHz 13C NMR Spectrum of Compound 12 (recorded in CDCl3) 
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400 MHz 1H NMR Spectrum of Compound 13 (recorded in CDCl3) 
 
100 MHz 13C NMR Spectrum of Compound 13 (recorded in CDCl3) 
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400 MHz 1H NMR Spectrum of Compound 14 (recorded in CD3OD) 
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ABSTRACT: Stereoselective total syntheses of the four stereoisomeric forms
of guaiacylglycerol 8-O-4′-coniferyl ether, viz., compounds 1, ent-1, 2, and ent-2,
have been established. The key step involves an Evans/Seebach auxiliary-
controlled and syn-selective aldol process followed, in the reaction sequences
leading to the anti-compounds, by a Mitsunobu reaction involving a benzylic
alcohol residue. The proangiogenic properties of the synthetic materials were
evaluated in a human microvascular endothelial cell tubule formation assay, thus
revealing that they are all active, with the 8S-configured compounds 1 and 2
being the most potent.
■ INTRODUCTION
Compounds that promote the formation of new blood vessels
from existing endothelia are described as proangiogenic and
could be beneficial in promoting wound healing, treating burns,
and the revascularization of ischemic tissues encountered in
stroke victims and those suffering from cardiac disorders.1
Screening plant extracts for such properties is an emerging area
of interest and the rat aortic ring model and related assays have
proven useful in identifying natural products that can modulate
angiogenesis.2,3 By such means, various extracts of soybean
(particularly the xylem sap) were evaluated recently, and two
proangiogenic principals were isolated.3 Although only small
quantities of these materials were obtained, 1H and 13C NMR
spectroscopic as well as mass spectral analyses suggested that
these are one or other of the neolignans 1 or ent-1 and 2 or ent-
2.3 The racemic forms of these compounds have previously
been isolated from various other plant sources and shown to
exhibit a range of biological effects.4 They are almost certainly
produced in vivo through peroxidase-mediated radical coupling
of coniferyl alcohol, and optically enriched forms of them (but
of undefined absolute stereochemistry) have been generated by
enzymatic dehydrogenative coupling of this monomer using
cell-free extracts of a producing organism.5
Given the very small amounts of these compounds available
from natural sources, the seasonal variations in their yields, and
the lack of information regarding their stereostructures (and, in
many instances, their optical purities), unambiguous syntheses
of the guaiacylglycerol 8-O-4′-coniferyl ethers 1, ent-1, 2, and
ent-2 were sought in an effort to clarify matters. Herein, we
detail the total syntheses of each of these four stereoisomeric 8-
O-4′-linked neolignans6,7 and report on their proangiogenic
properties (Figure 1).
■ RESULTS AND DISCUSSION
Syntheses of the Racemic Forms of Compounds 1
and 2. Although many neolignans have been the subject of
synthetic studies,8 enantioselective approaches to 8-O-4′ linked
systems, as required in accessing the compounds targeted here,
have received only modest attention.9,10 Our first approach to
compounds 1, ent-1, 2, and ent-2 is shown in Scheme 1, and in
this we sought, inter alia, to exploit key elements of Ley’s
asymmetric synthesis of the 8-O-4′ neolignan polysphorin.9a
This started with the conversion, by conventional means, of
commercially available ferulic acid (3) over four steps into bis-
methoxymethyl (MOM) ether 4 (79%) (see Experimental
Section for details). Asymmetric dihydroxylation of the olefinic
residue within compound 4 using AD-mix-α and methane-
sulfonamide afforded the diol 5 (78%), the configuration of
which was assigned using the Sharpless “mnemonic”.11
Although the enantiomeric excess (ee) of this oxidation
product was not established, the fact that it was optically
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active {[α]D + 10.7 (c = 1.02, CHCl3)} encouraged us to
continue exploring the reaction sequence, the next step of
which involved selective oxidation of the benzylic hydroxyl
group within compound 5 using 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) under ultrasonication conditions.12 By
such means, the acyloin 6 (86%) was obtained and the
Figure 1. Structures of the four stereoisomeric forms, 1, ent-1, 2, and ent-2, of guaiacylglycerol 8-O-4′-coniferyl ether targeted for synthesis.
Scheme 1. Synthesis of Compounds (±)-1 and (±)-2
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associated hydroxyl group was reacted with p-toluenesulfonic
anhydride in the presence of pyridine, thus giving the optically
active ester 7 in 93% yield. Although treating this last
compound with coniferyl aldehyde (8) in the presence of
cesium carbonate and 18-crown-6 (18-C-6) led to the
formation of the anticipated 8-O-4′-linked ether 9 (47%), this
proved to be an optically inactive material, thus suggesting
racemization of substrate 7 and/or the product had occurred
under the reaction conditions.1 Despite this, the completion of
the synthetic pathway was pursued because of the capacity it
provided to deliver the racemic forms of the target compounds
(materials that would prove useful in establishing the
enantiomeric excesses of their enantiomerically enriched
congeners). So, compound 9 was treated with a trace of
concentrated HCl in isopropanol, thus effecting cleavage of the
MOM-ether residues, and thereby affording the dihydroxy-
derivative 10 (76%). The required 2-fold reduction of the keto-
aldehyde 10 was best effected using polymer-supported
borohydride9a and, in a presumably sterically driven process,
this gave a ca. 7:1 mixture of the diastereoisomeric syn- and
anti-compounds (±)-1 and (±)-2, respectively, in 87%
combined yield. These could be separated from one another
using reverse phase high-performance liquid chromatography
(HPLC) and the spectral data derived from each were in
complete accord with those reported earlier4e,l for the natural
products (see Table 1 for relevant comparisons of the 13C
NMR data sets).
Although each of the synthetically derived compounds (±)-1
and (±)-2 could be separated into their constituent
enantiomers using chiral HPLC techniques, the equivalent
analysis of the soybean-derived natural products could not be
carried out due to their decomposition on prolonged (>12
months) standing (as a crude extract). That said, when samples
of these compounds have been isolated from other plant
sources, they tend to be obtained as racemates or, at best,
enantiomerically enriched (but certainly not homochiral)
materials.5a
Chiral Auxiliary-Controlled Syntheses of Homochiral
Compounds 1 and ent-1. The synthetic route successfully
employed in obtaining neolignan ent-1 is shown in Scheme 2
and involved, as the key feature, an Evans’ aldol reaction13
utilizing the readily available L-valine (11)-derived chiral
auxiliary 12 introduced by Seebach.14 This was coupled with
the eugenol (13)-derived and readily available α-aryloxyacetic
acid 14 (85%) through its conversion into the corresponding
acid chloride and reaction of this with the anion derived from
deprotonation of the 2-oxazolidinone 12 using n-butyl lithium.
Compound 15 (93%) so formed was then converted, on
treatment with dibutylboron triflate in the presence of Hünig’s
base,14a into the corresponding boron enolate that reacted
stereoselectively with aldehyde 16 embodying a tert-butyldi-
methylsilyl (TBDMS)-protected phenol residue. The auxiliary
associated with the aldol product so-formed was cleaved using
lithium borohydride/methanol, thus affording the 1°-alcohol 17
(76% from 15) as a single diastereoisomer and in optically
active form {[α]D = −63.3 (c = 0.8, CHCl3)}. The illustrated
structure was initially assigned to compound 17 on the basis of
the well-established syn-selective outcomes of Evans’ aldol
reactions9h,13,14 involving the types of auxiliaries used here, but
eventually it was confirmed through chemical correlation
studies (see below). Aerobic and palladium-catalyzed acetox-
ylation of compound 17 using a procedure reported by Stahl et
al.15 and employing 4,5-diazafluorenone as ligand then afforded
ester 18 in 48% yield and exclusively in the E-isomeric form.
Cleavage of both the acetate and silyl ether residues associated
with compound 18 was accomplished using potassium
carbonate in methanol, thus giving the target neolignan ent-1
in 79% yield.
All of the mass spectral as well as the NMR and IR
spectroscopic data acquired on compound ent-1 matched those
derived from the corresponding racemate [(±)-1], and the
specific rotation determined for the optically active material was
−36.7 (c = 0.9, methanol). Chiral HPLC analysis of compound
ent-1 established that it was of >99% enantiomeric excess and
represents the less mobile component of the racemate (±)-1.
The synthesis of compound 1 was readily achieved following
the reaction scheme shown above but using the auxilliary ent-12
derived from D-valine (ent-11). Although all of the spectral data
recorded on neolignan 1 matched those reported for its
enantiomer, the specific rotation of this material was of similar
magnitude but opposite sign {[α]D = +32.4 (c = 0.2,
methanol)}. Chiral HPLC analysis of compound 1 established
that it had been obtained in ca. 90% ee and represents the more
mobile component of the racemate (±)-1 obtained earlier.
The synthesis of the anti-compound ent-2 is shown in
Scheme 3 and involved, in the opening stages, selective mono-
protection of the 1°-alcohol residue within compound 17
followed by cleavage of the associated phenolic TBDMS ether.
Table 1. Comparison of the 13C NMR Chemical Shift Data
Recorded for Synthetically Derived Compounds (±)-1 and
(±)-2 with Those Reported for the Naturally Derived threo-
and erythro-Guaiacylglycerol 8-O-4′-Coniferyl Ethers (threo-
GCCE and erythro-GCCE, Respectively)
13C NMR
data for
compound
(±)-1 (δC)
a
13C NMR
data for
threo-GCCE
(δC)
b
Δδ
13C NMR
data for
compound
(±)-2 (δC)
c
13C NMR
data for
erythro-GCCE
(δC)
d
Δδ
151.6 151.8 −0.2 151.9 151.8 +0.1
149.1 149.3 −0.2 148.9 149.0 −0.1
148.8 148.8 0.0 148.7 148.6 +0.1
147.1 147.2 −0.1 147.0 147.2 −0.2
133.7 133.8 −0.1 134.1 134.2 −0.1
133.1 133.2 −0.1 133.0 133.1 −0.1
131.4 131.5 −0.1 131.4e 130.8 +0.6f
128.6 128.7 −0.1 128.5 128.6 −0.0
120.8 120.9 −0.1 121.0 121.1 +0.1
120.7 120.8 +0.1 120.7 120.8 −0.1
118.6 118.9 −0.3f 118.9 119.0 −0.1
115.8 115.9 −0.1 115.7 115.7 0.0
111.7 111.8 −0.1 111.9 111.9 0.0
111.2 111.3 −0.1 111.4g 110.8 +0.6f
87.0 87.2 −0.2 86.2 86.3 −0.1
74.0 74.1 −0.1 74.1 74.2 −0.1
63.7 63.8 −0.1 63.8 63.9 −0.1
61.9 62.0 −0.1 62.2 62.3 −0.1
56.6 56.6 0.0 56.5 56.6 −0.1
56.3 56.4 −0.1 56.4 56.6 −0.2
aSpectrum recorded in CD3OD at 100 MHz.
bData obtained from
Woo,4l spectrum recorded in CD3OD at 125 MHz.
cSpectrum
recorded in CD3OD at 100 MHz.
dData obtained from Li4e spectrum
recorded in CD3OD at 100 MHz.
eLourith et al. report10 a chemical
shift of 131.5 for the resonance due to this carbon. fWe attribute these
differences to variations in the pH of the media in which the spectra
were recorded. gLourith et al. report10 a chemical shift of 111.4 for the
resonance due to this carbon.
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This gave phenol 19 (96%) that was reacted with p-
toluenesulfonyl chloride (p-TsCl) in the presence of triethy-
amine and 4-(N,N-dimethylamino)pyridine (DMAP) to afford
ester 20 (87%). The introduction of the tosyl group was
necessary to attenuate the electron-donating properties of the
attached aryl oxygen such that this now did not facilitate
ionization of activated forms of the benzylic alcohol during the
subsequent Mitsunobu reaction.16 Consistent with such
expectations, when compound 20 was treated with triphenyl-
phosphine and diethyl azodicarboxylate (DEAD), and using p-
nitrobenzoic acid as nucleophile, benzoate 21 (84%) was
obtained. Confirmation of the illustrated S-configuration at the
PNB-ester bearing center in this product follows from its
conversion into the target neolignan ent-2. To such ends,
treatment of compound 21 with sodium hydroxide in
tetrahydrofuran (THF)/water afforded the alcohol 22 (74%)
that was itself subjected to allylic oxidation using Stahl’s
protocol,15 thereby affording acetate 23 in 64% yield.
Treatment of ester 23 with tetra-n-butylammonium fluoride
(TBAF) then sodium hydroxide in water/methanol resulted in
cleavage of the TBDMS ether, acetate, and tosyl groups such
that the targeted neolignan ent-2 was obtained in 73% yield. All
of the spectral data obtained on this material were consistent
with the assigned structure. Chiral HPLC analysis established
that it was of >99% ee. The specific rotation of this material was
[α]20D = −8.1 (c = 1.1, methanol), and it represents the more
mobile component of the racemate (±)-2.
The synthesis of compound 2 was readily achieved following
the reaction scheme shown but using compound ent-17 as
starting material. Although all of the spectral data recorded on
neolignan 2 matched those reported for its enantiomer, the
specific rotation of this material was of similar magnitude but
opposite sign {[α]20D = +7.4 (c = 0.5, methanol)}. Similarly,
chiral HPLC analysis of compound 2 established that it was of
>99% ee and that it represents the less mobile component of
the racemate (±)-2 obtained as described above.
Scheme 2. Synthesis of Compound ent-1
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To this point, the assignments of the illustrated structures to
compounds 1, ent-1, 2, and ent-2 are based on the assumption
that the pivotal Evans’ aldol reactions proceed in the
anticipated (syn-selective) manner and that the Mitsunobu
reactions take place with inversion of configuration. Further
support follows from the recent work of Nair et al.,9k who
employed closely related Evans’ aldol protocols to prepare
compound 2 and who undertook certain chemical correlation
studies and a single-crystal X-ray analysis to establish the
selectivities of their pivotal reaction. The NMR spectroscopic
data we acquired on compound 2 matched those reported by
Nair.9k
Initial Biological Evaluations of Compounds 1, ent-1,
2, and ent-2. Compounds 1 and 2 as well as their
enantiomers, ent-1 and ent-2, respectively, were each examined
for their abilities to enhance endothelial cell tubule formation
on reconstituted basement membrane matrix (see Figure 2 and
the Experimental Section) in an assay widely used to identify
proangiogenic and antiangiogenic factors and their underlying
mechanism(s) of action.17
All four compounds stimulated endothelial cell tubule
formation compared with media only, with compounds 1 and
2 being the most active and congener ent-2 the least active. It is
noteworthy that each of these neolignans exhibited significant
proangiogenic activity compared with media only, with
compound 1 being more active than the fibroblast growth
factor 2 (FGF-2) control.18 The flavone derivative PD98059, an
inhibitor of mitogen-activated protein kinase (MEK1/2) and
FGF-2 signaling, suppressed the proangiogenic activity of all of
the compounds, which is consistent with the title neolignans
acting via this pathway.
■ CONCLUSIONS
The work detailed here provides stereochemically unambiguous
routes to a quartet of neolignans that display varying degrees of
activity as proangiogenic agents. The variation in efficacy as a
function of stereochemistry indicates that the S-configuration at
C8 (as seen in neolignans 1 and 2) has a positive impact on
activity, with compound 1 being even more active than the
FGF-2 control. To the best of our knowledge, this work
represents the first time that a suite of diastereisomerically
related neolignans has been identified as proangiogenic agents.
As such, it should serve as an important consideration for the
development of proangiogenic compounds that might serve as
therapeutic agents.
■ EXPERIMENTAL SECTION
General Protocols. Unless otherwise specified, proton
(1H) and carbon (13C) NMR spectra were recorded at room
temperature in base-filtered CDCl3 on a Varian spectrometer
operating at 400 MHz for proton and 100 MHz for carbon
nuclei. The signal due to residual CHCl3 appearing at δH 7.26
and the central resonance of the CDCl3 triplet appearing at δC
77.1(6) were used to reference 1H and 13C NMR spectra,
Scheme 3. Synthesis of Compound ent-2
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respectively. 1H NMR data are recorded as follows: chemical
shift (δ) [multiplicity, coupling constant(s) J (Hz), relative
integral] where multiplicity is defined as: s = singlet; d =
doublet; t = triplet; q = quartet; m = multiplet or combinations
of the above. Infrared spectra (νmax) were recorded on a Fourier
transform infrared spectrometer. Samples were analyzed as thin
films on KBr plates or as neat material. Low-resolution
electrospray ionization (ESI) mass spectra were recorded on
a single quadrupole liquid chromatograph-mass spectrometer,
whereas high-resolution measurements were conducted on a
time-of-flight instrument. Low- and high-resolution electron
ionization (EI) mass spectra were recorded on a magnetic-
sector machine. Melting points were measured on an Optimelt
automated melting point system and are uncorrected. Analytical
thin layer chromatography was performed on aluminum-backed
0.2 mm thick silica gel 60 F254 plates as supplied by Merck.
Eluted plates were visualized using a 254 nm UV lamp and/or
by treatment with a suitable dip followed by heating. These dips
included phosphomolybdic acid/ceric sulfate/sulfuric acid
(conc.)/water (37.5 g:7.5 g:37.5 g:720 mL) or potassium
permanganate/potassium carbonate/5% sodium hydroxide
aqueous solution/water (3 g:20 g:5 mL:300 mL). Flash
chromatographic separations were carried out following
protocols defined by Still et al.19 with silica gel 60 (40−63
μm) as the stationary phase and using the AR- or HPLC-grade
solvents indicated. The melting points of solids purified by such
means were recorded directly (i.e., after they had crystallized
from the concentrated chromatographic fractions). Starting
materials and reagents were generally available from the Sigma-
Aldrich, Merck, TCI, Strem, or Lancaster Chemical Companies
and were used as supplied. Drying agents and other inorganic
salts were purchased from the AJAX, BDH, or Unilab Chemical
Companies. Tetrahydrofuran (THF), methanol, and dichloro-
methane were dried using a Glass Contour solvent purification
system that is based upon a technology originally described by
Grubbs et al.20 Where necessary, reactions were performed
under a nitrogen atmosphere.
Specific Chemical Transformations. (E)-2-Methoxy-1-
(methoxymethoxy)-4-(3-(methoxymethoxy)prop-1-en-1-yl)-
benzene (4). Step i: Using a procedure analogous to that
described by Bazin et al.,21 a magnetically stirred solution of
ferulic acid (3) (30.2 g, 155.5 mmol) in dry methanol (200
mL) was treated with five drops of concentrated sulfuric acid,
and the resulting mixture was heated under reflux for 24 h. The
solution was then cooled to room temperature, and the solvent
was removed under reduced pressure. The residue thus
obtained was dissolved in dichloromethane, and the resulting
solution was washed with NaHCO3 (2 × 100 mL of a saturated
aqueous solution) before being dried (MgSO4), filtered, and
concentrated under reduced pressure to afford a pale-yellow oil.
Subjection of this oil to flash chromatography [silica, petroleum
ether → 1:5 v/v ethyl acetate/petroleum ether gradient
elution] and concentration of the relevant fractions (Rf = 0.6
in 1:1 v/v ethyl acetate/petroleum ether) under reduced
pressure afforded ferulic acid methyl ester22 (30.0 g, 93%) as a
white, crystalline solid, mp = 60.9−62.1 °C (lit.22 mp = 65 °C).
1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 15.9 Hz, 1H), 7.07
(dd, J = 8.2 and 1.9 Hz, 1H), 7.02 (d, J = 1.9 Hz, 1H), 6.92 (d, J
= 8.2 Hz, 1H), 6.29 (d, J = 15.9 Hz, 1H), 5.90 (m, 1H), 3.92 (s,
3H), 3.79 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 167.8,
148.1, 146.9, 145.1, 127.1, 123.2, 115.3, 114.9, 109.5, 56.1, 51.7.
These spectral data matched those reported by Li et al.22
Step ii: Chloromethyl methyl ether (MOM-Cl) (12.0 mL,
158.3 mmol) was added dropwise to a magnetically stirred
solution of ferulic acid methyl ester (22.0 g, 105.6 mmol) and
Hünig’s base (i-Pr2NEt) (27.6 mL, 158.3 mmol) in dry
dichloromethane (100 mL) maintained at 0 °C. The resulting
mixture was allowed to warm to 22 °C and stirred at this
temperature for 14 h whilst being maintained under nitrogen
then quenched with NH4Cl (50 mL of a saturated aqueous
solution). The mixture thus obtained was stirred at 22 °C for a
further 1 h then treated with NaHCO3 (100 mL of a saturated
aqueous solution). The separated aqueous layer was extracted
with ethyl acetate (3 × 100 mL) and the combined organic
phases were washed with Na2CO3 (3 × 50 mL of a saturated
aqueous solution) and brine (3 × 50 mL) before being dried
(MgSO4), filtered, and concentrated under reduced pressure to
afford a yellow oil. This oil was subjected to flash
chromatography [silica, dichloromethane → 1:20 v/v Et2O/
dichloromethane gradient elution], and concentration of the
relevant fractions (Rf = 0.8 in 1:9 v/v Et2O/dichloromethane)
under reduced pressure afforded methyl (E)-3-(3-methoxy-4-
(methoxymethoxy)phenyl)acrylate23 (25.0 g, 94%) as a clear,
light-yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J =
16.0 Hz, 1H), 7.15 (d, J = 8.1 Hz, 1H), 7.07 (m, 2H), 6.33 (d, J
= 16.0 Hz, 1H), 5.26 (s, 2H), 3.91 (s, 3H), 3.80 (s, 3H), 3.51
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 167.7, 149.9, 148.6,
144.8, 128.8, 122.4, 116.2, 115.9, 110.4, 95.3, 56.5, 56.1, 51.8.
These spectral data matched those reported by Lui et al.23
Step iii: Aluminum trichloride (14.45 g, 109.2 mmol) was
added to dry THF (160 mL), and the resulting suspension was
stirred at 0 °C under nitrogen for 0.25 h. LiAlH4 (150 mL of a
1 M solution in THF, 150 mmol) was then added dropwise
over 0.5 h, and the resulting suspension was stirred for a further
0.5 h at 0 °C. A solution of methyl (E)-3-(3-methoxy-4-
Figure 2. Effect of neolignans 1, ent-1, 2, and ent-2 on tubule
formation by human microvascular endothelial cells (HMECs) on
reconstituted basement membrane matrix (Matrigel) over a 4 h period
compared with that of media (only) and fibroblast growth factor
(FGF)-2 (positive) controls as well as when coadministered with the
MEK1/2 inhibitor PD (PD98059). The columns represent the mean
of the means of 4 independent experiments with each condition
performed in triplicate. Error bars represent the standard error of the
mean. Statistical significance was determined by one-way ANOVA and
Dunnett’s multiple comparisons test (compared with media only, i.e.,
MCDB131 medium with supplements and 0.2% fetal bovine serum
(FBS)) using GraphPad Prism software, where **** denotes P <
0.0001, *** denotes P < 0.001, * denotes P < 0.05, ns denotes not
significant, and † denotes significance at P < 0.01 between FGF-2 and
compound 1. There was no significant difference between FGF-2 and
compounds 2, ent-1, or ent-2.
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(methoxymethoxy)phenyl)acrylate (24.97 g, 99.0 mmol) in dry
THF (20 mL) was then added (dropwise over 0.5 h) to the
reaction mixture that was then stirred at 0 °C for 0.5 h before
being allowed to warm to 22 °C and stirred for an additional 1
h at this temperature. The reaction mixture was then cooled to
0 °C, water (5.7 mL) was added dropwise (Caution: hydrogen
gas evolution), and stirring then continued for 0.25 h. After this
time, NaOH (5.7 mL of a 15% w/v aqueous solution) was
added to the reaction mixture, and stirring continued for an
additional 0.25 h before more water (17.1 mL) was added. The
resulting mixture was warmed to 22 °C, diluted with Et2O (10
mL), then dried (MgSO4), filtered, and concentrated under
reduced pressure to afford a light-yellow oil. Subjection of this
material to flash chromatography (silica, petroleum ether →
ethyl acetate gradient elution) and concentration of the relevant
fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/petroleum ether)
under reduced pressure afforded (E)-3-(3-methoxy-4-
(methoxymethoxy)phenyl)prop-2-en-1-ol24 (21.21 g, 96%) as
a white, crystalline solid, mp = 51.2−52.5 °C. 1H NMR (400
MHz, CDCl3) δ 7.09 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 2.0 Hz,
1H), 6.90 (dd, J = 8.3 and 2.0 Hz, 1H), 6.55 (d, J = 15.9 Hz,
1H), 6.26 (dt, J = 15.9 and 5.9 Hz, 1H), 5.23 (s, 2H), 4.31 (dd,
J = 5.9 and 1.5 Hz, 2H), 3.89 (s, 3H), 3.51 (s, 3H) (signal due
to hydroxyl group proton not observed); 13C NMR (100 MHz,
CDCl3) δ 149.8, 146.4, 131.4, 131.1, 127.2, 119.7, 116.3, 109.5,
95.5, 63.9, 56.4, 56.0; IR νmax 3399, 2935, 1512, 1464, 1417,
1263, 1154, 1132, 1077, 993, 969 cm−1; MS (ESI, +ve) m/z
247 (100) [M + Na]+; HRMS calcd for C12H16NaO4 [M +
Na]+: 247.0946, found: 219.0946.
Step iv: MOM-Cl (10.7 mL, 141.3 mmol) was added
dropwise to a magnetically stirred solution of (E)-3-(3-
methoxy-4-(methoxymethoxy)phenyl)prop-2-en-1-ol (21.18 g,
94.2 mmol) and Hünig’s base (24.6 mL, 141.3 mmol) in dry
dichloromethane (94 mL) maintained at 0 °C under a nitrogen
atmosphere. The resulting mixture was allowed to warm to 22
°C and stirred at this temperature for 14 h before being
quenched with NaHCO3 (50 mL of a saturated aqueous
solution). The mixture thus obtained was stirred for a further 1
h, then the organic layer was separated and washed with
NaHCO3 (1 × 50 mL of a saturated aqueous solution). The
combined aqueous layers were extracted with ethyl acetate (3 ×
100 mL), and then the combined organic phases were washed
with NH4Cl (3 × 50 mL of a saturated aqueous solution), water
(1 × 50 mL), and brine (3 × 50 mL) before being dried
(MgSO4), filtered, and concentrated under reduced pressure to
afford a light-yellow oil. This oil was subjected to flash
chromatography (silica, dichloromethane → 1:20 v/v Et2O/
dichloromethane gradient elution), and concentration of the
relevant fractions (Rf = 0.7 in 1:20 v/v Et2O/dichloromethane)
under reduced pressure afforded compound 4 (25.0 g, 94%) as
a clear, colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.09 (d, J =
8.2 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 6.91 (dd, J = 8.2 and 1.8
Hz, 1H), 6.57 (d, J = 15.9 Hz, 1H), 6.18 (dt, J = 15.9 and 6.2
Hz, 1H), 5.23 (s, 2H), 4.70 (s, 2H), 4.22 (d, J = 6.2 Hz, 1H),
3.89 (s, 3H), 3.51 (s, 3H), 3.41 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 149.8, 146.4, 132.6, 131.4, 124.2, 119.8, 116.3, 109.5,
95.7, 95.5, 68.0, 56.4, 56.0, 55.5; IR νmax 3375, 2934, 1512,
1464, 1265, 1152, 1133, 1102, 1078, 1036, 995, 920 cm−1; MS
(ESI, +ve) m/z 291 (100) [M + Na]+, 160 (85); HRMS calcd
for C14H20NaO5 [M + Na]
+: 219.1208, found: 219.1208.
(1R,2R)-1-(3-Methoxy-4-(methoxymethoxy)phenyl)-3-
(methoxymethoxy)propane-1,2-diol (5). MeSO2NH2 (856
mg, 9.0 mmol) was added to a magnetically stirred solution
of AD-mix-α (12.48 g) in t-butanol/water (120 mL of a 1:1 v/v
mixture) maintained at 22 °C, and the resulting suspension was
stirred for 0.5 h after which time both phases had become clear.
This mixture was then cooled to 0 °C before being treated with
a solution of alkene 4 (2.00 g, 7.8 mmol) in t-butanol (2 mL).
The reaction mixture thus obtained was stirred vigorously at 0
°C for 72 h, quenched with Na2SO3 (1.0 g), then allowed to
warm to 22 °C and stirred at this temperature 12 h. The
resulting solution was concentrated under reduced pressure,
and the residue thus obtained subjected to flash chromatog-
raphy [silica, 1:1 v/v ethyl acetate/petroleum ether → ethyl
acetate gradient elution]. Concentration of the relevant
fractions (Rf = 0.4 in ethyl acetate) under reduced pressure
afforded compound 5 (1.85 g, 78%) as a clear, colorless gum,
[α]25D = +10.7 (c = 1.02, CHCl3).
1H NMR (400 MHz,
CDCl3) δ 7.12 (d, J = 8.2 Hz, 1H), 6.98 (d, J = 1.9 Hz, 1H),
6.87 (dd, J = 8.2 and 1.9 Hz, 1H), 5.22 (s, 2H), 4.64 (m, 3H),
3.89 (s, 3H), 3.80 (m, 1H), 3.57 (dd, J = 10.7 and 3.3 Hz, 1H),
3.52 (dd, J = 10.7 and 5.5 Hz, 1H), 3.51 (s, 3H), 3.39 (s, 3H),
3.08 (broad d, J = 5.4 Hz, 1H), 3.00 (br d, J = 1.7 Hz, 1H); 13C
NMR (100 MHz, CDCl3) δ 150.0, 146.4, 134.8, 119.4, 116.4,
110.3, 97.5, 95.6, 75.0, 74.7, 70.1, 56.4, 56.1, 55.8; IR νmax 3435,
2937, 1594, 1513, 1265, 1153, 1034, 989, 920 cm−1; MS (ESI,
+ve) m/z 325 (100) [M + Na]+; HRMS calcd for C14H22NaO7
[M + Na]+: 325.1263, found: 325.1259.
(R)-2-Hydroxy-1-(3-methoxy-4-(methoxymethoxy)-
phenyl)-3-(methoxymethoxy)propan-1-one (6). DDQ (2.78
g, 12.25 mmol) was added to a magnetically stirred solution of
diol 5 (1.79 g, 5.92 mmol) in dry benzene (30 mL) maintained
under nitrogen at 22 °C. The resulting suspension was
sonicated for 5 h during which time the temperature of the
water in the sonication bath was maintained between 22 and 30
°C through the addition of ice. The reaction mixture thus
obtained was cooled then filtered, and the filtrate was
concentrated reduced pressure. The residue thus obtained
was triturated with cold dichloromethane (4 × 10 mL), and the
combined washings were filtered and the filtrate again
concentrated under reduced pressure to afford a black oil.
Subjection of this material to flash chromatography [silica,
dichloromethane → 3:7 v/v Et2O/dichloromethane gradient
elution] and concentration of the relevant fractions (Rf = 0.5 in
3:7 v/v Et2O/dichloromethane) under reduced pressure
afforded compound 6 (1.53 g, 86%) as a clear, pale-yellow
oil, [α]25D = −20.0 (c = 1.0, CHCl3).
1H NMR (400 MHz,
CDCl3) δ 7.53 (d, J = 2.0 Hz, 1H), 7.51 (dd, J = 8.4 and 2.0 Hz,
1H), 7.21 (d, J = 8.4 Hz, 1H), 5.32 (s, 2H), 5.19 (ddd
simplifies to a dd upon addition of D2O, J = 7.4, 4.5, and 3.1
Hz, 1H), 4.60 (d, J = 6.6 Hz, 1H), 4.56 (d, J = 6.6 Hz, 1H),
3.99 (ddisappears upon addition of D2O, J = 6.8 Hz, 1H),
3.95 (s, 3H), 3.92 (dd, J = 10.8 and 3.1 Hz, 1H), 3.85 (dd, J =
10.8 and 4.5 Hz, 1H), 3.52 (s, 3H), 3.22 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 197.8, 151.8, 150.0, 128.0, 123.1, 114.7,
111.4, 96.9, 95.2, 73.2, 71.1, 56.7, 56.3, 55.5; IR νmax 3444,
2937, 1676, 1595, 1512, 1464, 1266, 1148, 1115, 1080, 1032,
980, 920 cm−1; MS (ESI, +ve) m/z 323 (100) [M + Na]+;
HRMS calcd for C14H20NaO7 [M + Na]
+: 323.1107, found:
323.1107.
(R)-1-(3-Methoxy-4-(methoxymethoxy)phenyl)-3-(me-
thoxymethoxy)-1-oxopropan-2-yl 4-Methylbenzenesulfo-
nate (7). A magnetically stirred solution of alcohol 6 (1.52 g
5.06 mmol) in dry dichloromethane (20 mL) maintained under
nitrogen was cooled to 0 °C then treated with pyridine (600
μL, 7.59 mmol) and p-toluenesulfonic acid anhydride (2.48 g,
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7.6 mmol). The ensuing mixture was allowed to stir at 0 °C for
0.5 h then warmed to 22 °C and stirred at this temperature for
an additional 1 h before being re-cooled to 0 °C, quenched with
pH 7 buffer (2 mL of a 1 M aqueous solution), then allowed to
warm to 22 °C. The mixture thus obtained was diluted with
ethyl acetate (50 mL) before being washed with NH4Cl (1 ×
40 mL) and brine (1 × 10 mL) The separated aqueous phase
was extracted with ethyl acetate (3 × 20 mL), and the
combined organic phases were washed with brine (3 × 20 mL)
before being dried (MgSO4), filtered, then concentrated under
reduced pressure to afford an orange oil. This oil was subjected
to flash chromatography (silica, dichloromethane → 1:9 v/v
Et2O/dichloromethane gradient elution) and concentration of
the relevant fractions (Rf = 0.6 in 1:9 v/v Et2O/dichloro-
methane) under reduced pressure afforded ester 7 (2.14 g,
93%) as a white, crystalline solid, mp = 93.5−95.8 °C, [α]25D =
−34 (c = 1.0, CHCl3).
1H NMR (400 MHz, CDCl3) δ 7.75 (d,
J = 8.2 Hz, 2H), 7.53 (dd, J = 8.5 and 1.8 Hz, 1H), 7.46 (d, J =
1.8 Hz, 1H), 7.26 (d, J = 8.2 Hz, 2H), 7.17 (d, J = 8.5 Hz, 1H),
5.82 (t, J = 4.9 Hz, 1H), 5.32 (s, 2H), 4.54 (m, 2H), 3.93 (d, J =
4.9 Hz, 2H), 3.91 (s, 3H), 3.52 (s, 3H), 3.25 (s, 3H), 2.41 (s,
3H); 13C NMR (100 MHz, CDCl3) δ 191.6, 151.7, 149.8,
145.2, 133.5, 129.8, 128.7, 128.2, 123.5, 114.6, 111.6, 96.7, 95.2,
79.8, 67.4, 56.7, 56.2, 55.6, 21.8; IR νmax 3374, 2940, 1690,
1595, 1512, 1464, 1421, 1364, 1267, 1176, 1079, 1030, 976,
923, 814, 666 cm−1; MS (ESI, +ve) m/z 477 (100) [M + Na]+;
HRMS calcd for C21H26NaO9S [M + Na]
+: 477.1195, found:
477.1194.
(E)-3-(3-Methoxy-4-((1-(3-methoxy-4-(methoxymethoxy)-
phenyl)-3-(methoxymethoxy)-1-oxopropan-2-yl)oxy)-
phenyl)acrylaldehyde (9). Cesium carbonate (1.09 g, 3.34
mmol) was added to a solution of 18-crown-6 (874 mg, 3.31
mmol) and coniferaldehyde (8) (590 mg, 3.31 mmol) in dry
acetonitrile (9 mL) maintained under nitrogen at 22 °C. The
resulting suspension was sonicated for 0.5 h, then the
supernatant liquid was taken up in a syringe and added
dropwise, over 0.25 h, to a magnetically solution of tosylate 7
(990 mg, 2.17 mmol) in dry acetonitrile (20 mL) maintained
under nitrogen at 0 °C. The resulting solution was stirred at 0
°C for 5 h then quenched with pH 7 buffer (2 mL of a 1 M
aqueous solution) before being allowed to warm to 22 °C. The
ensuing mixture was diluted with ethyl acetate (20 mL), and
the separated aqueous phase was extracted with ethyl acetate (3
× 20 mL). The combined organic phases were washed with
brine (3 × 20 mL) then dried (MgSO4), filtered, and
concentrated under reduced pressure. The resulting light-
yellow oil was subjected to flash chromatography [silica,
dichloromethane → 3:7 v/v Et2O/dichloromethane gradient
elution], and concentration of the relevant fractions (Rf = 0.2 in
1:9 v/v Et2O/dichloromethane) under reduced pressure
afforded aryl ether 9 (470 mg, 47%) as a clear, pale-yellow
oil, [α]25D = 0 (c = 2.0, CHCl3).
1H NMR (400 MHz, CDCl3)
δ 9.63 (d, J = 7.7 Hz, 1H), 7.74 (dd, J = 8.5 and 1.1 Hz, 1H),
7.66 (s, 1H), 7.35 (d, J = 15.8 Hz, 1H), 7.18 (d, J = 8.5 Hz,
1H), 7.05 (s, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.81 (d, J = 8.3 Hz,
1H), 6.56 (dd, J = 15.8 and 7.7 Hz, 1H), 5.62 (m, 1H), 5.30 (s,
2H), 4.69 (s, 2H), 4.19−4.07 (complex m, 2H), 3.91 (s, 3H),
3.84 (s, 3H), 3.50 (s, 3H), 3.32 (s, 3H); 13C NMR (100 MHz,
CDCl3) δ 194.5, 193.6, 152.6, 151.6, 150.2, 150.0, 149.8, 129.0,
128.5, 127.3, 123.4, 123.1, 115.5, 114.6, 111.7, 111.2, 96.9, 95.1,
81.7, 68.1, 56.7, 56.1(1), 56.0(7), 55.6; IR νmax 3369, 2932,
1671, 1595, 1509, 1268, 1141, 1127, 1079, 1032, 975, 804
cm−1; MS (ESI, +ve) m/z 484 (100) [M + Na]+; HRMS calcd
for C24H28NaO9 [M + Na]
+: 483.1631, found: 483.1632.
(E)-3-(4-((3-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-1-
oxopropan-2-yl)oxy)-3-met-hoxyphenyl)acrylaldehyde (10).
A magnetically stirred solution of aryl ether 9 (465 mg, 1.02
mmol) in dry isopropanol (30 mL) was treated with
concentrated hydrochloric acid (3 drops), and the resulting
solution was heated at 60 °C for 22 h. The cooled reaction
mixture was quenched with NaHCO3 (20 mL of a saturated
solution) then diluted with ethyl acetate (60 mL) before being
washed with NaHCO3 (2 × 20 mL). The separated aqueous
phases were extracted with ethyl acetate (3 × 20 mL), and the
combined organic phases were washed with brine (3 × 20 mL)
then dried (MgSO4), filtered, and concentrated under reduced
pressure to afford a pale-yellow oil. This oil was subjected to
flash chromatography (silica, 1:1 v/v ethyl acetate/petroleum
ether → ethyl acetate gradient elution), and concentration of
the relevant fractions (Rf = 0.2 in 3:1 v/v ethyl acetate
/petroleum ether) under reduced pressure afforded alcohol 10
(291 mg, 76%) as a pale-yellow foam, [α]25D = 0 (c = 0.5,
CHCl3).
1H NMR (400 MHz, CDCl3) δ 9.65 (d, J = 7.7 Hz,
1H), 7.70 (dd, J = 8.4 and 1.9 Hz, 1H), 7.61 (d, J = 1.9 Hz,
1H), 7.37 (d, J = 15.9 Hz, 1H), 7.08 (d, J = 1.9 Hz, 1H), 7.04
(dd, J = 8.3 and 2.0 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.83 (d, J
= 8.3 Hz, 1H), 6.55 (dd, J = 15.9 and 7.7 Hz, 1H), 6.17 (broad
s, 1H), 5.55 (m, 1H), 4.13 (m, 2H), 3.94 (s, 3H), 3.90 (s, 3H),
2.79 (broad t, J = 6.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ
194.0, 193.6, 152.4, 151.5, 150.5, 149.7, 147.1, 129.1, 127.6(2),
127.5(7), 124.2, 123.1, 116.7, 114.3, 111.2, 110.7, 83.4, 63.9,
56.3, 56.1; IR νmax 3356, 2938, 1668, 1620, 1591, 1509, 1426,
1270, 1137, 1030, 734 cm−1; MS (ESI, +ve) m/z 395 (100) [M
+ Na]+; HRMS calcd for C20H20NaO7 [M + Na]
+: 395.1107,
found: 395.1110.
Compounds (±)-1 and (±)-2. Polymer-supported borohy-
dride (2.5 mmol g−1 on Amberlite A-26, 400 mg, 1.0 mmol)
was added in one portion to a magnetically stirred solution of
compound 10 (77 mg, 0.21 mmol) in methanol (5 mL)
maintained under nitrogen at 0 °C. The ensuing mixture was
stirred at this temperature for 4 h then allowed to warm to 22
°C before being filtered, and the solids thus retained were
washed with acetic acid in methanol (3 × 10 mL of a 1:99 v/v
mixture). The combined filtrates were concentrated under
reduced pressure to give a ca. 7:1 mixture of the title
compounds (68 mg, 87%) as a light-yellow oil. Subjection of
this material to preparative, reverse phase HPLC (Gemini C18
5μ 150 × 21.20 mm2 column, 25:74.95:0.05 v/v/v/v methanol/
water/acetic acid elution, flow rate 17.0 mL/min) afforded two
fractions, A and B.
Concentration of fraction A (tR = 12.0 min) afforded
compound (±)-24e,10 (9 mg, 12%) as a white powder. 1H NMR
[300 MHz, (CD3)2CO] δ 7.11 (d, J = 1.9 Hz, 1H), 7.06 (d, J =
1.9 Hz, 1H), 6.92 (d, J = 8.1 Hz, 1H), 6.90−6.85 (complex m,
2H), 6.76 (d, J = 8.1 Hz, 1H), 6.52 (dt, J = 15.8 and 1.7 Hz,
1H), 6.28 (dt, J = 15.8 and 5.3 Hz, 2H), 4.89 (d, J = 5.3 Hz,
1H), 4.30 (m, 1H), 4.19 (dd, J = 5.3 and 1.7 Hz, 2H), 3.85 (s,
3H), 3.82 (s, 3H), 3.79 (partially obscured m, 1H), 3.69 (dd, J
= 11.6 and 4.0 Hz, 1H) (signals due to three hydroxyl group
protons not observed); 1H NMR (400 MHz, CD3OD) δ 7.02
(d, J = 2.0 Hz, 1H), 7.00 (s, 1H), 6.87 (s, 2H), 6.84 (dd, J = 8.2
and 2.0 Hz, 1H), 6.73 (d, J = 8.2 Hz, 1H), 6.51 (dt, J = 15.7 and
1.6 Hz, 1H), 6.24 (dt, J = 15.7 and 5.7 Hz, 1H), 4.83 (d, J = 5.7
Hz, 1H), 4.36 (m, 1H), 4.20 (dd, J = 5.7 and 1.6 Hz, 2H), 3.85
(dd, J = 12.0 and 5.6 Hz, 1H), 3.80 (s, 3H), 3.80 (s, 3H), 3.76
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(partially obscured d, J = 3.6 Hz, 1H) (signals due to hydroxyl
group protons not observed); 13C NMR (100 MHz, CD3OD)
δ see Table 1; IR νmax 3369, 2918, 1509, 1266, 1152, 1122,
1029 cm−1; MS (EI, +ve) m/z 376 (15) (M+•), 358 (50), 328
(45), 206 (100); HRMS calcd for C20H24O7 (M
+•): 376.1522,
found: 376.1524.
Concentration of fraction B (tR = 13.2 min) afforded
compound (±)-14l,10 (57 mg, 73%) as a white powder. 1H
NMR [300 MHz, (CD3)2CO] δ 7.11 (d, J = 8.4 Hz, 1H),
7.10−7.09 (complex m, 2H), 6.91 (dd, J = 8.4 and 2.1 Hz, 1H),
6.90 (dd, J = 8.1 and 1.9 Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 6.54
(dt, J = 15.9 and 1.7 Hz, 1H), 6.30 (dt, J = 15.9 and 5.3 Hz,
1H), 4.88 (d, J = 6.3 Hz, 1H), 4.20 (m, 3H), 3.90 (s, 3H), 3.81
(s, 3H), 3.68 (dd, J = 11.8 and 3.7 Hz, 1H), 3.50 (dd, J = 11.8
and 5.7 Hz, 1H) (signals due to hydroxyl group protons not
observed); 1H NMR (400 MHz, CD3OD) δ 7.05 (s, 1H), 7.03
(s, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.86
(d, J = 8.2 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.53 (d, J = 15.8
Hz, 1H), 6.25 (dt, J = 15.8 and 5.7 Hz, 1H), 4.90 (partially
obscured m, 1H), 4.31 (app. q, J = 5.0 Hz, 1H), 4.20 (d, J = 5.7
Hz, 2H), 3.87 (s, 3H), 3.81 (s, 3H), 3.74 (dd, J = 12.1, 3.7 Hz,
1H), 3.48 (dd, J = 12.0, 5.2 Hz, 1H) (signals due to hydroxyl
group protons not observed); 13C NMR (100 MHz, CD3OD)
δ see Table 1; IR νmax 3369, 2931, 1604, 1510, 1263, 1129,
1079, 1029, 965 cm−1; MS (ESI, +ve) m/z 399 (100) [M +
Na]+; HRMS calcd for C20H24NaO7 [M + Na]
+: 399.1420,
found: 399.1420.
2-(4-Allyl-2-methoxyphenoxy)acetic Acid (14). Compound
14 was prepared in 85% overall yield from ethyl α-
bromoacetate and eugenol (13) following a protocol reported
by Spurg and Waldvogel25 to give a white, crystalline solid. 1H
NMR (400 MHz, CDCl3) δ 6.91 (d, J = 7.9 Hz, 1H), 6.76 (m,
2H), 5.94 (m, 1H), 5.11 (m, 1H), 5.08 (m, 1H), 4.63 (s, 2H),
3.90 (s, 3H), 3.36 (d, J = 6.7 Hz, 2H) (signal due to carboxylic
acid group proton not observed); 13C NMR (100 MHz,
CDCl3) δ 171.4, 149.9, 145.7, 137.2, 136.5, 121.3, 117.6, 116.3,
112.7, 69.0, 56.1, 40.0. These spectral data matched those
reported by Labarrios and co-workers.26
(S)-3-(2-(4-Allyl-2-methoxyphenoxy)acetyl)-4-isopropyl-
5,5-diphenyloxazolidin-2-one (15). Oxalyl chloride (710 μL,
8.14 mmol) was added dropwise over 0.08 h to a magnetically
stirred solution of carboxylic acid 14 (1.65 g, 7.40 mmol) and
dimethylformamide (DMF) (28 μL, 0.37 mmol) in dichloro-
methane (15 mL) maintained at 0 °C under a nitrogen
atmosphere. The ensuing mixture was allowed to warm to 22
°C and stirred until gas evolution ceased (ca. 1 h). The
dichloromethane was then removed by sparging the reaction
mixture with a stream of nitrogen followed by further
concentration of the reaction mixture under reduced pressure.
The acid chloride thus obtained was dissolved in dry THF (15
mL). In a separate flask, n-BuLi (4.52 mL of a 1.5 M solution in
hexanes, 6.79 mmol) was added dropwise over 0.25 h to a
magnetically stirred solution of (S)-4-isopropyl-5,5-diphenylox-
azolidin-2-one (12)14b (1.74 g, 6.17 mmol) in dry THF (150
mL) maintained at 0 °C. The resulting solution was stirred at
this temperature for 0.5 h then cooled to −78 °C. The
previously formed solution of the acid chloride in THF was
then added dropwise over 0.25 h, and stirring of the combined
solutions continued at −78 °C for 0.5 h. The cooling bath was
then removed, and the reaction mixture was allowed to warm to
22 °C and stirring was continued for 3 h. After this time, the
reaction mixture was cooled to 0 °C and quenched with NH4Cl
(30 mL of a saturated aqueous solution) then acetic acid (5
mL). The ensuing mixture was allowed to warm, over 0.25 h, to
22 °C then it was extracted with ethyl acetate (3 × 30 mL).
The combined organic phases were washed with NaHCO3 (2 ×
10 mL of a saturated aqueous solution) and brine (2 × 20 mL)
before being dried (Na2SO4), filtered, and concentrated under
reduced pressure. The ensuing viscous, clear, and light-yellow
oil was subjected to flash column chromatography (silica,
hexane → 1:4 v/v ethyl acetate/hexane gradient elution), and
concentration of the appropriate fractions (Rf = 0.3 in 1:4 v/v
ethyl acetate/hexane) afforded amide 15 (2.79 g, 93%) as a
white foam, [α]20D = −156 (c = 0.3, CHCl3).
1H NMR (400
MHz, CDCl3) δ 7.52−7.27 (complex m, 10H), 6.70 (d, J = 2.0
Hz, 1H), 6.57 (dd, J = 8.2 and 2.0 Hz, 1H), 6.46 (d, J = 8.2 Hz,
1H), 5.94 (m, 1H), 5.37 (d, J = 3.3 Hz, 1H), 5.24 (d, J = 17.7
Hz, 1H), 5.12−5.01 (complex m, 3H), 3.82 (s, 3H), 3.31 (d, J =
6.8 Hz, 2H), 2.00 (m, 1H), 0.90 (d, J = 7.0 Hz, 3H), 0.79 (d, J
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.2, 153.2,
149.4, 145.6, 142.1, 137.9, 137.7, 134.1, 129.2, 129.0, 128.6,
128.3, 126.0, 125.8, 120.4, 115.8, 113.6, 112.6, 91.1, 68.1, 64.9,
56.0, 40.0, 30.0, 21.9, 16.6; IR νmax 2969, 1780, 1724, 1510,
1257, 1209, 1178, 1147, 1035, 992, 733, 701 cm−1; MS (ESI,
+ve) m/z 508 (100) [M + Na]+; HRMS calcd for
C30H31NNaO5 [M + Na]
+: 508.2100, found: 508.2099.
(R)-3-(2-(4-Allyl-2-methoxyphenoxy)acetyl)-4-isopropyl-
5,5-diphenyloxazolidin-2-one (ent-15). Compound ent-15
was prepared in an analogous fashion to that described
immediately above from compounds ent-12 and 14. Flash
chromatographic purification then gave oxazolidin-2-one ent-15
(8.79 g, quantitative yield) as a white foam, [α]20D = +160 (c =
0.3, CHCl3). All the other spectral data acquired on this
material were identical with those detailed above for compound
15.
(1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-1-(4-((tert-
butyldimethylsilyl)oxy)-3-methoxyphe-nyl)propane-1,3-diol
(17). Step i: A magnetically stirred solution of amide 15 (2.00 g,
4.12 mmol) in dry dichloromethane (8 mL) maintained at 0 °C
under a nitrogen atmosphere was treated, dropwise over 0.08 h,
with freshly prepared14b Bu2BOTf (1.07 mL, 1.35 g, 4.94
mmol). The ensuing mixture was allowed to warm to 22 °C,
stirred at this temperature for 0.25 h, then freshly distilled
Hünig’s base (970 μL, 5.56 mmol) was added dropwise over
0.08 h. Stirring was continued at 22 °C for another 0.5 h then
the reaction mixture was cooled to −78 °C before a solution of
aldehyde 1627 (1.35 g, 4.94 mmol) in dichloromethane (4 mL)
was added via syringe pump over 0.75 h. The ensuing mixture
was stirred at −78 °C for a further 1 h then warmed to 0 °C,
stirred at this temperature for 4 h, then quenched with
phosphate buffer (15 mL of a 1 M aqueous solution at pH 7)
before being treated with methanol/30% aq. hydrogen peroxide
(10 mL of a 1:1 v/v mixture) and allowed to warm to 22 °C
over 1 h. The biphasic mixture thus obtained was diluted with
water (20 mL), and the separated aqueous layer was extracted
with dichloromethane (3 × 10 mL). The combined organic
phases were washed with brine (1 × 10 mL) then dried
(Na2SO4), filtered, and concentrated under reduced pressure.
The ensuing thick oil was subjected to flash column
chromatography (silica, dichloromethane → 1:19 v/v Et2O/
dichloromethane gradient elution), and concentration of the
appropriate fractions (Rf = 0.5 in 1:19 v/v Et2O/dichloro-
methane) afforded the anticipated aldol product (2.58 g, 83%)
as a white foam, [α]20D = −78.5 (c = 1, CHCl3).
1H NMR (400
MHz, CDCl3) δ 7.36−7.27 (complex m, 10H), 6.87 (d, J = 2.0
Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 2.0 Hz, 1H),
ACS Omega Article
DOI: 10.1021/acsomega.7b01459
ACS Omega 2017, 2, 7375−7388
7383
231
6.63 (dd, J = 8.1 and 2.0 Hz, 1H), 6.57 (dd, J = 8.1 and 2.0 Hz,
1H), 6.48 (d, J = 8.1 Hz, 1H), 6.10 (m, 1H), 5.89 (m, 1H), 5.35
(d, J = 2.9 Hz, 1H), 5.05 (m 1H), 5.01 (m, 1H), 4.67 (t, J = 5.0
Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H), 3.28 (m, 3H), 1.95 (m,
1H), 0.98 (s, 9H), 0.86 (d, J = 7.0 Hz, 3H), 0.68 (d, J = 6.7 Hz,
3H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 169.3, 152.9, 150.7, 150.4, 145.5, 144.7, 141.6, 138.1, 137.5,
135.6, 131.9, 129.0(3), 129.0(0), 128.5, 128.1, 125.9, 125.4,
120.8, 120.5, 119.3, 118.5, 115.9, 113.1, 110.6, 90.1, 81.4, 74.0,
65.1, 56.0, 55.3, 40.0, 30.1, 25.9, 21.8, 18.6, 16.3, −4.5, −4.6; IR
νmax 3452, 2954, 2930, 2858, 1777, 1716, 1510, 1450, 1369,
1283, 1210, 1153, 1035, 908, 702 cm−1; MS (ESI, +ve) m/z
774 (100) [M + Na]+; HRMS calcd for C44H53NNaO8Si [M +
Na]+: 774.3438, found: 774.3433.
Step ii: Methanol (230 μL, 5.65 mmol) was added to a
magnetically stirred solution of the above-mentioned aldol
product (1.70 g, 2.26 mmol) in THF (25 mL) maintained
under nitrogen at 22 °C. The resulting solution was cooled to 0
°C, and lithium borohydride (123 mg, 5.65 mmol) was then
added in portions over 0.08 h. The ensuing mixture was stirred
at 0 °C for 0.5 h then warmed to 22 °C and stirred at this
temperature for 2 h before being quenched with NH4Cl (20
mL of a saturated aqueous solution) then diluted with Et2O
(100 mL). The separated aqueous layer was extracted with
Et2O (2 × 20 mL), and the combined organic extracts were
washed with brine (2 × 20 mL) then dried (Na2SO4), filtered,
and concentrated under reduced pressure. The ensuing pale-
yellow residue was subjected to flash column chromatography
(silica, 1:19 v/v Et2O/dichloromethane → 1:4 v/v Et2O/
dichloromethane gradient elution), and concentration of the
appropriate fractions (Rf = 0.4 in 1:4 v/v Et2O/dichloro-
methane) afforded diol 17 (982 mg, 92%) as a clear, colorless
oil, [α]20D = −63.3 (c = 0.8, CHCl3).
1H NMR (400 MHz,
CDCl3) δ 7.01 (d, J = 8.0 Hz, 1H), 6.95 (d, J = 1.9 Hz, 1H),
6.88 (dd, J = 8.1 and 1.9 Hz, 1H), 6.82 (d, J = 8.1 Hz, 1H), 6.76
(d, J = 1.9 Hz, 1H), 6.74 (dd, J = 8.0 and 1.9 Hz, 1H), 5.95 (m,
1H), 5.11 (m, 1H), 5.07 (t, J = 1.4 Hz, 1H), 4.95 (d, J = 8.0 Hz,
1H), 3.97 (dt, J = 7.6 and 3.6 Hz, 1H), 3.90 (s, 3H), 3.80 (s,
3H), 3.60 (dd, J = 12.5 and 3.2 Hz, 1H), 3.47 (dd, J = 12.5 and
4.0 Hz, 1H), 3.35 (d, J = 6.8 Hz, 2H), 0.99 (s, 9H), 0.14 (s,
6H) (signals due to hydroxyl group protons not observed); 13C
NMR (100 MHz, CDCl3) δ 151.3, 151.2, 146.0, 145.1, 137.3,
136.5, 133.2, 121.7, 121.2, 119.8, 116.2, 112.6, 110.8, 90.0, 74.2,
61.3, 56.0, 55.6, 40.1, 25.9, 18.6, −4.5(0), −4.5(2) (one signal
obscured or overlapping); IR νmax 3453, 2954, 2931, 2857,
1510, 1465, 1419, 1283, 1264, 1228, 1156, 1034, 911, 840, 782
cm−1; MS (ESI, +ve) m/z (%) 497 (100) [M + Na]+; HRMS
calcd for C26H38NaO6Si [M + Na]
+: 497.2335, found:
497.2332.
(1S,2S)-2-(4-Allyl-2-methoxyphenoxy)-1-(4-((tert-
butyldimethylsilyl)oxy)-3-methoxyphen-yl)propane-1,3-diol
(ent-17). Diol ent-17 was prepared as described immediately
above from precursor ent-15 and aldehyde 16. Flash chromato-
graphic purification of the product from step i gave the
expected aldol product (2.15 g, 69%) as a clear, colorless oil,
[α]20D = +77.7 (c = 1, CHCl3). All the other spectral data
acquired on this material were identical with those reported
above for the product from step i. The conditions defined in
step ii above were employed to produce diol ent-17 (684 mg,
96%), which was obtained as a clear, colorless oil, [α]20D =
+66.2 (c = 0.7, CHCl3). All other spectral data acquired on this
material were identical with those reported above for
compound 17.
(E)-3-(4-(((1R,2R)-1-(4-((tert-Butyldimethylsilyl)oxy)-3-me-
thoxyphenyl)-1,3-dihydroxypr-oxypropan-2-yl)oxy)-3-
methoxyphenyl)allyl Acetate (18). Acetic acid (370 μL, 6.5
mmol), sodium acetate (6.5 mg, 0.08 mmol), molecular sieves
(2 mg of activated 4 Å material), 4,5-DAF (5.1 mg, 7 mol %),
and Pd(OAc)2 (6.3 mg, 7 mol %) were added sequentially to a
magnetically stirred solution of compound 17 (190 mg, 0.40
mmol) in 1,4-dioxane (2.4 mL) maintained at 22 °C. Oxygen
from a balloon was bubbled through the resulting solution for
0.25 h, which was then heated to 60 °C and maintained under
an atmosphere of oxygen. After 48 h, the reaction mixture was
cooled to 22 °C, and the solvent was removed under reduced
pressure. The black residue thus obtained was subjected to flash
column chromatography (silica, hexane → 3:2 v/v ethyl
acetate/hexane gradient elution), and concentration of the
appropriate fractions (Rf = 0.2 in 1:1 v/v EtOAc/hexane)
afforded acetate 18 (103 mg, 48%) as a pale-yellow oil, [α]20D =
−69.1 (c = 0.6, CHCl3).
1H NMR (400 MHz, CDCl3) δ 7.04
(d, J = 8.2 Hz, 1H), 7.01−6.92 (complex m, 3H), 6.87 (dd, J =
8.0 and 1.9 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 15.9
Hz, 1H), 6.21 (dt, J = 15.9 and 6.5 Hz, 1H), 4.95 (dd, J = 7.9
and 2.0 Hz, 1H), 4.72 (dd, J = 6.5 and 1.3 Hz, 2H), 4.03 (m,
1H), 3.93 (s, 3H), 3.80 (s, 3H), 3.61 (m, 1H), 3.55−3.46
(complex m, 2H), 2.57 (m, 1H), 2.11 (s, 3H), 0.99 (s, 9H),
0.14 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.0, 151.4,
151.3, 147.9, 145.2, 133.8, 133.1, 132.6, 122.9, 121.0, 120.9,
120.5, 119.7, 110.8, 110.0, 89.7, 74.2, 65.1, 61.4, 56.1, 55.7,
25.9, 21.2, 18.6, −4.5(0), −4.5(2); IR νmax 3467, 2952, 2933,
2857, 1739, 1510, 1465, 1419, 1251, 1232, 1158, 1128, 1030,
908, 840 cm−1; MS (ESI, +ve) m/z 555 (100) [M + Na]+;
HRMS calcd for C28H40NaO8Si [M + Na]
+: 555.2390, found:
555.2390.
(E)-3-(4-(((1S,2S)-1-(4-((tert-Butyldimethylsilyl)oxy)-3-me-
thoxypheny l ) -1 ,3 -d ihydroxypro-pan-2-y l )oxy ) -3 -
methoxyphenyl)allyl Acetate (ent-18). Allylic oxidation of
compound ent-17 in the same manner as that described above
for congener 17 afforded, after flash chromatographic
purification, compound ent-18 (71 mg, 65%) as a pale-yellow
oil, [α]20D = +47.5 (c = 1.6, CHCl3). All other spectral data
acquired on this material were identical with those reported
above for compound 18.
(1R,2R)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hy-
droxyprop-1-en-1-yl)-2-methox-yphenoxy)propane-1,3-diol
(ent-1). K2CO3 (270 mg, 1.95 mmol) was added to a
magnetically stirred solution of acetate 18 (45 mg, 0.085
mmol) in methanol (5 mL) containing water (100 μL) and
maintained at 22 °C under a nitrogen atmosphere. The ensuing
mixture was stirred at this temperature for 18 h then diluted
with ethyl acetate (20 mL), acidified (to pH 5) using acetic acid
(ca. 200 μL), then washed with water (1 × 5 mL) and brine (2
× 5 mL) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The ensuing pale-yellow
oil was subjected to flash column chromatography (silica, 1:19
v/v methanol/dichloromethane → 1:9 v/v methanol/dichloro-
methane gradient elution). Concentration of the appropriate
fractions (Rf = 0.2 in 1:19 v/v methanol/dichloromethane)
afforded compound ent-1 (25 mg, 79%) as a clear, colorless
gum, [α]20D = −36.7 (c = 0.9, methanol).
1H NMR (400 MHz,
CD3OD) δ 7.06 (s, 1H), 7.03 (s, 1H), 7.00 (d, J = 8.3 Hz, 1H),
6.91 (d, J = 8.3 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.75 (dd, J =
8.2 and 1.4 Hz, 1H), 6.53 (d, J = 16.0 Hz, 1H), 6.26 (dt, J =
16.0 and 5.4 Hz, 1H), 4.88 (m, 1H), 4.29 (m, 1H), 4.20 (d, J =
5.7 Hz, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.73 (dd, J = 11.9 and
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4.0 Hz, 1H), 3.47 (dd, J = 11.9 and 5.4 Hz, 1H) (signals due to
hydroxyl group protons not observed); 13C NMR (100 MHz,
CD3OD) δ 151.8, 149.2, 148.8, 147.2, 133.8, 133.1, 131.4,
128.6, 120.8, 120.7, 118.8, 115.8, 111.7, 111.3, 87.1, 74.0, 63.8,
61.9, 56.5, 56.3; IR νmax 3348, 2934, 1602, 1509, 1464, 1263,
1226, 1156, 1130, 1027, 968 cm−1; MS (ESI, +ve) m/z 399
(100) [M + Na]+; HRMS calcd for C20H24NaO7 [M + Na]
+:
399.1420, found: 399.1419; HPLC analysis: Trefoil CEL1
column, 98:2 v/v methanol/supercritical CO2 elution, flow rate
2 mL/min, temperature 40 °C, detection at λ = 254 nm, tmajor =
6.03 min, ee > 99%.
(1S,2S)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hy-
droxyprop-1-en-1-yl)-2-methoxy-phenoxy)propane-1,3-diol
(1). Treatment of acetate ent-18 with potassium carbonate in
the same manner as that described above gave neolignan 1 (28
mg, 93%) as a clear, colorless gum, [α]20D = +32.4 (c = 0.2,
methanol). All other spectral data acquired on this material
were identical with those reported above for compound ent-1.
HPLC analysis: Trefoil CEL1 column, 98:2 v/v methanol/
supercritical CO2 elution, flow rate 2 mL/min, temperature 40
°C, detection at λ = 254 nm, tminor = 5.86 min, tmajor = 6.05 min,
ee = 90%.
4-((1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxyprop-yl)-2-methoxyphenol
(19). The following one-pot procedure for preparing
compound 19 was established after that used to prepare its
enantiomer (ent-19) and proved to be the more efficient one.
Thus, a magnetically stirred solution of diol 17 (565 mg, 1.19
mmol) in DMF (4 mL) was cooled to 0 °C and treated
sequentially with imidazole (162 mg, 2.38 mmol) and TBDMS-
Cl (194 mg, 1.25 mmol). The ice bath was then removed, and
the resulting solution was stirred at 22 °C for 1.5 h before being
treated with Cs2CO3 (774 mg, 3.38 mmol) and water (400 μL).
The resulting mixture was stirred at 22 °C for 2 h then heated
at 40 °C for 4 h. The cooled reaction mixture was stirred at 22
°C for 16 h before being diluted with ethyl acetate (30 mL) and
washed with NH4Cl (3 × 10 mL of a saturated aqueous
solution). The combined aqueous phases were extracted with
ethyl acetate (3 × 10 mL) and the combined organic phases
washed with brine (2 × 10 mL) then dried (Na2SO4), filtered,
and concentrated under reduced pressure. The resulting pale-
yellow residue was subjected to flash column chromatography
(silica, 1:9 v/v Et2O/dichloromethane), and concentration of
the appropriate fractions (Rf = 0.2 in 1:19 v/v Et2O/
dichloromethane) afforded phenol 19 (544 mg, 96%) as a
clear, colorless oil, [α]20D = −103 (c = 1, CHCl3).
1H NMR
(400 MHz, CDCl3) δ 7.11 (d, J = 8.1 Hz, 1H), 6.93 (s, 1H),
6.87 (m, 2H), 6.74 (d, J = 2.0 Hz, 1H), 6.71 (dd, J = 8.1 and 2.0
Hz, 1H), 5.96 (m, 1H), 5.10 (m, 1H), 5.07 (m, 1H), 4.82 (dd, J
= 7.7 and 2.6 Hz, 1H), 4.21 (d, J = 2.6 Hz, 1H), 4.03 (m, 1H),
3.88 (s, 3H), 3.86 (s, 3H), 3.72 (dd, J = 11.2 and 3.4 Hz, 1H),
3.63 (dd, J = 11.2 and 5.4 Hz, 1H), 3.37 (d, J = 6.8 Hz, 2H),
0.88 (s, 9H), 0.00 (s, 3H), −0.01 (s, 3H) (signal due to one
hydroxyl group protons not observed); 13C NMR (100 MHz,
CDCl3) δ 150.7, 147.0, 146.6, 145.5, 137.6, 135.4, 132.4, 121.1,
120.6, 120.3, 116.0, 114.2, 112.4, 109.6, 89.0, 74.0, 62.7, 56.1,
55.9, 40.1, 26.0, 18.5, −5.3(0), −5.3(4); IR νmax 3466, 2954,
2930, 2856, 1606, 1509, 1454, 1266, 1227, 1127, 1035, 836,
779 cm−1; MS (ESI, +ve) m/z (%) = 497 (100) [M + Na]+;
HRMS calcd for C26H38NaO6Si [M + Na]
+: 497.2335, found:
497.2334.
4-((1S,2S)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxypropy-l)-2-methoxyphenol
(ent-19). A magnetically stirred solution of diol ent-17 (452 mg,
0.95 mmol) in dichloromethane (6 mL) was cooled to −5 °C
and treated sequentially with imidazole (129 mg, 1.9 mmol)
and TBDMS-Cl (155 mg, 1.00 mmol). The cooling bath was
then removed, and the reaction mixture was stirred at 22 °C for
16 h before being quenched with NH4Cl (10 mL of a saturated
aqueous solution). The separated aqueous phase was extracted
with dichloromethane (3 × 10 mL) and the combined organic
phases were then washed with brine (2 × 10 mL) before being
dried (Na2SO4), filtered, and concentrated under reduced
pressure to give the anticipated bis-TBDMS ether (386 mg) as
a light-yellow oil. This oil was dissolved in DMF (1 mL), and
the resulting solution was treated with Cs2CO3 (307 mg, 0.95
mmol) and water (100 μL) then stirred at 22 °C for 24 h. After
this time, another batch of Cs2CO3 (200 mg, 0.62 mmol) was
added, and stirring continued for an additional 24 h. The
reaction mixture was then diluted with ethyl acetate (30 mL)
before being washed with NH4Cl (3 × 10 mL of a saturated
aqueous solution). The combined aqueous washings were
extracted with ethyl acetate (3 × 10 mL), and the combined
organic phases were then washed with brine (2 × 10 mL)
before being dried (Na2SO4), filtered, and concentrated under
reduced pressure. The ensuing pale-yellow residue was
subjected to flash column chromatography (silica, 1:9 v/v
Et2O/dichloromethane), and concentration of the appropriate
fractions (Rf = 0.2 in 1:19 v/v Et2O /DCM) afforded phenol
ent-19 (232 mg, 51% over two steps) as a clear, colorless oil,
[α]20D = +98.8 (c = 0.7, CHCl3). All other spectral data
acquired on this material were identical with those reported
above for compound 19.
4-((1R,2R)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxyprop-yl)-2-methoxyphenyl
4-Methylbenzenesulfonate (20). p-Toluenesulfonyl chloride
(216 mg, 1.13 mmol) was added in one portion to a
magnetically stirred solution of phenol 19 (512 mg, 1.08
mmol) and triethylamine (225 μL, 1.62 mmol) in dichloro-
methane (50 mL) maintained at 0 °C. DMAP (6.6 mg, 0.05
mmol) was then added to the reaction mixture, and stirring was
continued at 0 °C for 1 h. The resulting mixture was quenched
with NH4Cl (20 mL of an aqueous solution), and the separated
aqueous layer was extracted with dichloromethane (2 × 10
mL). The combined organic phases were washed with brine (2
× 15 mL) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The pale-yellow oil
thus obtained was subjected to flash column chromatography
(silica, 1:24 v/v Et2O/dichloromethane), and concentration of
the appropriate fractions (Rf = 0.6 in 1:19 v/v Et2O/
dichloromethane) afforded phenol 20 (590 mg, 87%) as a
clear, colorless oil, [α]20D = −54.2 (c = 1.1, CHCl3).
1H NMR
(400 MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 8.3
Hz, 2H), 7.10 (d, J = 8.0 Hz, 1H), 7.02 (d, J = 8.0 Hz, 1H),
6.94−6.88 (complex m, 2H), 6.73−6.67 (complex m, 2H), 5.95
(m, 1H), 5.12−5.18 (complex m 1H), 5.06 (m, 1H), 4.89 (dd, J
= 7.0 and 3.2 Hz, 1H), 4.24 (d, J = 3.2 Hz, 1H), 4.01 (m, 1H),
3.85 (s, 3H), 3.73 (dd, J = 11.2 and 3.8 Hz, 1H), 3.62 (dd, J =
11.2 and 4.9 Hz, 1H), 3.51 (s, 3H), 3.34 (d, J = 6.7 Hz, 2H),
2.42 (s, 3H), 0.89 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR
(100 MHz, CDCl3) δ 151.6, 150.6, 146.4, 144.9, 140.7, 137.8,
137.3, 135.6, 133.2, 129.3, 128.7, 123.6, 121.0, 120.0, 119.3,
115.9, 112.4, 111.3, 87.8, 73.4, 62.3, 55.7, 55.5, 39.9, 25.9, 21.7,
18.3, −5.5 (one signal obscured or overlapping); IR νmax 3475,
2951, 2931, 2856, 1600, 1506, 1464, 1419, 1264, 1176, 1092,
1035, 837, 779 cm−1; MS (ESI, +ve) m/z 651 (100) [M +
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Na]+; HRMS calcd for C33H44NaO8SSi [M + Na]
+: 651.2424,
found: 651.2423.
4-((1S,2S)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxypropy-l)-2-methoxyphenyl
4-Methylbenzenesulfonate (ent-20). Treatment of compound
ent-19 with p-toluenesulfonyl chloride, Et3N, and DMAP in the
same manner as that described immediately above gave ester
ent-20 (252 mg, 91%) as a clear, colorless oil, [α]20D = +58.4 (c
= 0.8, CHCl3). All other spectral data acquired on this material
were identical with those reported above for compound 20.
(1S ,2R) -2- (4 -A l l y l -2 -methoxyphenoxy) -3 - ( ( te r t -
butyldimethylsilyl)oxy)-1-(3-methoxy-4-(tosyloxy)phenyl)-
propyl 4-Nitrobenzoate (21). A magnetically stirred solution of
compound 20 (580 mg, 0.92 mmol), triphenylphosphine (290
mg, 1.11 mmol), and p-nitrobenzoic acid (185 mg, 1.11 mmol)
in dry THF (40 mL) was cooled to −10 °C, and DEAD (180
μL, 1.11 mmol) was then added to the reaction mixture over
0.25 h. The resulting solution was stirred at −10 °C for 0.5 h
before being warmed to 22 °C, and stirring then continued for
an additional 16 h. The resulting solution was concentrated
under reduced pressure, and the light-yellow solid thus
obtained was subjected to flash chromatography (silica, hexane
→ 3:17 v/v ethyl acetate/hexane gradient elution). Concen-
tration of the relevant fractions (Rf = 0.3 in 1:4 v/ethyl acetate/
hexane) afforded p-nitrobenzoate 21 (602 mg, 84%) as a white,
crystalline solid, mp = 107−108 °C, [α]20D = −4.3 (c = 1.2,
CHCl3).
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 8.8 Hz,
2H), 8.04 (d, J = 8.8 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.26 (d,
J = 8.2 Hz, 2H), 7.20 (s, 1H), 7.15 (m, 2H), 6.89 (d, J = 8.1 Hz,
1H), 6.71 (d, J = 2.0 Hz, 1H), 6.67 (dd, J = 8.1 and 2.0 Hz,
1H), 6.25 (d, J = 4.4 Hz, 1H), 5.93 (m, 1H), 5.07 (s, 1H), 5.05
(m, 1H), 4.74 (m, 1H), 3.87 (dd, J = 10.6 and 5.2 Hz, 1H),
3.75 (s, 3H), 3.62−3.55 (complex m, 4H), 3.32 (d, J = 7.0 Hz,
2H), 2.42 (s, 3H), 0.89 (s, 9H), 0.02 (s, 6H); 13C NMR (100
MHz, CDCl3) δ 163.6, 151.7, 150.7, 150.6, 146.4, 145.1, 138.6,
137.5, 135.9, 135.5, 135.1, 133.5, 130.9, 129.5, 128.7, 123.7,
123.6, 120.8(3), 120.7(7), 118.3, 116.0, 113.4, 113.1, 81.7, 76.4,
61.9, 55.9, 55.8, 40.0, 26.0, 21.8, 18.3, −5.2(9), −5.3(4); IR νmax
2930, 2856, 1728, 1602, 1527, 1505, 1464, 1373, 1261, 1177,
1155, 1091, 1034, 835, 813, 780, 750, 717 cm−1; MS (ESI, +ve)
m/z 800 (100) [M + Na]+; HRMS calcd for C40H47NNaO11SSi
[M + Na]+: 800.2537, found: 800.2537.
(1R ,2S) -2- (4 -A l l y l -2 -methoxyphenoxy) -3 - ( ( te r t -
butyldimethylsilyl)oxy)-1-(3-methoxy-4-(tosyloxy)phenyl)-
propyl 4-Nitrobenzoate (ent-21). Treatment of compound
ent-20 with p-nitrobenzoic acid, Ph3P, and DEAD in the same
manner as that described above gave ester ent-21 (256 mg,
82%) as a white, crystalline solid, [α]20D = +4.3 (c = 1.1,
CHCl3). All other spectral data acquired on this material were
identical with those reported above for compound 21.
4-((1S,2R)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxypropy-l)-2-methoxyphenyl
4-Methylbenzenesulfonate (22). A magnetically stirred
solution of p-nitrobenzoate 21 (569 mg, 0.73 mmol) in THF
(10 mL) maintained at 0 °C under a nitrogen atmosphere was
treated with NaOH (5 mL of a 1 M aqueous solution, 5 mmol).
The ensuing mixture was stirred at 0 °C for 0.5 h then warmed
to 22 °C, and after 0.5 h, diluted with ethyl acetate (50 mL).
The separated organic layer was washed with NaHCO3 (2 × 10
mL), and the combined aqueous washings were extracted with
ethyl acetate (2 × 10 mL). The combined organic phases were
washed with brine (2 × 15 mL) before being dried (Na2SO4),
filtered, and concentrated under reduced pressure. The
resulting yellow oil was subjected to flash column chromatog-
raphy (silica, 1:49 v/v Et2O/dichloromethane), and concen-
tration of the appropriate fractions (Rf = 0.3 in 1:49 v/v Et2O/
DCM) afforded alcohol 22 (340 mg, 74%) as a clear, colorless
oil, [α]20D = −8.0 (c = 0.9, CHCl3).
1H NMR (400 MHz,
CDCl3) δ 7.71 (d, J = 8.3 Hz, 2H), 7.26 (partially obscured d, J
= 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 1.9 Hz,
1H), 6.89 (s, 1H), 6.87 (s, 1H), 6.72 (m, 2H), 5.95 (m, 1H),
5.10 (m, 1H), 5.06 (s, 1H), 4.92 (t, J = 4.7 Hz, 1H), 4.26 (d, J =
4.9 Hz, 1H), 4.17 (m, 1H), 3.84 (s, 3H), 3.83 (partially
obscured m, 1H), 3.63 (dd, J = 11.0 and 5.1 Hz, 1H), 3.52 (s,
3H), 3.34 (d, J = 6.8 Hz, 1H), 2.42 (s, 3H), 0.88 (s, 9H), 0.03
(s, 3H), 0.02 (s, 3H) (signal due to the hydroxyl group proton
not observed); 13C NMR (100 MHz, CDCl3) δ 151.7, 151.3,
145.6, 145.0, 140.7, 137.7, 137.4, 135.9, 133.4, 129.4, 128.8,
123.7, 121.3, 120.5, 118.9, 116.1, 112.7, 111.2, 85.5, 73.8, 62.6,
56.0, 55.6, 40.1, 26.0, 21.8, 18.3, −5.3, −5.4; IR νmax 3473,
2952, 2930, 2856, 1600, 1505, 1463, 1418, 1373, 1262, 1175,
1117 1090, 1034, 836, 777, 716, 662 cm−1; MS (ESI, +ve) m/z
651 (100) [M + Na]+; HRMS calcd for C33H44NaO8SSi [M +
Na]+: 651.2424, found: 651.2424.
4-((1R,2S)-2-(4-Allyl-2-methoxyphenoxy)-3-((tert-
butyldimethylsilyl)oxy)-1-hydroxypropy-l)-2-methoxyphenyl
4-Methylbenzenesulfonate (ent-22). Treatment of ester ent-
21 with NaOH in THF in the same manner as that described
immediately above gave alcohol ent-22 (171 mg, 83%) as a
clear, colorless oil, [α]20D = +7.5 (c = 0.6, CHCl3). All other
spectral data acquired on this material were identical with those
reported above for compound 22.
(E)-3-(4-(((1S,2R)-3-((tert-Butyldimethylsilyl)oxy)-1-hy-
droxy-1-(3-methoxy-4-(tosyloxy)-phenyl)propan-2-yl)oxy)-3-
methoxyphenyl)allyl Acetate (23). Acetic acid (85 μL, 1.5
mmol), sodium acetate (1.5 mg, 0.02 mmol), molecular sieves
(2 mg of activated 4 Å material), 4,5-DAF (1.2 mg, 8 mol %),
and Pd(OAc)2 (1.5 mg, 8 mol %) were added, sequentially, to a
magnetically stirred solution of alkene 22 (48 mg, 0.076 mmol)
in 1,4-dioxane (800 μL) maintained at 22 °C. Oxygen from a
balloon was gently bubbled through the reaction mixture for
0.25 h, then the solution was heated at 60 °C with vigorous
stirring under an atmosphere of oxygen. After 66 h, the reaction
mixture was cooled to 22 °C, and the solvent was removed
under reduced pressure. The ensuing black residue was
subjected to flash column chromatography (silica, hexane →
3:2 v/v ethyl acetate/hexane gradient elution), and concen-
tration of the appropriate fractions (Rf = 0.3 in 1:1 v/v ethyl
acetate/hexane) afforded ester 23 (33 mg, 64%) as a clear,
colorless oil, [α]20D = −18.6 (c = 0.7, CHCl3).
1H NMR (400
MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 2H), 7.24 (partially
obscured m, 2H), 7.10 (d, J = 8.3 Hz, 1H), 6.99 (m, 1H), 6.93
(s, 1H), 6.91−6.87 (complex m, 3H), 6.59 (dt, J = 15.8 and 1.1
Hz, 1H), 6.19 (dt, J = 15.8 and 6.5 Hz, 1H), 4.93 (t, J = 4.8 Hz,
1H), 4.71 (dd, J = 6.5 and 1.1 Hz, 2H), 4.23 (m, 1H), 4.10 (d, J
= 4.8 Hz, 1H), 3.86 (s, 3H), 3.83 (partially obscured m, 1H),
3.68 (m, 1H), 3.53 (s, 3H), 2.42 (s, 3H), 2.10 (s, 3H), 0.88 (s,
9H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (100 MHz, CDCl3)
δ 171.0, 151.7, 151.3, 147.5, 145.0, 140.6, 137.7, 134.0, 133.3,
131.9, 129.4, 128.8, 123.7, 122.5, 120.2, 119.7, 118.9, 111.2,
110.1, 85.0, 74.0, 65.2, 62.6, 56.0, 55.6, 26.0, 21.8, 21.2, 18.3,
−5.3, −5.4; IR νmax 3475, 2932, 2856, 1737, 1600, 1506, 1464,
1418, 1372, 1251, 1229, 1175, 1117, 1091, 1031, 964, 837, 752,
716, 662 cm−1; MS (ESI, +ve) m/z 709 (100) [M + Na]+;
HRMS calcd for C35H46NaO10SSi [M + Na]
+: 709.2479, found:
709.2478.
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(E)-3-(4-(((1R,2S)-3-((tert-Butyldimethylsilyl)oxy)-1-hy-
droxy-1-(3-methoxy-4-(tosyloxy)-phenyl)propan-2-yl)oxy)-3-
methoxyphenyl)allyl Acetate (ent-23). Oxidation of alkene
ent-22 in an analogous fashion to that described immediately
above gave acetate ent-23 (67 mg, 33%) as a clear, colorless oil,
[α]20D = +17.7 (c = 1, CHCl3). All other spectral data acquired
on this material were identical with those reported above for
compound 23.
(1S,2R)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hy-
droxyprop-1-en-1-yl)-2-methoxyp-henoxy)propane-1,3-diol
(ent-2). TBAF·xH2O (37 mg, ca. 0.12 mmol) was added in one
portion to a magnetically stirred solution of acetate 23 (55 mg,
0.080 mmol) in THF (3 mL) maintained at 22 °C under a
nitrogen atmosphere. After 1 h, the reaction mixture was
treated with methanol (3 mL) then NaOH (1 mL of a 3 M
aqueous solution, 3 mmol) before being heated at 80 °C. After
3 h, the reaction mixture was cooled to 22 °C, acidified to pH 5
using acetic acid, then diluted with ethyl acetate (15 mL). The
separated organic phase was washed with brine (3 × 5 mL of a
ca. 13 wt % solution), and the combined aqueous washings
were extracted with ethyl acetate (3 × 5 mL). The combined
organic phases were washed with brine (1 × 5 mL of a ca. 13 wt
% solution) before being dried (Na2SO4), filtered, and
concentrated under reduced pressure. The ensuing pale-yellow
residue was subjected to flash column chromatography (silica,
1:19 v/v methanol/dichloromethane → 1:9 v/v methanol/
dichloromethane gradient elution), and concentration of the
appropriate fractions (Rf = 0.5 in 1:9 v/v methanol/dichloro-
methane) afforded compound ent-2 (22 mg, 73%) as a clear,
colorless gum, [α]20D = −8.2 (c = 1.1, methanol).
1H NMR
(400 MHz, CD3OD) δ 7.02 (d, J = 1.9 Hz, 1H), 6.99 (broad s,
1H), 6.88−6.86 (complex m, 2H), 6.84 (dd, J = 8.1 and 1.9 Hz,
1H), 6.73 (d, J = 8.1 Hz, 1H), 6.51 (dt, J = 15.9 and 1.5 Hz,
1H), 6.23 (dt, J = 15.8 and 5.8 Hz, 1H), 4.83 (d, J = 5.8 Hz,
1H), 4.36 (ddd, J = 5.8, 5.7 and 3.7 Hz, 1H), 4.19 (dd, J = 5.8
and 1.5 Hz, 2H), 3.85 (dd, J = 12.0 and 5.7 Hz, 1H), 3.80 (s,
3H), 3.77 (dd, J = 12.0 and 3.7 Hz, 1H); 13C NMR (100 MHz,
CD3OD) δ 151.9, 148.9, 148.7, 147.0, 134.1, 133.0, 131.4,
128.5, 121.0, 120.6, 118.9, 115.6, 111.9, 111.4, 86.2, 74.1, 63.7,
62.2, 56.5, 56.3; IR νmax 3345, 2937, 1602, 1509, 1463, 1264,
1128, 1028, 968 cm−1; MS (ESI, +ve) m/z 399 (100) [M +
Na]+; HRMS calcd for C20H24NaO7 [M + Na]
+: 399.1420,
found: 399.1419; HPLC analysis: Chiracel AS-H column, 85:15
v/v n-hexane/ethanol elution, flow rate 1.0 mL/min, detection
at λ = 254 nm, t = 35.8 min, ee > 99%.
(1R,2S)-1-(4-Hydroxy-3-methoxyphenyl)-2-(4-((E)-3-hy-
droxyprop-1-en-1-yl)-2-methoxyp-henoxy)propane-1,3-diol
(2). Treatment of compound ent-23 with TBAF then aqueous
sodium hydroxide in an analogous fashion to that described
immediately above gave compound 29k (6.8 mg, 73%) as a
clear, colorless gum, [α]20D = +7.4 (c = 0.5, methanol) {lit.
9k
[α]20D = +10.8 (c = 1, CHCl3)}.
1H NMR [600 MHz,
(CD3)2SO] δ 8.71 (s, 1H), 6.99 (m, 2H), 6.91 (d, J = 8.4 Hz,
1H), 6.83 (dd, J = 8.4 and 2.0 Hz, 1H), 6.72 (m, 2H), 6.43 (dt,
J = 15.9 and 1.9 Hz, 1H), 6.22 (dt, J = 15.9 and 5.5 Hz, 1H),
5.27 (d, J = 4.7 Hz, 1H), 4.75 (app. t, J = 5.6 Hz, 1H), 4.70
(app. t, J = 4.9 Hz, 1H), 4.56 (app. t, J = 5.6 Hz, 1H), 4.29 (m,
1H), 4.08 (m, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 3.60 (m, 2H);
13C NMR [150 MHz, (CD3)2SO] δ 149.6, 147.4, 146.8, 145.3,
133.0, 129.9, 128.4, 128.3, 119.3, 118.8, 115.5, 114.4, 111.3,
109.8, 83.6, 71.5, 61.4, 60.0, 55.5, 55.3. These spectral data
matched those reported by Nair and co-workers.9k All other
spectral data acquired on this material were identical with those
reported above for compound ent-2. HPLC analysis: Chiracel
AS-H column, 85:15 v/v n-hexane/ethanol elution, flow rate
1.0 mL/min, detection at λ = 254 nm, t = 43.2 min, ee > 99%.
Endothelial Cell Tubule Formation Assay. Human
microvascular endothelial cells (HMECs) were grown in
MCDB131 media supplemented with 10% fetal bovine serum
(FBS), hydrocortisone (500 μg/mL), epidermal growth factor
(0.01 mg/mL), L-glutamine (2 mM), and antibiotics. At 80−
90% confluency, the cells were trypsinized, pelleted by
centrifugation, and resuspended in MCDB131 medium
containing 0.2% FBS at 4 × 105/mL cell density. One mL of
the cell suspension was then transferred to microfuge tubes and
incubated with 30 μM PD98059 for 0.5 h at room temperature
prior to the addition of 12.5 ng/mL FGF-2 or 0.1 μM of each
of the compounds 1, ent-1, 2, and ent-2 (final concentrations).
Alternately, 1 mL of cell suspension was incubated with FGF-2
alone (12.5 ng/mL) or each neolignan (0.1 μM). The
suspensions were gently mixed (pipetting up and down three
times), and 100 μL (4 × 104 cells) was aliquoted into a 96 well
plate that had been pre-coated overnight at 4 °C with Matrigel
basement membrane matrix. The plates were incubated at 37
°C, and the cells in each well were photographed (under 40×
magnification) 4 h after seeding. Microtubules were counted
using Image J software. Each treatment was performed in
triplicate, and four independent experiments were performed.
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■ ADDITIONAL NOTE
1It is also possible that the conversion 7 + 8 → 9 proceeds via
an SN1 pathway.
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Appendix One 
 
Single-crystal x-ray report for compound ent-2 of publication 3. 
 
 
 
 
 
 
 
CCDC Deposition Number: 1517512
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Appendix Two 
 
Single-crystal x-ray report for compound ent-15 of publication 3. 
 
 
 
 
 
CCDC Deposition Number: 1517513
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Appendix Three 
 
Single-crystal x-ray report for compound 9 of publication 4. 
 
 
 
 
 
 
CCDC Deposition Number: 1491822 
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Appendix Four 
 
Single-crystal X-ray report for compound 14 of publication 5. 
 
 
 
 
 
CCDC Deposition Number: 1533559 
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